Conditions: Lung Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 569
Healthy volunteers: no

Brief summary:
The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.

Detailed description:

Arms:
arm 1: Nivolumab intravenous infusion as specified arm 2: Topotecan as specified arm 3: Amrubicin intravenous infusion as specified (upon investigator's choice, where locally approved for 2nd line SCLC treatment)

Interventions: intervention 1: Nivolumab intervention 2: Topotecan intervention 3: Amrubicin
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None

Protocol document:
Prot_002.pdf: 
Page:
1
Protocol Number:
CA209331
IND Number:
100,052
Ex-US
Non-IND
EUDRACT Number
2015-001097-18
Date:
22-Apr-2015
Revised Date
20-Mar-2018
Clinical Protocol CA209331
An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with 
Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy
(CheckMate 331: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 331)
Revised Protocol Number: 03
Incorporates amendment(s) 17 and Administrative Letter 04, 05 and 06
Study Director
Medical Monitor
5 Research Parkway
Wallingford, CT 06492
USA
3401 Princeton Pike
Lawrenceville, NJ 08648
USA
Telephone (office): 
Telephone (office): 
Fax: 
24-hr Emergency Telephone Number
USA:
International: 
Bristol-Myers Squibb Research and Development
B-1420 Braine-l’Alleud, Belgium
3401 Princeton Pike
Lawrenceville, NJ 08648
This document is the confidential and proprietary information of Bristol-Myers Squibb 
Company and its global affiliates (BMS). By reviewing this document, you agree to keep it 
confidential and to use and disclose it solely for the purpose of assessing whether your 
organization will participate in and/or the performance of the proposed BMS-sponsored 
study. Any permitted disclosures will be made only on a confidential "need to know" basis 
within your organization or to your independent ethics committee(s). Any other use, 
copying, disclosure or dissemination of this information is strictly prohibited unless 
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Revised Protocol No: 03
Date:  20-Mar-2018
2
expressly authorized in writing by BMS. Any supplemental information (eg, amendments) 
that may be added to this document is also confidential and proprietary to BMS and must 
be kept in confidence in the same manner as the contents of this document. Any person 
who receives this document without due authorization from BMS is requested to return it 
to BMS or promptly destroy it. All other rights reserved. References to BMS in this 
protocol may apply to partners to which BMS has transferred obligations, eg, a Contract 
Research Organization (CRO).
Replace all previous version(s) of the protocol with this revised protocol and please provide a 
copy of this revised protocol to all study personnel under your supervision, and archive the 
previous versions.
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Revised Protocol No: 03
Date:  20-Mar-2018
3
DOCUMENT HISTORY
Document
Date of Issue
Summary of Change
Revised 
Protocol 03
20-Mar-2018
Incorporates Amendment 17 and Administrative Letters 04, 05 and 06
Amendment 17
20-Mar-2018
•
Updated study personnel
•
Added additional China cohorts in Arm A and Arm B
•
Added tumor mutational burden and time to symptom deterioration 
as exploratory objectives
•
Updated protocol as per nivolumab program standards
Administrative 
Letter 06
19-Dec-2017
Change in Medical Monitor contact
Administrative 
Letter 05
06-Dec-2017
Change in Medical Monitor contact
Administrative 
Letter 04
29-Jun-2017
Change in Medical Monitor contact
Revised 
Protocol 02
07-Sep-2016
Incorporates Amendment(s) 15 and Administrative Letter 03
Amendment 15
07-Sep-2016
•
Remove the planned interim analysis and to modify the timing of the
final analysis as a result from a phase 1/2 study (CheckMate 032) 
which suggested a treatment delayed effect for immunotherapy in 
Small Cell Lung Cancer. The amendment will also add a sub-study 
in China to comply with regulatory requirement in that country
•
Revise the exploratory objective of Lung Cancer Symptom Scale 
based on results of Checkmate 017 and Checkmate 057
•
Other changes include correction of inconsistencies, alignment with 
latest Nivolumab standards, and investigator brochure.
Administrative 
Letter 03
05-Feb-2016
Edited misleading/ambiguous sentence about the contraception method 
to be used.
Revised 
Protocol 01
15-Dec-2015
Incorporates Amendment(s) 11 and Administrative Letters 01 & 02
Amendment 11
15-Dec-2015
The main purpose of this amendment is to allow the use of different 
topotecan formulations (powder for injection and oral capsules).
Other changes include modification of the treatment assignment for 
Arm B to allow for treatment with topotecan or amrubicin (upon 
investigator’s choice, where locally approved for 2nd line SCLC 
patients), clarification of some inclusion/exclusion criteria, correction of 
inconsistencies and typographical revisions throughout the protocol.
Change of Medical Monitor
Administrative 
Letter 02
08-Dec-2015
Change of Study Director and Medical Monitor
Administrative 
Letter 01
14-Jun-2015
Criterion deleted given because not applicable to the approved original 
protocol
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Revised Protocol No: 03
Date:  20-Mar-2018
4
Document
Date of Issue
Summary of Change
Original 
Protocol
22-Apr-2015
Not applicable
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
SYNOPSIS
Clinical Protocol CA209331
Protocol Title: An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with 
Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy
Investigational Product(s), Dose and Mode of Administration, Duration of Treatment with Investigational 
Product(s): 
•
Nivolumab 240 mg (flat dose) on Day 1 of a 14-day cycle as an IV infusion over 30 minutes.
•
Topotecan: 1.5 mg/m2 administered as 30-minute IV infusion or 2.3 mg/ m2 oral capsule (round dose to nearest 
0.25 mg) once daily on Days 1 to 5 of a 21-day cycle. 
•
Amrubicin (upon investigator’s choice, where locally approved for 2nd line SCLC treatment): 40 mg/m2
administered as 5-minute IV infusion once daily on Days 1 to 3 of a 21-day cycle.
Treatment is continued until disease progression, unacceptable toxicity, or other protocol-defined reasons.
Study Phase:  3
Research Hypothesis: 
Treatment with nivolumab will increase overall survival (OS) as compared with 
chemotherapy in subjects with relapsed small-cell lung cancer (SCLC) treated with prior platinum-based, first-line 
chemotherapy.
Objectives: 
Primary Objectives
•
To compare the OS of nivolumab versus chemotherapy in subjects with relapsed SCLC after platinum-based,
first-line chemotherapy.
Secondary Objectives
•
To compare the progression free survival (PFS) of nivolumab versus chemotherapy
•
To compare the objective response rate (ORR) of nivolumab versus chemotherapy
Exploratory Objectives
•
To evaluate the safety and tolerability of nivolumab versus chemotherapy
•
To characterize pharmacokinetics of nivolumab and explore exposure response (exposure-safety and 
exposure-efficacy) relationships with respect to selected safety and efficacy endpoints
•
To explore PD-L1 expression as an independent predictive biomarker for OS, ORR, or PFS in nivolumab and 
chemotherapy groups
•
To explore tumor mutational burden expression as an independent predictive biomarker for efficacy in 
nivolumab and chemotherapy groups
•
To correlate potential predictive biomarkers in peripheral blood and tumor specimens, including proteins 
involved in regulating immune responses (eg, 
 PD-L1, 
), mutational as well as 
Revised Protocol No: 03
Date: 20-Mar-2018
5
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
immunohistochemistry (IHC) spectrum, with endpoints such as ORR, PFS and OS in nivolumab and 
chemotherapy groups
•
•
To characterize immunogenicity of nivolumab
•
To evaluate the proportion of subjects exhibiting disease-related symptom deterioration by 12 weeks and by 24 
weeks, as measured by the Lung Cancer Symptom Scale (LCSS) in nivolumab and chemotherapy groups
•
To evaluate the time to symptom deterioration (TTSD), as measured by the average symptom burden index 
(ASBI) of the Lung Cancer Symptom Scale (LCSS), in subjects receiving nivolumab versus chemotherapy
•
To assess the subject’s overall health status using the EQ-5D Index and visual analog scale in nivolumab and 
chemotherapy groups.
Study Design:  This is a randomized, open-label, two-arm, multicenter, Phase 3 study in adult subjects with 
relapsed SCLC treated with prior platinum-based, first-line chemotherapy. Subjects must have had at least 4 cycles 
of platinum-based, first-line chemotherapy, or if they received less than 4 cycles, they must have had a best overall 
response (BOR) of a partial or complete response after completion of chemotherapy.
a
Subjects must have had at least 4 cycles of platinum-based, first-line chemotherapy, or if they received less than 
4 cycles of platinum-based first-line chemotherapy, they must have had a best overall response (BOR) of at 
least a partial or complete response after completion of chemotherapy.
Revised Protocol No: 03
Date: 20-Mar-2018
6
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Study Population:
Key Inclusion Criteria:
Adult men and women with histologically or cytologically confirmed SCLC that recurred or progressed after 
platinum-based, first-line chemotherapy or chemoradiation therapy. Subjects must have had at least 4 cycles of 
platinum-based, first-line chemotherapy for either limited or extensive stage disease or if less than 4 cycles, must 
have had a BOR of at least partial or complete response.
Key Exclusion Criteria:
Active symptomatic central nervous system metastases, documented carcinomatous meningitis, active, known or 
suspected autoimmune disease, and prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or 
anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell 
co-stimulation or checkpoint pathways), topotecan, or amrubicin.
Study Drug: includes both Investigational [Medicinal] Products (IP/IMP) and Non-investigational [Medicinal] 
Products (Non-IP/Non-IMP) as listed below.
Study Drugs for CA209331 - Treatment Phase
Study Drug
Potency
IP/Non-IP
Nivolumab Solution for Injection
100 mg (10 mg/mL)
IP
Topotecan hydrochloride concentrate 
for solution for infusion
4 mg (1 mg/mL)
IP
Topotecan hydrochloride powder for 
infusion
4 mg
IP
Topotecan hydrochloride capsules
0.25 mg and 1 mg
IP
Amrubicin hydrochloride powder for 
solution for injection
50 mg
IP
Study Assessments: OS is the primary endpoint of the study. OS will be followed continuously while subjects are 
on the study drugs and every 3 months via in-person or phone contact after subject discontinued the study drugs. 
Subjects will be assessed for response by computed tomography (CT) or magnetic resonance imaging (MRI)
beginning at 6 weeks (± 5 days) (from the first dose of study treatment) and continuing every 6 weeks (± 5 days) 
until Week 30 and then every 12 weeks (± 5 days). Tumor assessment will continue until disease progression (or 
until discontinuation of study drug in patients receiving nivolumab beyond progression), lost to follow-up, 
withdrawal of study consent, or the study ends. All randomized subjects will be evaluated.
Statistical Considerations:
Sample Size: A total of approximately 560 subjects will be randomized at a ratio of 1:1 into two arms: Arm A 
(nivolumab); Arm B (chemotherapy – ie, topotecan or amrubicin). This includes approximately 78 subjects enrolled 
in China (~ 16% of the 480 subjects planned to be randomized in global population). If necessary, the China 
enrollment will continue until the pre-specified sample size of the China sub-population is filled. Additional 
analyses exploring the consistency of findings in the China sub-population may be conducted. Details of these 
analyses will be provided in the analysis plan.
The decision to incorporate the China sub-population into the overall population for analysis is the result of a review 
of the protocol statistical assumptions in comparison to recent data from the CA209032 study in 2L+ SCLC subjects 
(Hellman MD et al, 2017). The data from CA209032, which were not available at the time of protocol design, 
Revised Protocol No: 03
Date: 20-Mar-2018
7
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
suggest a delayed effect of nivolumab with a non-proportional hazard for survival. Additionally, review of recently 
generated real-world data for topotecan resulted in updated assumptions for the control arm. Given the updated 
statistical assumptions, incorporation of the China sub-population into the study analyses grants adequate statistical 
power by increasing the study sample size.
In this study, the primary endpoint of OS will be evaluated for treatment effect at the overall alpha level of 0.05 
(two-sided). For sample size calculation, non-proportional hazard model with a piecewise exponential distributions 
in both arms are assumed. Based on published survival curves for topotecan, a 2-piece exponential distribution with 
an 8-month median OS and taking into account that a limited number of subjects might receive immuno-oncology
agents as subsequent therapy in this open-label study, a conservative 5% 2-year survival rate is assumed for the 
control arm. A delayed effect for nivolumab with a hazard ratio (HR) of 1 for the first 8 months and an HR of 0.5 
thereafter is assumed 
The final analysis will take place 34 months after FPFV and no formal interim analysis will be conducted. It is 
anticipated that approximately 480 events will be observed at the time of the analysis, leading to 90% power to 
detect a difference in overall survival as tested via a log-rank test with a two-sided 0.05 type I error rate. Power 
calculations were performed using EAST® Software (version 6.4.1).
The secondary endpoints PFS and ORR will be tested hierarchically. 
Table 1:
Sample Size Justification
Primary Endpoint
OS
Power 
90%
Alpha level
0.05
Sample size
560
Accrual duration 
18 months 
Timing of the analysis from randomization of first 
subject (months)
34
Hypothesized OS rate at 8 months
50% in both arms (HR=1 up to Month 8)
Hypothesized OS rate at 24 months
5% vs 16% (HR=0.5 from Month 8)
Expected Average HR 
~0.745
Expected number of event at 34 months
482
Endpoints: The primary endpoint for the study is OS. It is defined as the time from randomization to the date of 
death. A subject who has not died will be censored at last known date alive. OS will be followed continuously while 
subjects are on the study drug and every 3 months via in-person or phone contact after subjects discontinue the study 
drug. Secondary endpoints include ORR and PFS.
Analyses: All hypothesis testing will be two-sided based on a significance level of 0.05 except for OS. If superiority 
of OS is demonstrated, a hierarchical hypothesis testing approach for the key secondary endpoints will be used to 
preserve a study-wise type I error rate at 0.05. The key secondary endpoints will be tested in the following 
hierarchical order: 
1)
PFS
2)
ORR
The formal statistical testing for PFS will take place only if OS is statistically significant and the statistical testing 
for ORR will take place only if both OS and PFS are statistically significant.
Revised Protocol No: 03
Date: 20-Mar-2018
8
4.0
Approved
930089510
4.0
v
Approved
1.0
v


TABLE OF CONTENTS 
TITLE PAGE ................................................................................................................ 
DOCUMENT HISTORY .............................................................................................. 
SYNOPSIS .................................................................................................................... 
TABLE OF CONTENTS .............................................................................................. 
1 INTRODUCTION AND STUDY RATIONALE ..................................................... 
1.1 Study Rationale ................................................................................................. 
1.1.1 Rationale for Investigating Relapsed Small Cell Lung Cancer (SCLC) .. 
1.1.2 Rationale for Immuno-oncology Therapeutic Approaches in SCLC ....... 
1.1.3 Rationale for Nivolumab .......................................................................... 
1.1.3.1 Mechanism of Action....................................................................... 
1.1.3.2 Phase 1/2 Data for Nivolumab in SCLC ......................................... 
1.1.3.3 Safety Profile of Nivolumab Monotherapy ..................................... 
1.1.3.4 Standard of Care for the Treatment of Relapsed or Recurrent SCLC
...............................................................................................................
1.1.3.5 Rationale for Use of Nivolumab Monotherapy as Experimental 
Agent (Arm A) ....................................................................................... 
1.1.4 Rationale to Support Topotecan and Amrubicin as Comparators (Arm B)
.....................................................................................................................
1.1.4.1 Topotecan and Amrubicin Safety Profile ........................................ 
1.1.5 Rationale for Open-label Study Design ................................................... 
1.1.6 Rationale to Support Nivolumab Monotherapy Flat Dose (Arm A) ........ 
1.1.7 Rationale for Shorter Infusion Times for Nivolumab .............................. 
1.1.8 Rationale for Collection of Tumor Tissue and Evaluation of Tumor PD-
L1 Expression and Tumor Mutational Burden as Potential Predictive 
Biomarkers .................................................................................................. 
1.1.9 Rationale for Permitting Continued Treatment in Select Cases of 
Progressive Disease .................................................................................... 
1.2 Research Hypothesis ......................................................................................... 
1.3 Objectives(s) ..................................................................................................... 
1.3.1 Primary Objectives .................................................................................. 
1.3.2 Secondary Objectives ............................................................................... 
1.3.3 Exploratory Objectives ............................................................................ 
1.4 Product Development Background ................................................................... 
1.5 Overall Risk/Benefit Assessment ..................................................................... 
2 ETHICAL CONSIDERATIONS ............................................................................... 
2.1 Good Clinical Practice ...................................................................................... 
2.2 Institutional Review Board/Independent Ethics Committee ............................. 
2.3 Informed Consent.............................................................................................. 
3 INVESTIGATIONAL PLAN .................................................................................... 
3.1 Study Design and Duration ............................................................................... 
3.1.1 Study Phases ............................................................................................ 
3.1.1.1 Screening ......................................................................................... 
3.1.1.2 Treatment ........................................................................................ 
3.1.1.3 Follow up ........................................................................................ 
1
3
5
9
13
13
13
14
14
14
15
15
18
18
18
19
19
20
20
21
21
22
22
22
22
22
23
23
23
23
24
24
25
25
27
27
28
28
Clinical Protocol
BMS-936558
CA209331
nivolumab
Revised Protocol No: 03
Date: 20-Mar-2018
9
4.0
Approved
930089510
4.0
v
Approved
1.0
v


3.2 Post Study Access to Therapy ........................................................................... 
3.3 Study Population ............................................................................................... 
3.3.1 Inclusion Criteria ..................................................................................... 
3.3.2 Exclusion Criteria .................................................................................... 
3.3.3 Women of Childbearing Potential ........................................................... 
3.4 Concomitant Treatments ................................................................................... 
3.4.1 Prohibited and/or Restricted Treatments................................................. 
3.4.2 Other Restrictions and Precautions ......................................................... 
3.4.3 Permitted Therapy ................................................................................... 
3.5 Discontinuation of Subjects following any Treatment with Study Drug .......... 
3.6 Post Study Drug Study Follow up .................................................................... 
3.6.1 Withdrawal of Consent ............................................................................ 
3.6.2 Lost to Follow-Up .................................................................................... 
4 STUDY DRUG .......................................................................................................... 
4.1 Investigational Product ..................................................................................... 
4.1.1 Nivolumab ................................................................................................ 
4.1.2 Topotecan ................................................................................................. 
4.1.3 Amrubicin ................................................................................................. 
4.2 Non-investigational Product ............................................................................. 
4.3 Storage and Dispensing..................................................................................... 
4.4 Method of Assigning Subject Identification ..................................................... 
4.4.1 Screening.................................................................................................. 
4.4.2 Randomization ......................................................................................... 
4.5 Selection and Timing of Dose for Each Subject ............................................... 
4.5.1 Dosing Schedule....................................................................................... 
4.5.1.1 Nivolumab ....................................................................................... 
4.5.1.2 Topotecan ........................................................................................ 
4.5.1.3 Amrubicin ........................................................................................ 
4.5.2 Dose Modifications and Dose Delays ...................................................... 
4.5.2.1 Nivolumab ....................................................................................... 
4.5.2.2 Topotecan ........................................................................................ 
4.5.2.3 Amrubicin ........................................................................................ 
4.5.3 Discontinuation Criteria .......................................................................... 
4.5.3.1 Nivolumab ....................................................................................... 
4.5.3.2 Topotecan ........................................................................................ 
4.5.3.3 Amrubicin ........................................................................................ 
4.5.4 Treatment Beyond Disease Progression .................................................. 
4.5.5 Treatment of Nivolumab-related Infusion Reactions ............................... 
4.6 Blinding/Unblinding ......................................................................................... 
4.7 Treatment Compliance ...................................................................................... 
4.8 Destruction of Study Drug ................................................................................ 
4.9 Return of Study Drug ........................................................................................ 
5 STUDY ASSESSMENTS AND PROCEDURES ..................................................... 
5.1 Flow Chart/Time and Events Schedule ............................................................. 
5.1.1 Retesting During Screening ..................................................................... 
5.2 Study Materials ................................................................................................. 
29
29
29
32
34
34
34
35
35
36
36
37
37
37
39
39
39
39
39
40
40
40
40
41
41
41
42
43
43
43
44
46
47
47
48
48
49
50
51
52
52
52
53
53
63
63
Clinical Protocol
BMS-936558
CA209331
nivolumab
Revised Protocol No: 03
Date: 20-Mar-2018
10
4.0
Approved
930089510
4.0
v
Approved
1.0
v


5.3 Safety Assessments ........................................................................................... 
5.3.1 Imaging Assessment for the Study............................................................ 
5.4 Efficacy Assessments ........................................................................................ 
5.4.1 Primary Efficacy Assessment ................................................................... 
5.4.2 Secondary Efficacy Assessment ............................................................... 
5.5 Pharmacokinetic and Immunogenicity Assessments ........................................ 
5.6 Biomarker Assessments .................................................................................... 
5.6.1 Tumor Tissue Specimens .......................................................................... 
 
 
5.6.1.2 DNA and RNA Genomic Assessment .............................................. 
5.6.1.3 Tumor Sample Collection Details ................................................... 
5.6.2 Peripheral Blood Markers ....................................................................... 
5.6.2.1 Single Nucleotide Polymorphisms (SNPs) ...................................... 
 
 
5.7 Outcomes Research Assessments ..................................................................... 
5.8 Other Assessments ............................................................................................ 
5.8.1 Immunogenicity Assessments ................................................................... 
6 ADVERSE EVENTS ................................................................................................. 
6.1 Serious Adverse Events .................................................................................... 
6.1.1 Serious Adverse Event Collection and Reporting .................................... 
6.2 Nonserious Adverse Events .............................................................................. 
6.2.1 Nonserious Adverse Event Collection and Reporting .............................. 
6.3 Laboratory Test Result Abnormalities .............................................................. 
6.4 Pregnancy .......................................................................................................... 
6.5 Overdose ........................................................................................................... 
6.6 Potential Drug Induced Liver Injury (DILI) ..................................................... 
6.7 Other Safety Considerations ............................................................................. 
7 DATA MONITORING COMMITTEE AND OTHER EXTERNAL COMMITTEES
................................................................................................................................. 
8 STATISTICAL CONSIDERATIONS....................................................................... 
8.1 Sample Size Determination ............................................................................... 
8.2 Populations for Analyses .................................................................................. 
8.3 Endpoints .......................................................................................................... 
8.3.1 Primary Endpoint(s) ................................................................................ 
8.3.2 Secondary Endpoint(s) ............................................................................. 
8.3.2.1 Progression Free Survival .............................................................. 
8.3.2.2 Objective Response Rate ................................................................. 
8.3.3 Exploratory Endpoint(s) .......................................................................... 
8.4 Analyses ............................................................................................................ 
8.4.1 Demographics and Baseline Characteristics........................................... 
8.4.2 Efficacy Analyses ..................................................................................... 
8.4.2.1 Methods of Primary Endpoint ......................................................... 
8.4.2.2 Methods for Secondary Endpoint.................................................... 
8.4.3 Safety Analyses......................................................................................... 
63
63
63
64
65
65
66
68
68
69
69
69
70
70
70
70
71
71
71
72
73
74
74
74
75
75
75
76
76
76
76
77
78
78
78
78
78
79
80
80
80
81
81
81
Clinical Protocol
BMS-936558
CA209331
nivolumab
Revised Protocol No: 03
Date: 20-Mar-2018
11
4.0
Approved
930089510
4.0
v
Approved
1.0
v


8.4.4 Pharmacokinetic Analyses ....................................................................... 
8.4.5 Biomarker Analyses ................................................................................. 
8.4.5.1 Pharmacodynamic Analyses ........................................................... 
8.4.5.2 Pharmacogenomic Analyses ........................................................... 
8.4.6 Outcomes Research Analyses .................................................................. 
8.4.7 Other Analyses ......................................................................................... 
8.5 Interim Analyses ............................................................................................... 
9 STUDY MANAGEMENT ........................................................................................ 
9.1 Compliance ....................................................................................................... 
9.1.1 Compliance with the Protocol and Protocol Revisions ........................... 
9.1.2 Monitoring ............................................................................................... 
9.1.2.1 Source Documentation .................................................................... 
9.1.3 Investigational Site Training.................................................................... 
9.2 Records ............................................................................................................. 
9.2.1 Records Retention .................................................................................... 
9.2.2 Study Drug Records ................................................................................. 
9.2.3 Case Report Forms .................................................................................. 
9.3 Clinical Study Report and Publications ............................................................ 
10 GLOSSARY OF TERMS ........................................................................................ 
11 LIST OF ABBREVIATIONS .................................................................................. 
12 REFERENCES ........................................................................................................ 
APPENDIX 1 MANAGEMENT ALGORITHMS ....................................................... 
APPENDIX 2 RECIST 1.1 ........................................................................................... 
81
82
82
82
83
83
83
83
83
83
84
84
85
85
85
85
86
86
88
89
93
96
104
Clinical Protocol
BMS-936558
CA209331
nivolumab
Revised Protocol No: 03
Date: 20-Mar-2018
12
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
1
INTRODUCTION AND STUDY RATIONALE
CA209331 is a randomized, open-label, multinational Phase 3 trial of nivolumab (also known as 
BMS-936558) monotherapy versus chemotherapy in subjects with small cell lung cancer (SCLC)
whose disease has relapsed or progressed after prior platinum-based chemotherapy regimen. This 
study will determine if nivolumab improves overall survival (OS) over chemotherapy in this 
subject population. Additional objectives include further characterization of the efficacy, adverse 
event profile, pharmacokinetics, patient reported outcomes, and potential predictive biomarkers 
of nivolumab in subjects with SCLC.
1.1
Study Rationale
1.1.1
Rationale for Investigating Relapsed Small Cell Lung Cancer (SCLC)
SCLC accounts for 15 to 20% of new cases of lung cancer, and nearly 33,900 new cases are 
expected in the United States (US) in 2012.1 SCLC is traditionally classified as Limited Stage 
Disease (LD-SCLC: tumor tissue encompassed within a single radiation port) and Extensive 
Stage Disease (ED-SCLC: tumor that extends beyond the boundaries of a single radiation port).2
For LD-SCLC, or Stage IA-IIIB localized disease (T1-4, N0-3, M0), a combined therapeutic 
approach of radiotherapy, chemotherapy and rarely surgery is used with curative intent.3 Most 
patients at diagnosis have ED-SCLC, or Stage IV disease, and are treated with four to six cycles 
of platinum plus etoposide (PE) which remains the standard chemotherapy regimen for LD- and 
ED-SCLC.4 Initial response rate is robust with 70 to 90% response seen in LD-SCLC and 50 to 
70% response seen in ED-SCLC.3 However, overall survival remains poor with median survival 
for LD-SCLC at 18 to 30 months5 and for ED-SCLC in the range of 10 to 12 months.6
Following platinum-based first-line therapy, about 80% LD-SCLC patients and all of ED SCLC 
patients have disease progression.7 Patients whose response after first-line platinum-based 
therapy last beyond 180 days are the candidates for rechallenge with platinum doublet therapy. 
Others are treated with single-agent topotecan, the only approved second-line therapy in the US. 
Approval was based on a Phase 3 study of single agent intravenous topotecan versus a regimen 
consisting of cyclophosphamide, doxorubicin, and vincristine (CAV) which showed an improved 
objective response rate (ORR, 24.3% vs 18.3%, P = 0.285) while median survival was similar 
between two arms (25 weeks vs 24.7 weeks).8 In another Phase 3 trial comparing supportive care 
alone with supportive care with oral topotecan in patients with relapsed SCLC, the median 
survival was statistically significantly improved for the topotecan arm (25.9 weeks [95% 
confidence interval {CI}, 18.3 to 31.6]), compared to supportive care only (13.9 weeks [95% CI, 
11.1 to 18.6]).9 In a randomized Phase 3 trial of amrubicin versus topotecan as second-line 
treatment for patients with SCLC, amrubicin did not improve survival when compared with 
topotecan.10 For second-line SCLC, the median OS was 6.7 months based on a meta analysis 
using 21 studies published between 1984 and 2011.11 In summary, there is a high unmet medical 
need for the treatment of patients with recurrent or relapsed SCLC.
Revised Protocol No: 03
Date: 20-Mar-2018
13
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
1.1.2
Rationale for Immuno-oncology Therapeutic Approaches in SCLC
An analysis of peripheral blood mononuclear cells (PBMCs) from SCLC patients has shown a 
higher number of T-effector cells in LD-SCLC compared to ED-SCLC subjects and long-term 
survivors of SCLC have a higher T-effector to T regulator ratio.12 In a Phase 2 randomized 
study, phased ipilimumab (placebo plus paclitaxel/carboplatin followed by ipilimumab plus 
paclitaxel/carboplatin) showed improved progression free survival (PFS) versus carboplatin and 
paclitaxel (5.7 months vs 4.6 months, Hazard Ratio (HR) = 0.72, P = 0.05), though there was no 
improvement when used concurrently.13 Nivolumab at doses of 1, 3, and 10 mg/kg has been 
shown to be effective against non-small cell lung cancer (NSCLC) in a Phase 1 study (N = 122) 
with ORR of 6%, 27%, and 17% and PFS rates at 24 weeks of 25%, 44%, and 31%.14,15
Preliminary results in a Phase 1/2 trail with nivolumab in SCLC are provided in Section 1.1.3.2. 
Considering the immune response seen in SCLC patients, and the results of checkpoint inhibitors 
nivolumab and ipilimumab in NSCLC patients, it is reasonable to expect that nivolumab 
monotherapy is likely to provide benefit in second-line treatment of SCLC.
1.1.3
Rationale for Nivolumab 
1.1.3.1
Mechanism of Action
Nivolumab is a fully human, IgG4 (kappa) isotype mAb that binds the programmed death 
receptor-1 (PD-1) on activated immune cells and disrupts engagement of the receptor with its 
ligands PD-L1 (B7-H1/CD274) and PD-L2 (B7-DC/CD273), thereby abrogating inhibitory 
signals and augmenting the host antitumor response. Programmed death receptor-1 (PD-1, 
CD279), a 55 kD type I transmembrane protein, is a member of the CD28 family of T-cell 
co-stimulatory receptors that also includes CD28, CTLA 4, ICOS, and BTLA.2 PD-1 contains an 
intracellular membrane proximal immunoreceptor tyrosine inhibitory motif (ITIM) and a 
membrane distal immunoreceptor tyrosine-based switch motif (ITSM). Two ligands specific for 
PD-1 have been identified: PD-L1 (B7-H1/CD274) and PD-L2 (B7-DC/CD273). PD-L1 and 
PD-L2 have been shown to down-regulate T-cell activation upon binding to PD-1 in both murine 
and human systems. PD-1 delivers a negative signal by the recruitment of SHP-2 to the 
phosphorylated tyrosine residue in the ITSM in its cytoplasmic region. PD-1 is primarily 
expressed on activated T cells, B cells, and myeloid cells. Further evidence for a negative 
regulatory role of PD-1 comes from studies of PD-1-deficient mice. PD-1-deficient mice develop 
various autoimmune phenotypes, including dilated cardiomyopathy, a lupus-like syndrome with 
arthritis and nephritis, and accelerated diabetes mellitus. The emergence of these autoimmune 
phenotypes is dependent upon the genetic background of the mouse strain and many of these 
phenotypes emerge at different times and show variable penetrance. In addition to the 
phenotypes of null mutations, PD-1 inhibition by antibody-mediated blockade in several murine 
models has been found to play a role in the development of autoimmune diseases such as 
encephalomyelitis, graft-versus-host disease, and type I diabetes. Taken together, these results 
suggest that PD-1 blockade has the potential to activate anti-self T cell responses, but these 
responses are variable and dependent upon various host genetic factors. Thus, PD-1 deficiency or 
inhibition is not accompanied by a universal loss of tolerance to self antigens.
Revised Protocol No: 03
Date: 20-Mar-2018
14
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Preclinical animal models of tumors have shown that blockade by PD-1 by monoclonal 
antibodies (mAbs) can enhance the anti-tumor immune response and result in tumor rejection. 
Antitumor activity by PD-1 blockade functions in PD-L1-positive tumors as well as in tumors 
that are negative for the expression of PD-L1. This suggests that host mechanisms (ie, expression 
of PD-L1 in antigen-presenting cells) limit the antitumor response. Consequently, both PD-L1 
positive and negative tumors may be targeted using this approach. In humans, constitutive 
PD-L1 expression is normally limited to macrophage-lineage cells, although expression of 
PD-L1 can be induced on other hematologic cells as well, including activated T cells. However, 
aberrant expression of PD-L1 by tumor cells has been reported in a number of human 
malignancies. PD-L1 expressed by tumor cells has been shown to enhance apoptosis of activated 
tumor specific T cells in vitro. Moreover, the expression of PD-L1 may protect the tumor cells 
from the induction of apoptosis by effector T cells. Additional details are available in the 
Nivolumab Investigator Brochure.
1.1.3.2
Phase 1/2 Data for Nivolumab in SCLC
In a Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent SCLC 
(CA209032) subjects who were platinum sensitive or refractory, and had progressive disease 
were enrolled regardless of tumor PD-L1 status or number of prior chemotherapy regimens. This 
open-label study randomized subjects to nivolumab 3 mg/kg by intravenous (IV) infusion every 
2 weeks (Q2W) or nivolumab + ipilimumab (1 + 1 mg/kg, 1 + 3 mg/kg or 3 + 1 mg/kg) IV every 
3 weeks (Q3W) for 4 cycles followed by nivolumab 3 mg/kg Q2W. Primary objective was ORR. 
Other objectives were safety, PFS, OS and biomarker analysis. Seventy-five subjects were 
enrolled (nivolumab, n = 40; nivolumab + ipilimumab, n = 35); 59% had at least 2 prior 
regimens. Drug-related adverse events (AEs) in ≥10% of subjects were fatigue (18%), diarrhea 
(13%), nausea (10%), and decreased appetite (10%) with nivolumab; and fatigue (29%), diarrhea 
(17%), pruritus (14%), nausea, endocrine disorders and rash (11% each) with nivolumab + 
ipilimumab. Grade 3/4 drug-related AEs with nivolumab occurred in 7 (18%) subjects (all in 
n = 1 [3%]: stomatitis, fatigue, hyperglycemia, ALT increased, GGT increased, encephalitis, 
infusion related reaction).Grade 3/4 drug-related AEs in ≥5% included diarrhea and rash (6% 
each; nivolumab + ipilimumab). Drug-related pneumonitis occurred in 2 pts (1 per arm). Limbic 
encephalitis was reported in 2 subjects in the nivolumab arm and 1 subject in the 
nivolumab + ipilimumab arm.  The event resolved under steroid treatment in 2 subjects and 
continued despite immunosuppressive treatment in 1 subject. Of 40 evaluable subjects treated 
with nivolumab, partial response (PR) was seen in 6, 15% (duration of ongoing responses [DOR] 
80 - 251+ days); stable disease (SD) in 9, 22.5%; and progressive disease (PD) in 25, 62.5%. In 
conclusion, in this PD-L1 unselected heavily pretreated SCLC population including platinum 
based first-line treatment, nivolumab treatment was well tolerated. The ORR was 15% for 
subjects with nivolumab with long lasting responses beyond 251 days, all ongoing at the time of 
the data cut off.
1.1.3.3
Safety Profile of Nivolumab Monotherapy
In clinical trials, nivolumab has demonstrated an acceptable benefit-risk across multiple tumor 
types, including advanced melanoma, renal cell carcinoma (RCC), NSCLC, and lymphomas. The 
Revised Protocol No: 03
Date: 20-Mar-2018
15
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
two clinical trials that have contributed the most to the clinical experiences of nivolumab 
monotherapy are studies CA209003 and CA209037. Overall, the safety profile is quite similar 
between these two studies and is discussed further in the sections below.
CA209003 is a completed Phase 1 open label, multiple dose escalation study in 306 subjects with 
select previously treated advanced solid tumors, including melanoma, RCC, NSCLC, colorectal 
cancer, and hormone-refractory prostate cancer. Subjects received nivolumab at doses of 0.1, 0.3, 
1, 3, or 10 mg/kg IV Q2W, up to a maximum of 2 years of total therapy. A total of 306 subjects 
were treated with nivolumab in the dose range of 0.1 to 10 mg/kg.
No maximal tolerated dose was identified in CA209003. The incidence, severity and relationship 
of AEs were generally similar across dose levels and tumor types. Nivolumab related AEs of any 
grade occurred in 75.2% of subjects. Of the 306 treated subjects, 303 (99.0%) subjects had at 
least 1 reported AE regardless of causality. The most frequently reported AEs were fatigue 
(54.9%), decreased appetite (35.0%), diarrhea (34.3%), nausea (30.1%), and cough (29.4%). 
Treatment-related AEs were reported in 230 (75.2%) of the 306 subjects. The most frequently 
reported treatment-related AEs were fatigue (28.1%), rash (14.7%), diarrhea (13.4%), and
pruritus (10.5%). Most treatment-related AEs were low grade. Treatment-related high grade 
(Grade 3 - 4) AEs were reported in 52 (17.0%) of subjects. The most common treatment-related 
high grade AEs were fatigue (2.3%) and diarrhea (1%). Drug related SAEs occurred in 11.5% of 
subjects. Grade 3 - 4 drug-related SAEs reported in at least 2 subjects included: diarrhea 
(3 subjects, 1.0%), pneumonitis (3 subjects, 1.0%), pneumonia (2 subjects, 0.7%) and lipase 
increased (2 subjects, 0.7%).
Select AE categories (events with a potential inflammatory mechanism requiring more frequent 
monitoring and/or unique intervention such as immunosuppressants and/or endocrine 
replacement therapy) include: GI AEs, pulmonary AEs, renal AEs, hepatic AEs, skin AEs, and 
endocrinopathies. In addition, select AEs include a category for infusion reactions. Each 
category is composed of a discrete set of preferred terms, including those of greatest clinical 
relevance. These select AEs are considered events of interest based on the mechanism of action 
and were previously referred to as immune-related AEs or immune-mediated AEs. Most high 
grade events resolved following the treatment guidelines for the treatment of pulmonary events, 
GI events, hepatic events, renal events, and endocrine events, respectively. Overall, the safety 
profile at 3 mg/kg (n = 54) was similar to safety profile across the dose ranges from 0.1 mg/kg to 
10 mg/kg (n = 306).
Treatment-related AEs leading to discontinuation were reported in 32 (10.5%) of the 306 treated 
subjects on CA209003. The most frequent of these were pneumonitis (8 subjects; 2.6%) and 
colitis (3 subjects; 1.0%). There were 3 (1%) drug related deaths; each occurred after 
development of pneumonitis.
CA209037 is an ongoing Phase 3, open-label study of nivolumab (3 mg/kg IV Q2W) vs 
investigator’s choice therapy in subjects with previously-treated advanced melanoma. As of 
30-Apr-2014, 268 subjects have been treated with 3 mg/kg IV nivolumab in CA209037 with 
Revised Protocol No: 03
Date: 20-Mar-2018
16
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
safety results as outlined below (source document interim CSR, DCN930081508) that are 
consistent with the Phase 1 experience of CA209003.
In CA209037, nivolumab-related AEs of any grade occurred in 67.5% of subjects. Of the 
268 subjects treated with nivolumab, 255 (95.1%) subjects had at least 1 reported AE regardless 
of causality. The most frequently reported treatment-related AEs were fatigue (25.0%), pruritus 
(16.0%), diarrhea (11.2%), and nausea (9.3%). Most treatment-related AEs were low grade. 
Treatment -related high grade (Grade 3 - 4) AEs were reported in 24 (9.0%) of subjects. The 
most common treatment-related high grade AEs were fatigue (0.7 %), anemia (0.7%), diarrhea 
(0.4%), and vomiting (0.4%). Drug-related SAEs occurred in 4.5% of subjects. Grade 3 - 4 drug 
related SAEs reported in at least 2 subjects included diarrhea (2 subjects, 0.7%). In addition, 
drug related SAE of hyperglycemia occurred in 0.7%.
Select AE categories (events with a potential inflammatory mechanism requiring more frequent 
monitoring and/or unique intervention such as immunosuppressants and/or endocrine 
replacement therapy) were:
•
Skin (29.1%) including pruritus (16.0%) and rash (9.3%)
•
GI (11.6%) including diarrhea (11.2%) and colitis (1.1%)
•
Endocrine (7.8%) including hypothyroidism (7.8%) and hyperthyroidism (1.9%)
•
Hepatic (4.5%) including AST increased (4.1%) and ALT increased (2.6%)
•
Pulmonary (2.2%) including pneumonitis (1.9%)
•
Hypersensitivity/infusion reaction (1.9%)
•
Renal (1.5%) including increased creatinine (0.7%), increased urea (0.4%), and 
tubulointerstitial nephritis (0.4%).
In general, these select AEs were considered by the investigator to be related to study drug, 
except for AEs in the hepatic and renal select AE categories. There were few high-grade select 
AEs (n = 20), and the majority of high-grade events (13 of 20) subsequently resolved, including 
those for which immunosuppressive therapy was not initiated.
Treatment-related AEs leading to discontinuation were reported in 6 (2.2%) of the 268 treated 
subjects in CA209037 including single events of colitis, pancreatitis, increased ALT, increased 
lipase, autoimmune neuropathy, and demyelination. There were no deaths due to drug related 
toxicity in CA209037; however, 1 subject experienced drug-related Grade 5 hypoxia, possibly 
pneumonitis, in the setting of lymphangitic spread and possible pneumonia.
Taken together, these data from studies from CA209003 and CA209037 highlight the acceptable 
safety profile with similar trends in AEs in the 574 subjects treated with nivolumab in these 
2 studies. Available safety data in SCLC subjects as described in Section 1.1.3.2 do not hint 
towards a different safety profile in SCLC compared to the tumor types investigated in studies 
CA209003 and CA209037. Additional details on the safety profile of nivolumab, including 
results from other clinical studies, are also available in the BMS-936558 (nivolumab) IB.
Revised Protocol No: 03
Date: 20-Mar-2018
17
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
1.1.3.4
Standard of Care for the Treatment of Relapsed or Recurrent SCLC
Although SCLC is very responsive to initial treatment, most patients relapse with relatively 
resistant disease16
The National Comprehensive Cancer Network (NCCN)
guidelines 
recommend for second- or later-line treatment enrollment in a clinical trial. For patients with a 
relapse > 6 months after completion of the first-line treatment, the original treatment regimen can 
be considered, although no Phase 3 study has proven an overall survival benefit of this approach. 
Other single agent chemotherapy options include paclitaxel, docetaxel, topotecan, irinotecan, 
temozolomide, gemcitabine, ifosfamide, vinorelbine, etoposide, or CAV (cyclophosphamide, 
doxorubicin, vincristine). All of these recommendations are category 2A per NCCN categories of 
evidence and consensus, except for the treatment of patients with a relapse > 2 to 3 months up to 
6 months post completion of first-line treatment, where topotecan has a Phase 3 proven overall 
survival advantage and a category 1 recommendation. Similarly, the ESMO SCLC clinical 
practice guidelines which were also endorsed by the Japanese Society of Medical Oncology 
(JSMO) recommend a clinical trial participation for refractory patients and resistant patients with 
early relapse (< 6 weeks), topotecan for patients having resistant or sensitive relapse with CAV 
being an alternative option, and for patients with sensitive relapse reintroduction of the first-line 
regimen.17 Amrubicin is approved in Japan for the treatment of SCLC patients.
1.1.3.5
Rationale for Use of Nivolumab Monotherapy as Experimental Agent
(Arm A)
Substantial monotherapy clinical activity has been observed in ≥second-line SCLC subjects 
treated in the ongoing Phase 1 study of nivolumab (CA209032). The ORR was 15% for subjects 
with nivolumab with long lasting responses up to 251 days, all ongoing at the time of the data cut 
off. The ORR with topotecan in a second-line SCLC Phase 3 trial was 16.9%, however, the 
response duration only 4.2 months, at 6 months all but one patient had progressed. Although the 
ORR with nivolumab in the heavily pretreated SCLC subjects is in the same range as the ORR 
under topotecan therapy, the response duration for subjects treated with nivolumab indicates 
toward a potential overall survival benefit in a Phase 3 trial. The use of nivolumab monotherapy 
for the experimental arm appears to be justified.
1.1.4
Rationale to Support Topotecan and Amrubicin as Comparators
(Arm B)
As described in Section 1.1.3.4, topotecan is the only treatment with proven overall survival 
benefit in a larger randomized trial and recommended by NCCN and ESMO treatment guidelines 
for patients with platinum resistant and sensitive disease with a relapse less than 6 months post 
completion of first-line treatment. The recommendation to reintroduce the first-line regimen for 
patients with a disease relapse more than 6 months post first-line treatment completion is not 
based on a Phase 3 randomized trial actually showing improved overall survival. Therefore, it is 
justified to use topotecan in Study CA209331 also as a control agent for subjects with a longer 
than 6 months treatment free interval. Topotecan is approved in the US and Europe for the 
second-line treatment of platinum resistant and sensitive patients. Oral topotecan was found to 
demonstrate similar efficacy and safety to IV topotecan in a randomized Phase 3 study, and will 
Revised Protocol No: 03
Date: 20-Mar-2018
18
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
be permitted in CA290331.18 Amrubicin is approved for the treatment of SCLC patients in Japan 
and commonly used in this setting. In a Phase 2 study with amrubicin the response rate in SCLC 
patients was 75.8% (25/33 patients).19 Topotecan and amrubicin are considered suitable 
comparators given that they are the only approved second-line treatments for SCLC in the EU, 
US, and Japan, respectively.
1.1.4.1
Topotecan and Amrubicin Safety Profile
The safety profile of topotecan and amrubicin is characterized mainly by myelotoxicity (Table 
1.1.4.1-1).
Table 1.1.4.1-1:
Most Common Grade > 3 Treatment-emergent Adverse Events 
(Occurring in > 5% of Patients)
Amrubicin
(N = 408)
Topotecan
(N = 197)
Adverse Event
No.
%
No.
%
Hematologic
Anemia
65
15.9
60
30.5
Febrile neutropenia
41
10.0
6
3.0
Leukopenia
62
15.2
43
21.8
Neutropenia
169
41.4
106
53.8
Thrombocytopenia
86
21.1
107
54.3
Nonhematologic
Dyspnea
18
4.4
13
6.6
Fatigue
43
10.5
24
12.2
Hyponatremia
21
5.1
11
5.6
Infections
64
15.7
19
9.6
Pneumonia
27
6.6
6
3.0
Source: Adapted from Von Pawel et al, JCO, Dec 201410
1.1.5
Rationale for Open-label Study Design
This study will use an open-label design. Due to the obvious difference in chemotherapy and 
immunotherapy related toxicities, the different schedules and durations of therapy in the 
treatment arms, different dose modification rules for safety management, and different 
premedication requirements according to chemotherapy, an open-label design is appropriate. An 
open-label design will also help ensure that immune-related toxicities in subjects receiving 
immunotherapy are promptly identified and managed.
Revised Protocol No: 03
Date: 20-Mar-2018
19
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
1.1.6
Rationale to Support Nivolumab Monotherapy Flat Dose (Arm A)
Nivolumab monotherapy has been extensively studied in NSCLC patient population in studies 
CA209003, CA209063, CA209017, and CA209057 with body weight normalized 
dosing (mg/kg). Nivolumab pharmacokinetics (PK) and exposures of subjects in these studies 
have been characterized by population pharmacokinetic (PPK) analysis of data collected in these 
studies, together with PK data from several Phase 1, 2, and 3 clinical studies of nivolumab 
monotherapy in solid tumors. Nivolumab PK was determined to be linear, with dose proportional 
exposures over a dose range of 0.1 to 10 mg/kg. Nivolumab clearance and volume of distribution 
was found to increase with increasing body weight, but the increase was less than proportional, 
indicating that a mg/kg dose represents an over-adjustment for the effect of body weight on 
nivolumab PK. Conversely, given the relationship between nivolumab PK and body weight, a 
flat dose is expected to lead to lower exposures in heavier patients, relative to the exposures in 
lighter patients. Table 1.1.6-1 presents summary statistics of the estimated nivolumab 
steady-state trough, peak and time-averaged concentration (Cminss, Cmaxss, and Cavgss, 
respectively) in NSCLC subjects receiving 3 mg/kg, together with corresponding statistics of 
exposures predicted for a flat nivolumab dose of 240 mg. It should be noted that a dose of 
240 mg nivolumab is identical to a dose of 3 mg/kg for subjects weighing 80 kg, which is the 
approximate median body weight of NSCLC subjects in the 3 Phase 2 and 3 clinical studies of 
nivolumab monotherapy in NSCLC patients (CA209017, CA209057, and CA209063). As 
evident from the data presented in Table 1.1.6-1, the geometric mean values of Cminss, Cmaxss, 
and Cavgss with flat dosing are slightly (< 15%) higher than that produced by a 3 mg/kg dose, 
and the coefficient of variation (cv%) in these measures of exposure are only slightly (< 10%) 
greater than that of 3 mg/kg dosing.
Table 1.1.6-1:
Summary Statistics of Nivolumab Steady-state Exposure
Nivolumab Dose
Cminss Geo. Mean 
[ug/mL] (cv%)
Cmaxss Geo. Mean 
[ug/mL] (cv%)
Cavgss Geo Mean 
[ug/mL] (cv%)
240 mg
61.5 (44.6)
133.7 (35.0)
84.2 (38.2)
3 mg/kg
54.7 (41.9)
118.9 (31.8)
73.3 (35.6)
Nivolumab has been shown to be safe and well tolerated up to a dose level of 10 mg/kg, and the 
relationship between nivolumab exposure produced by 3 mg/kg and efficacy has been found to 
be relatively flat. Taken together, the PK, safety, and efficacy data indicate that the safety and 
efficacy profile of 240 mg nivolumab will be similar to that of 3 mg/kg nivolumab.
Based on these clinical results, the experimental arm in CA209331 will be nivolumab 
monotherapy 240 mg Q2W for subjects with relapsed SCLC.
1.1.7
Rationale for Shorter Infusion Times for Nivolumab
Long infusion times place a burden on patients and treatment centers. Establishing that 
nivolumab can be safely administered using shorter infusion times of 30 minutes duration will 
diminish the burden provided no change in safety profile.
Revised Protocol No: 03
Date: 20-Mar-2018
20
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Previous clinical studies of nivolumab monotherapy have used a 60-minute infusion duration for 
nivolumab (1 - 3 mg/kg). However, nivolumab has been administered safely over 60 minutes at 
doses ranging up to 10 mg/kg over long treatment duration. In Study CA209010, (a Phase 2, 
randomized, 
double-blinded, 
dose-ranging 
study 
of 
nivolumab 
in 
subjects 
with 
advanced/metastatic clear cell RCC) a dose association was observed for infusion site reactions 
and hypersensitivity reactions (1.7% at 0.3 mg/kg, 3.7% at 2 mg/kg and 18.5% at 10 mg/kg). All 
the events were Grade 1 - 2 and were manageable. An infusion duration of 30 minutes for 
3 mg/kg nivolumab (30% of the dose provided at 10 mg/kg) is not expected to present any safety 
concerns compared to the prior experience at 10 mg/kg nivolumab dose infused over a 60-minute 
duration.
Overall, infusion reactions including high-grade hypersensitivity reactions have been uncommon 
across the nivolumab program. A change in safety profile is not anticipated with 30-minute 
infusion of nivolumab.
1.1.8
Rationale for Collection of Tumor Tissue and Evaluation of Tumor PD-
L1 Expression and Tumor Mutational Burden as Potential Predictive 
Biomarkers
The role of PD-L1 as a potential predictive biomarker in SCLC is unknown. Preliminary internal 
data from SCLC tumor samples show that less than 10% of tumor samples have ≥5% PD-L1 
positive tumor cells. A preliminary analysis of tumor samples in Study CA209032 showed no 
suggestion of a correlation of PD-L1 expression and tumor shrinkage under nivolumab therapy. 
Recently, expression of PD-L1 was shown to be positively correlated with a LD stage, and to be 
an independently predictive factor of a favorable overall survival versus PD-L1-negative 
tumors.20
In order to more thoroughly assess the role of PD-L1 protein expression as a predictive 
biomarker in SCLC, archival or recent tumor tissue will be collected prospectively from all 
randomized subjects in this study, and a retrospective analysis of efficacy by PD-L1 expression 
status will be conducted. Subjects enrolled to CA209331 will not be selected or stratified by 
PD-L1 expression status. However, based on preliminary PD-L1 prevalence estimates in SCLC a 
reasonable number of PD-L1 positive subjects are anticipated to accrue to each treatment arm for 
an exploratory analysis.
In addition, tumor mutational burden will be evaluated as an independent predictive biomarker 
for efficacy, following recently presented data from the CA209032 SCLC cohort,21 as part of the 
exploratory analyses.
1.1.9
Rationale for Permitting Continued Treatment in Select Cases of 
Progressive Disease
Accumulating clinical evidence indicates some subjects treated with immune system stimulating 
agents may develop progression of disease (by conventional response criteria) before 
demonstrating clinical objective responses and/or stable disease. This phenomenon was observed 
in a Phase 1 study of nivolumab14 and also in combination with ipilimumab.22 Two hypotheses 
have been put forth to explain this phenomenon. First, enhanced inflammation within tumors 
Revised Protocol No: 03
Date: 20-Mar-2018
21
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
could lead to an increase in tumor size which would appear as enlarged index lesions and as 
newly visible small non-index lesions. Over time, both the malignant and inflammatory portions 
of the mass may then decrease leading to overt signs of clinical improvement. Alternatively, in 
some individuals, the kinetics of tumor growth may initially outpace anti-tumor immune activity. 
With sufficient time, the anti-tumor activity will dominate and become clinically apparent. 
Therefore subjects randomized to nivolumab monotherapy will be allowed to continue study 
therapy after initial investigator-assessed Response Evaluation Criteria in Solid Tumors 
(RECIST 1.1) defined progression if they are assessed to be deriving clinical benefit and 
tolerating study drug (Section 4.5.4). Such subjects must discontinue study therapy upon 
evidence of further progression.
1.2
Research Hypothesis
Treatment with nivolumab will increase OS as compared with chemotherapy in subjects with 
relapsed SCLC treated with prior platinum-based, first-line chemotherapy.
1.3
Objectives(s)
1.3.1
Primary Objectives
To compare the OS of nivolumab versus chemotherapy in subjects with relapsed SCLC after 
platinum-based, first-line chemotherapy.
1.3.2
Secondary Objectives
Secondary objectives are:
•
To compare the PFS of nivolumab versus chemotherapy
•
To compare the ORR of nivolumab versus chemotherapy.
1.3.3
Exploratory Objectives
The exploratory objectives are:
•
To evaluate the safety and tolerability of nivolumab versus chemotherapy
•
To characterize pharmacokinetics of nivolumab and explore exposure response 
(exposure-safety and exposure-efficacy) relationships with respect to selected safety and 
efficacy endpoints
•
To explore PD-L1 expression as an independent predictive biomarker for OS, ORR, or PFS 
in nivolumab and chemotherapy groups
•
To explore tumor mutational burden expression as an independent predictive biomarker for 
efficacy in nivolumab and chemotherapy groups
•
To correlate potential predictive biomarkers in peripheral blood and tumor specimens, 
including proteins involved in regulating immune responses (eg, 
, PD-L1, 
), 
mutational as well as immunohistochemistry (IHC) spectrum, with endpoints such as ORR, 
PFS and OS in nivolumab and chemotherapy groups
•
 
 
 
 
 
Revised Protocol No: 03
Date: 20-Mar-2018
22
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
•
To characterize immunogenicity of nivolumab
•
To evaluate the proportion of subjects with meaningful symptom deterioration by 12 weeks
and by 24 weeks, as measured using the Lung Cancer Symptom Scale (LCSS) average 
symptom burden index (ASBI), between nivolumab and chemotherapy groups
•
To evaluate the time to symptom deterioration (TTSD), as measured by the average symptom 
burden index (ASBI) of the Lung Cancer Symptom Scale (LCSS), in subjects receiving 
nivolumab versus chemotherapy
•
To assess the subject’s overall health status using the EQ-5D index and visual analog scale in 
nivolumab and chemotherapy groups.
1.4
Product Development Background
Nivolumab is in clinical development for the treatment of subjects with NSCLC, RCC, 
glioblastoma and other cancer types. Recently, nivolumab was approved for the treatment of 
patients with advanced squamous NSCLC and melanoma.
In a Phase 1/2 trial in subjects with heavily pretreated SCLC, nivolumab monotherapy showed 
an ORR of 15%.23 Study CA209331 will be the first Phase 3 study in the clinical development 
program for SCLC and will evaluate the efficacy and safety of nivolumab monotherapy, as
second-line therapy,
in subjects with relapsed SCLC after platinum-based first-line 
chemotherapy.
1.5
Overall Risk/Benefit Assessment
Subjects with SCLC who relapse or progress after platinum based first-line therapy represent a 
great unmet medical need. Responses to salvage chemotherapy are short lived and the overall 
survival benefit of chemotherapy is modest. The clinical activity of nivolumab monotherapy 
observed to date in SCLC suggests the potential for improved clinical outcomes relative to 
approved chemotherapy. However, nivolumab has not been directly compared to any approved 
chemotherapy in SCLC previously. Topotecan, the only approved 2nd line treatment for SCLC in 
the US and Europe, has a well characterized AE profile consistent with cytotoxic chemotherapy, 
such as pancytopenia including febrile neutropenia, nausea, fatigue, vomiting, stomatitis, fever, 
and diarrhea. Amrubicin is approved for SCLC in Japan and its safety profile is characterized as 
well by pancytopenia including febrile neutropenia. Nivolumab can cause clinically relevant AEs 
including liver toxicities, thyroiditis, pneumonitis, and diarrhea. The activity and manageable AE
profile observed with nivolumab supports a head-to-head evaluation versus chemotherapy in 
second-line SCLC. To assure an ongoing favorable benefit-risk assessment for subjects enrolled 
onto CA209331, an independent Data Monitoring Committee (DMC) will be utilized to monitor 
the activity and safety of nivolumab versus chemotherapy throughout the conduct of the trial.
2
ETHICAL CONSIDERATIONS
2.1
Good Clinical Practice
This study will be conducted in accordance with Good Clinical Practice (GCP), as defined by the 
International Conference on Harmonisation (ICH) and in accordance with the ethical principles 
Revised Protocol No: 03
Date: 20-Mar-2018
23
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
underlying European Union Directive 2001/20/EC and the United States Code of Federal 
Regulations, Title 21, Part 50 (21CFR50).
The study will be conducted in compliance with the protocol. The protocol and any amendments 
and the subject informed consent will receive Institutional Review Board/Independent Ethics 
Committee (IRB/IEC) approval/favorable opinion prior to initiation of the study.
All potential serious breaches must be reported to Bristol-Myers Squibb (BMS) immediately. A 
serious breach is a breach of the conditions and principles of GCP in connection with the study 
or the protocol, which is likely to affect, to a significant degree, the safety or physical or mental 
integrity of the subjects of the study or the scientific value of the study.
Personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks.
This study will not use the services of study personnel where sanctions have been invoked or 
where there has been scientific misconduct or fraud (eg, loss of medical licensure, debarment). 
2.2
Institutional Review Board/Independent Ethics Committee 
Before study initiation, the investigator must have written and dated approval/favorable opinion 
from the IRB/IEC for the protocol, consent form, subject recruitment materials (eg, 
advertisements), and any other written information to be provided to subjects. The investigator or 
BMS should also provide the IRB/IEC with a copy of the Investigator Brochure or product 
labeling information to be provided to subjects and any updates. 
The investigator or BMS should provide the IRB/IEC with reports, updates and other 
information (eg, expedited safety reports, amendments, and administrative letters) according to 
regulatory requirements or institution procedures.
2.3
Informed Consent
Investigators must ensure that subjects are clearly and fully informed about the purpose, potential 
risks, and other critical issues regarding clinical studies in which they volunteer to participate. 
In situations where consent cannot be given to subjects, their legally acceptable representatives
(as per country guidelines) are clearly and fully informed about the purpose, potential risks, and 
other critical issues regarding clinical studies in which the subject volunteers to participate. 
BMS will provide the investigator with an appropriate (ie, Global or Local) sample informed 
consent form which will include all elements required by ICH, GCP and applicable regulatory 
requirements. The sample informed consent form will adhere to the ethical principles that have 
their origin in the Declaration of Helsinki.
Investigators must:
1) Provide a copy of the consent form and written information about the study in the language 
in which the subject is most proficient prior to clinical study participation. The language 
must be non-technical and easily understood. 
Revised Protocol No: 03
Date: 20-Mar-2018
24
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
2) Allow time necessary for subject or subject's legally acceptable representative to inquire 
about the details of the study.
3) Obtain an informed consent signed and personally dated by the subject or the subject's 
legally acceptable representative and by the person who conducted the informed consent 
discussion. 
4) Obtain the IRB/IEC’s written approval/favorable opinion of the written informed consent 
form and any other information to be provided to the subjects, prior to the beginning of the 
study, and after any revisions are completed for new information.
5) If informed consent is initially given by a subject’s legally acceptable representative or legal 
guardian, and the subject subsequently becomes capable of making and communicating his 
or her informed consent during the study, consent must additionally be obtained from the 
subject.
6) Revise the informed consent whenever important new information becomes available that is 
relevant to the subject's consent. The investigator, or a person designated by the investigator, 
should fully inform the subject or the subject's legally acceptable representative or legal 
guardian, of all pertinent aspects of the study and of any new information relevant to the 
subject's willingness to continue participation in the study. This communication should be 
documented. 
The confidentiality of records that could identify subjects must be protected, respecting the 
privacy and confidentiality rules applicable to regulatory requirements, the subjects' signed ICF 
and, in the US, the subjects’ signed Health Insurance Portability and Accountability Act 
(HIPAA) Authorization.
The consent form must also include a statement that BMS and regulatory authorities have direct 
access to subject records. 
Subjects unable to give their written consent (eg, stroke or subjects with or severe dementia) may 
only be enrolled in the study with the consent of a legally acceptable representative. The subject 
must also be informed about the nature of the study to the extent compatible with his or her
understanding, and should this subject become capable, he or she should personally sign and date 
the consent form as soon as possible. The explicit wish of a subject who is unable to give his or 
her written consent, but who is capable of forming an opinion and assessing information to 
refuse participation in, or to be withdrawn from, the clinical study at any time should be 
considered by the investigator.
The rights, safety, and well-being of the study subjects are the most important considerations and 
should prevail over interests of science and society.
3
INVESTIGATIONAL PLAN
3.1
Study Design and Duration
This is a randomized, open-label, two-arm, multicenter, Phase 3 study in adult subjects with 
relapsed SCLC treated with prior platinum-based, first-line chemotherapy. Subjects must have 
had at least 4 cycles of platinum-based, first-line chemotherapy, or if they received less than 
Revised Protocol No: 03
Date: 20-Mar-2018
25
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
4 cycles, they must have had a best overall response (BOR) of a partial or complete response
after completion of chemotherapy.
Approximately 480 subjects will be randomized in a 1:1 ratio to treatment with either nivolumab 
(Arm A) or chemotherapy (either topotecan or amrubicin, Arm B) in the Global Population. In 
addition, this study includes a cohort of at least 78 additional randomized patients from China 
(~ 16% of the global number of randomized subjects). The primary population for safety and 
efficacy analysis will include subjects from the Global Population as well as subjects from the 
additional China cohort, leading to a total sample size of about 560 subjects.
Subjects will be stratified according to the following factors:
•
Response to first-line platinum based treatment: platinum sensitive (progression-free interval 
≥90 days after completion of platinum therapy) vs platinum resistant (progression-free 
interval < 90 days after completion of platinum therapy)
•
Brain metastases at baseline: yes vs no.
Treatments will be administered as follows: 
Arm A:
•
Nivolumab 240 mg (flat dose) on Day 1 of a 14-day cycle as an IV infusion over 30 minutes.
Arm B:
•
Topotecan: 1.5 mg/m2 administered as 30-minute IV infusion or 2.3 mg/m2 administered as 
an oral capsule (round dose to nearest 0.25 mg) once daily on Days 1 to 5 of a 21-day cycle.
•
Amrubicin (upon investigator’s choice, where locally approved for 2nd line SCLC
treatment): 40 mg/m2 administered as 5-minute IV infusion once daily on Days 1 to 3 of a 
21-day cycle.
On-study tumor assessments will begin at Week 6 post randomization (± 5 days) and be 
performed every 6 weeks (± 5 days) until Week 30. After Week 30, tumor assessments will be 
performed every 12 weeks (± 5 days) until disease progression (or until discontinuation of study 
drug in subjects receiving nivolumab beyond investigator-assessed progression [Section 4.5.4]), 
lost to follow-up, withdrawal of study consent, or the study ends.
Enrollment will end after approximately 560 subjects have been randomized (including ~78 
additional subjects in China).
The primary endpoint of the study is OS.
The study design schematic is presented in Figure 3.1-1.
Accrual duration is expected to be approximately 18 months; overall study duration will be 
approximately 34 months (18 months accrual + minimum follow up of 16 months). The study 
will end when analysis of survival is complete. Additional survival follow-up may continue for 
up to 5 years from the time of this analysis.
Revised Protocol No: 03
Date: 20-Mar-2018
26
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
A DMC will be utilized to provide general oversight and safety considerations for this study, 
CA209331 (Section 7).
Figure 3.1-1:
Study Schematic
a Subjects must have had at least 4 cycles of platinum-based, first-line chemotherapy, or if they received less than 
4 cycles of platinum-based first-line chemotherapy, they must have had a best overall response (BOR) of at least a 
partial or complete response after completion of chemotherapy.
3.1.1
Study Phases
The study is divided into the following phases: Screening, Treatment, and Follow-up
3.1.1.1
Screening
•
Screening begins after the subject signs the informed consent form (ICF). Subjects will 
undergo screening evaluations to determine eligibility.
Revised Protocol No: 03
Date: 20-Mar-2018
27
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
•
Tumor tissue (archival or recent tumor biopsy) must be available and received by the central 
lab for correlative studies in order for a subject to be randomized. Subjects must consent to 
allow the acquisition of tumor tissue by study personnel for performance of the correlative 
studies.
•
Baseline disease or tumor assessments should be performed within 28 days of randomization.
•
The screening phase either ends with confirmation of full eligibility and randomization of the 
subject or with the confirmation that the subject is a screen failure.
Subject is assessed for study eligibility as described in Table 5.1-1.
3.1.1.2
Treatment
•
The treatment phase begins with the randomization call to the interactive voice response 
system (IVRS). The subject is randomly assigned to one of the 2 treatment arms. Treatment 
should begin within 3 business days of randomization.
•
Study drug is administered as an IV infusion or oral capsule beginning on Treatment Day 1 
of each cycle (frequency is dependent on the treatment arm) until disease progression, 
discontinuation due to toxicity, withdrawal of consent, or the study ends.
•
Subjects will be evaluated for response according to the RECIST 1.1 criteria. Radiographic 
assessments will be obtained in all treatment arms at Week 6 (± 5 days) and every 6 weeks 
from Week 6 (± 5 days) for the first 30 weeks, and subsequently every 12 weeks (± 5 days), 
until disease progression (or until discontinuation of study drug in subjects receiving 
nivolumab beyond progression), lost to follow-up, withdrawal of study consent, or the study 
ends.
•
Subjects 
in 
Arm 
A 
may 
continue 
treatment 
beyond 
investigator-assessed 
RECIST 1.1-defined progression as defined in Section 4.5.4.
•
This phase ends when the subject is discontinued from study drug.
Study assessments are to be collected as outlined in Table 5.1-2 or Table 5.1-3 for subjects 
randomized to nivolumab monotherapy or chemotherapy, respectively.
3.1.1.3
Follow up
•
Begins when the decision to discontinue a subject from study drug is made (no further 
treatment with study drug).
•
Follow-up consists of 2 follow-up visits within approximately 100 days of the last dose of 
study drug followed by survival visits that will continue every 3 months after Follow-up 
Visit 2 until death, lost to follow-up, or withdrawal of study consent.
•
Subjects who discontinue study drug for reasons other than disease progression will continue 
to have radiographic assessments every 6 weeks (± 5 days) for the first 30 weeks, and 
subsequently every 12 weeks (± 5 days), until disease progression (or until discontinuation of 
study drug in subjects receiving nivolumab beyond progression), lost to follow-up, 
withdrawal of study consent, or the study ends.
Revised Protocol No: 03
Date: 20-Mar-2018
28
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Study assessments are to be collected as outlined in Table 5.1-4.
3.2
Post Study Access to Therapy
At the conclusion of the study, subjects who continue to demonstrate clinical benefit will be 
eligible to receive BMS supplied study drug consistent with the original study drug assignment. 
Study drug will be provided via an extension of the study, a rollover study requiring approval by 
responsible health authority and ethics committee or through another mechanism at the discretion 
of BMS. BMS reserves the right to terminate access to BMS supplied study drug if any of the 
following occur: a) the marketing application is rejected by responsible health authority; b) the 
study is terminated due to safety concerns; c) the subject can obtain medication from a 
government sponsored or private health program; or d) therapeutic alternatives become available 
in the local market.
3.3
Study Population
For entry into the study, the following criteria MUST be met.
3.3.1
Inclusion Criteria
1. Signed Written Informed Consent
a) Subjects must have signed and dated an IRB/IEC approved written informed consent 
form in accordance with regulatory and institutional guidelines. This must be obtained 
before the performance of any protocol related procedures that are not part of normal 
subject care.
b) Subjects must be willing and able to comply with scheduled visits, treatment schedule, 
laboratory tests and other requirements of the study.
2. Target Population
a) Histologically or cytologically confirmed SCLC. 
b) Subjects with either limited or extensive disease stage at the initial diagnosis are eligible.
c) Must have recurrence or progression after platinum-based, first-line chemotherapy or 
chemoradiation therapy for the treatment of limited or extensive disease stage SCLC:
i)
Subjects must have received at least 4 cycles of platinum-based, first-line
chemotherapy for either limited or extensive stage disease or if they received less 
than 4 cycles, they must have had a best overall response (BOR) of a partial or 
complete response after completion of chemotherapy.
ii) Subjects must have had only 1 prior regimen of platinum-based, first-line treatment.
Subjects receiving maintenance therapy following platinum-based, first-line treatment 
are excluded.
d) Evaluable disease by CT/MRI per RECIST 1.1 criteria (Appendix 2).
e) Subject must have demonstrated disease progression based on at least one tumor 
assessment done after completion of chemotherapy and prior to randomization. The 
tumor assessment performed during screening will be used as a baseline for efficacy 
assessments.
Revised Protocol No: 03
Date: 20-Mar-2018
29
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
f)
A formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or unstained slides of 
tumor sample (archival or recent) must be available for biomarker evaluation, as 
described in Section 5.6.1. Specimens must be received by the central laboratory prior to 
randomization. Biopsy should be excisional, incisional or core needle. Fine needle 
aspiration is insufficient.
g) Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
h) Subject Re-enrollment: This study permits the re-enrollment of a subject that has 
discontinued the study as a pre-treatment failure (ie, subject has not been randomized/has 
not been treated). If re-enrolled, the subject must be re-consented. Only the screening 
procedures performed outside of the protocol specified timing (eg, > 28 days) must be 
repeated. 
i)
Any prior radiotherapy, including radiosurgery to metastases of the brain must have been 
completed at least 2 weeks prior to randomization.
3. Age and Reproductive Status
a) Males and females, ≥18 to years of age.
b) Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta-human chorionic 
gonadotrophin) within 24 hours prior to the start of study drug.
c) Women must not be breastfeeding.
d) WOCBP must agree to follow instructions for method(s) of contraception for the duration 
of treatment with plus 5 half-lives of nivolumab plus 30 days (duration of ovulatory 
cycle) for a total of 5 months post-treatment completion (for subjects treated in Arm A).
WOCBP must also agree to follow instructions for method(s) of contraception for the 
duration of treatment plus 5-half-lives of chemotherapy plus 30 days (duration of 
ovulatory cycle) for a total of 30 days post treatment completion or a duration specified 
by the local labels of the chemotherapy drugs received , whichever is longer (for subjects 
treated with Arm B).
e) Males who are sexually active with WOCBP must agree to follow instructions for 
method(s) of contraception for the duration of treatment with nivolumab plus 5 half-lives 
of nivolumab plus 90 days (duration of sperm turnover) for a total of 7 months post
treatment completion (for subjects treated in Arm A).
Males who are sexually active with WOCBP must also agree to follow instructions for 
method(s) of contraception for the duration of treatment with chemotherapy plus 
5 half-lives of chemotherapy plus 90 days (duration of sperm turnover) for a total of 
90 days post treatment completion or a duration specified by the local labels of the 
chemotherapy drugs received, whichever is longer (for subjects treated in Arm B).
f)
Azoospermic males and WOCBP who are continuously not heterosexually active are 
exempt from contraceptive requirements. However they must still undergo pregnancy 
testing as described in this section.
Revised Protocol No: 03
Date: 20-Mar-2018
30
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on 
the importance of pregnancy prevention and the implications of an unexpected pregnancy. 
Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on 
the use of highly effective methods of contraception. Highly effective methods of contraception 
have a failure rate of < 1% when used consistently and correctly.
At a minimum, subjects must agree to use one highly effective method of contraception as listed 
below:
HIGHLY EFFECTIVE METHODS OF CONTRACEPTION
Highly effective methods of contraception have a failure rate of < 1% when used consistently 
and correctly. WOCBP and female partners of male subjects, who are WOCBP, are expected to 
use one of the highly effective methods of contraception listed below. Male subjects must inform 
their female partners who are WOCBP of the contraceptive requirements of the protocol and are 
expected to adhere to using contraception with their partner. Contraception methods are as 
follows:
•
Progestogen only hormonal contraception associated with inhibition of ovulation.
•
Hormonal methods of contraception including oral contraceptive pills containing combined 
estrogen + progesterone, vaginal ring, injectables, implants and intrauterine devices (IUDs) 
such as Mirena®
•
Nonhormonal IUDs, such as ParaGard®
•
Bilateral tubal occlusion
•
Vasectomised partner with documented azoospermia 90 days after procedure
o
Vasectomised partner is a highly effective birth control method provided that partner is 
the sole sexual partner of the WOCBP trial participant and that the vasectomised partner 
has received medical assessment of the surgical success.
•
Intrauterine hormone-releasing system (IUS).
•
Complete abstinence*
o
*Complete abstinence is defined as the complete avoidance of heterosexual intercourse 
(refer to Glossary of Terms). 
o
Complete abstinence is an acceptable form of contraception for all study drug and must 
be used throughout the duration of the study treatment (plus 5 half-lives of the 
investigational drug plus 30 days).
o
It is not necessary to use any other method of contraception when complete abstinence is 
elected.
o
Subjects who choose complete abstinence must continue to have pregnancy tests as 
specified in Section 6.4. 
o
Acceptable alternate methods of highly effective contraception must be discussed in the 
event that the subject chooses to forego complete abstinence.
o
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the 
clinical trial and the preferred and usual lifestyle of the subject.
Revised Protocol No: 03
Date: 20-Mar-2018
31
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
MALE SUBJECTS WITH PARTNERS WHO ARE WOCBP:
Are required to use condoms, in addition to the requirement for their female partners who are
WOCBP to use a highly effective method of contraception listed above
UNACCEPTABLE METHODS OF CONTRACEPTION
•
Periodic abstinence (calendar, symptothermal, post-ovulation methods)
•
Withdrawal (coitus interruptus)
•
Spermicide only
•
Lactation amenorrhea method (LAM)
•
Vaginal sponge
•
progestin only pills
•
cervical cap with spermicide
•
a male and female condom must not be used together.
Note: Local laws and regulations may require use of alternative and/or additional contraception 
methods.
3.3.2
Exclusion Criteria
1. Target Disease Exceptions
a) Subject with untreated or symptomatic CNS metastases are excluded. Subjects are 
eligible if CNS metastases have been treated and subjects have neurologically returned to 
baseline (except for residual signs or symptoms related to the CNS treatment) for at least 
2 weeks prior to randomization. In addition, subjects must have been either off 
corticosteroids, or on a stable or decreasing dose of ≤10 mg daily prednisone (or 
equivalent) for at least 2 weeks prior to randomization. 
2. Medical History and Concurrent Diseases
a) Not applicable
b) Documented carcinomatous meningitis
c) Active, known or suspected autoimmune disease. Subjects with an autoimmune 
paraneoplastic syndrome requiring concurrent immunosuppressive treatment are 
excluded. However, subjects with type I diabetes mellitus, hypothyroidism only requiring 
hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not 
requiring systemic treatment, or conditions not expected to recur in the absence of an 
external trigger are permitted to enroll. 
d) A condition requiring systemic treatment with either corticosteroids (> 10 mg daily 
prednisone equivalent) or other immunosuppressive medications within 14 days of 
randomization. However, corticosteroids with minimal systemic absorption (inhaled or 
topical steroids or as specified in Section 3.4.3), and adrenal replacement steroid doses 
> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune 
disease
Revised Protocol No: 03
Date: 20-Mar-2018
32
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
e) Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 
antibody (including ipilimumab or any other antibody or drug specifically targeting 
T-cell co-stimulation or checkpoint pathways)
f)
Prior treatment with topotecan or amrubicin
g) Interstitial lung disease that is symptomatic or may interfere with the detection or 
management of suspected drug-related pulmonary toxicity
h) All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must 
have been resolved to grade 1 (National Cancer Institute Common Toxicity Criteria for 
Adverse Events [NCI CTCAE] version 4) or baseline before administration of study 
drug. Subjects with toxicities attributed to prior anti-cancer therapy that are not expected 
to resolve and resulted in long lasting sequelae, such as neuropathy after platinum based 
therapy, are permitted to enroll
i)
Other active malignancy requiring concurrent intervention
j)
Previous malignancies (except non-melanoma skin cancers, and the following in situ 
cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast) 
unless a complete remission was achieved at least 2 years prior to study entry AND no 
additional therapy is required during the study period
k) Known medical condition that, in the investigator’s opinion, would increase the risk 
associated with study participation or study drug administration or interfere with the 
interpretation of safety results
l)
Treatment with any chemotherapy, biologics for cancer, or investigational therapy within 
28 days of first administration of study drug (subjects with prior cytotoxic or 
investigational products < 4 weeks prior to treatment might be eligible after discussion 
between investigator and sponsor, if toxicities from the prior treatment have been 
resolved to CTC grade 1 level)
m) Major surgery or significant traumatic injury that is not recovered at least 14 days before 
the first dose of study drug
3. Physical and Laboratory Test Findings
a) Positive test for hepatitis B virus (HBV) using HBV surface antigen (HBVsAg) test or 
positive test for hepatitis C virus (HCV) using HCV ribonucleic acid (RNA) or HCV 
antibody test indicating acute or chronic infection. Subjects with a positive test for HCV 
antibody but no detection of HCV RNA indicating no current infection are eligible.
b) Known medical history of testing positive for human immunodeficiency virus (HIV) or 
known medical history of acquired immunodeficiency syndrome (AIDS)
c) Inadequate hematologic function defined by:
i)
White blood cells (WBCs) < 2000/mm3
ii) Absolute neutrophil count (ANC) < 1500/mm3, or 
iii) Platelet count < 100,000/mm3, or
iv) Hemoglobin level < 9 g/dL.
Revised Protocol No: 03
Date: 20-Mar-2018
33
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
d) Inadequate hepatic function as defined by either:
i)
Total bilirubin level ≥2.5 times the ULN, or
ii) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels 
≥2.5 times the ULN or ≥5 times the ULN if liver metastases are present.
e) Creatinine Clearance (Cockcroft-Gault) < 20 mL/min
4. Allergies and Adverse Drug Reaction
a) History of allergy or hypersensitivity to any of the study drugs or study drug components
5. Other Exclusion Criteria
a) Prisoners or subjects who are involuntarily incarcerated
b) Subjects who are compulsorily detained for treatment of either a psychiatric or physical 
(eg, infectious disease) illness.
Eligibility criteria for this study have been carefully considered to ensure the safety of the study 
subjects and that the results of the study can be used. It is imperative that subjects fully meet all 
eligibility criteria.
3.3.3
Women of Childbearing Potential
A Women of childbearing potential (WOCBP) is defined as any female who has experienced 
menarche and who has not undergone surgical sterilization (hysterectomy or bilateral 
oophorectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in 
a woman over age 45 years in the absence of other biological or physiological causes. In 
addition, females under the age of 55 years must have a serum follicle stimulating hormone, 
(FSH) level > 40mIU/mL to confirm menopause.
* Females treated with hormone replacement therapy, (HRT) are likely to have artificially 
suppressed FSH levels and may require a washout period in order to obtain a physiologic FSH 
level. The duration of the washout period is a function of the type of HRT used. The duration of 
the washout period below are suggested guidelines and the investigators should use their 
judgement in checking serum FSH levels. If the serum FSH level is > 40 mIU/ml at any time 
during the washout period, the woman can be considered postmenopausal:
•
1 week minimum for vaginal hormonal products (rings, creams, gels)
•
4 week minimum for transdermal products
•
8 week minimum for oral products
Other parenteral products may require washout periods as long as 6 months.
3.4
Concomitant Treatments
3.4.1
Prohibited and/or Restricted Treatments
The following medications are prohibited during the study:
Revised Protocol No: 03
Date: 20-Mar-2018
34
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
•
Immunosuppressive agents (except to treat a drug-related AE
or an autoimmune 
paraneoplastic syndrome). Subjects with an autoimmune paraneoplastic syndrome at 
enrollment requiring concurrent immunosuppressive treatment are not eligible.
•
Systemic corticosteroids > 10 mg daily prednisone equivalent, except as stated in 
Section 3.4.3 or to treat a drug-related AE. 
•
Any concurrent antineoplastic therapy (ie, chemotherapy, hormonal therapy, immunotherapy, 
standard or investigational agents for treatment of cancer or radiation therapy, except for 
palliative radiation therapy described in Section 3.4.2). On study radiation treatment to brain 
metastases is not permitted.
•
Surgical resection of tumor.
Supportive care for disease-related symptoms may be offered to all subjects on the trial.
Caution should be used regarding the use of herbal medications as there may be as yet unknown 
interactions with nivolumab. Discontinuation of the use of herbal medications prior to study 
enrollment is encouraged.
3.4.2
Other Restrictions and Precautions
Only non-target bone lesions that do not include lung tissue in the planned radiation field may 
receive palliative radiotherapy while on study treatment. Details of palliative radiotherapy should 
be documented in the source records and case report form (CRF). Details in the source records 
should include: dates of treatment, anatomical site, dose administered and fractionation schedule, 
and AEs. 
Subjects requiring palliative radiotherapy should be assessed for disease progression. Subjects 
considered as having progressive disease are required to discontinue study therapy, or in Arm A, 
if appropriate, continue nivolumab therapy as treatment beyond progression. Administration of 
additional nivolumab to subjects who experienced disease progression at the time of palliative 
radiotherapy should follow guidelines specified in Section 4.5.4 Treatment Beyond Disease 
Progression.
3.4.3
Permitted Therapy
Subjects are permitted the use of topical, ocular, intra-articular, intranasal, and inhalational 
corticosteroids (with minimal systemic absorption). Adrenal replacement steroid doses including 
doses > 10 mg daily prednisone are permitted. A brief (less than 3 weeks) course of 
corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune 
conditions (eg, delayed-type hypersensitivity reaction caused by a contact allergen) is permitted.
Subjects receiving topotecan or amrubicin may receive growth factors (including G-CSF and 
erythropoietin) at the discretion of the investigator.
Concomitant palliative and supportive care for disease related symptoms (including 
bisphosphonates and RANK-L inhibitors) is an allowed therapy (prior radiotherapy must have 
been completed at least 2 weeks prior to randomization per inclusion criterion 2i) in Section 
3.3.1. See Section 3.4.2 for guidance on concomitant palliative radiotherapy.
Revised Protocol No: 03
Date: 20-Mar-2018
35
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
3.5
Discontinuation of Subjects following any Treatment with Study Drug 
Subjects MUST discontinue investigational product (and non-investigational product at the 
discretion of the investigator) for any of the following reasons:
•
Disease progression as assessed by RECIST 1.1 criteria (Appendix 2), unless the subject 
is assigned to the nivolumab treatment arm and meets criteria for treatment beyond 
progression (Section 4.5.4).
•
Subject’s request to stop study treatment
•
Any clinical AE, laboratory abnormality or intercurrent illness which, in the opinion of 
the investigator, indicates that continued participation in the study is not in the best 
interest of the subject
•
Termination of the study by BMS
•
Loss of ability to freely provide consent through imprisonment or involuntarily
incarceration for treatment of either a psychiatric or physical (eg, infectious disease) 
illness
•
Additional protocol specified reasons for discontinuations, see Section 4.5.3.
In the case of pregnancy, the investigator must immediately notify the BMS Medical 
Monitor/designee of this event. In most cases, the study drug will be permanently discontinued in 
an appropriate manner. If the investigator determines a possible favorable benefit/risk ratio that 
warrants continuation of study drug, a discussion between the investigator and the BMS Medical 
Monitor/designee must occur.
All subjects who discontinue study drug should comply with protocol specified follow-up 
procedures as outlined in Section 5. The only exception to this requirement is when a subject 
withdraws consent for all study procedures including post-treatment study follow-up or loses the 
ability to consent freely (ie, is imprisoned or involuntarily incarcerated for the treatment of either 
a psychiatric or physical illness).
If study drug is discontinued prior to the subject’s completion of the study, the reason for the 
discontinuation must be documented in the subject’s medical records and entered on the 
appropriate CRF page.
3.6
Post Study Drug Study Follow up
In this study, overall survival is a key endpoint of the study. Post study follow-up is of critical 
importance and is essential to preserving subject safety and the integrity of the study. Subjects 
who discontinue study drug must continue to be followed for collection of outcome and/or 
survival follow-up data as required and in line with Section 5 until death or the conclusion of the 
study. BMS may request that survival data be collected on all randomized subjects outside of the 
protocol defined window (Table 5.1-4). At the time of this request, each subject will be contacted 
to determine their survival status unless the subject has withdrawn consent for all contact.
Revised Protocol No: 03
Date: 20-Mar-2018
36
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
3.6.1
Withdrawal of Consent
Subjects who request to discontinue study drug will remain in the study and must continue to be 
followed for protocol specified follow-up procedures. The only exception to this is when a 
subject specifically withdraws consent for any further contact with him/her or persons previously 
authorized by subject to provide this information. Subjects should notify the investigator of the 
decision to withdraw consent from future follow-up in writing, whenever possible. The 
withdrawal of consent should be explained in detail in the medical records by the investigator, as 
to whether the withdrawal is from further treatment with study drug only or also from study 
procedures and/or post treatment study follow-up, and entered on the appropriate CRF page. In 
the event that vital status (whether the subject is alive or dead) is being measured, publicly 
available information should be used to determine vital status only as appropriately directed in 
accordance with local law.
3.6.2
Lost to Follow-Up
All reasonable efforts must be made to locate subjects to determine and report their ongoing 
status. This includes follow-up with persons authorized by the subject as noted above. Lost to 
follow-up is defined by the inability to reach the subject after a minimum of three documented 
phone calls, faxes, or emails as well as lack of response by subject to one registered mail letter. 
All attempts should be documented in the subject’s medical records. If it is determined that the 
subject has died, the site will use permissible local methods to obtain the date and cause of death.
If investigator’s use of third-party representative to assist in the follow-up portion of the study 
has been included in the subject’s informed consent, then the investigator may use a 
Sponsor-retained third-party representative to assist site staff with obtaining subject’s contact 
information or other public vital status data necessary to complete the follow-up portion of the 
study. The site staff and representative will consult publicly available sources, such as public 
health registries and databases, in order to obtain updated contact information. If after all 
attempts, the subject remains lost to follow-up, then the last known alive date as determined by 
the investigator should be reported and documented in the subject’s medical records.
4
STUDY DRUG
Study drug includes both Investigational [Medicinal] Product (IP/IMP) and Non-investigational 
[Medicinal] Product (Non-IP/Non-IMP). All study drugs are listed in Table 4-1.
Revised Protocol No: 03
Date: 20-Mar-2018
37
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Table 4-1:
Study Drugs for BMS-936558 - Treatment Phase
Product Description / 
Class and Dosage Form
Potency
IP/Non-IMP
Blinded or Open 
Label
Packaging/
Appearance
Storage Conditions
(per label)
Nivolumab Solution for 
Injectiona
100 mg (10 mg/mL)
IP
Open Label
10 mL per vial/
5 or 10 vials per box
Vials contain clear to 
opalescent colorless to 
pale yellow liquid. May 
contain particles
2° to 8°C. Protect from 
light and freezing
Topotecan hydrochloride 
concentrate for solution 
for infusionb
4 mg (1 mg/mL)
IP
Open Label
4 mg per vial/
1 or 5 vials per box
Vials contain clear 
yellow to yellow/green 
solution
Store at 2° to 8°C. 
Protect from freezing 
and light. Store in outer 
carton.
Topotecan hydrochloride 
powder for infusionb
TBC
IP
Open Label
TBC
Store at 15° to 25°C. 
Protect from freezing 
and light. Store in outer 
carton.
Topotecan capsuleb
0.25 mg/ 1 mg
IP
Open Label
TBC
Store at 2° to 8°C. 
Protect from freezing 
and light. Store in outer 
carton.
Amrubicin hydrochloride 
powder for solution for 
injectionb
50 mg 
IP
Open Label
50 mg per vial/
1 vial per box
Vials contain 
yellow-red powder or 
mass
Store at 15° to 25°C.
a Labeled as either “BMS-936558-01” or “Nivolumab”
b For sites/countries in which the marketed product of topotecan and/or amrubicin, will be procured locally, the potency, packaging configuration and storage 
conditions may differ based on the locally available product.
Revised Protocol No: 03
Date: 20-Mar-2018
38
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
4.1
Investigational Product
An investigational product, also known as investigational medicinal product in some regions, is 
defined a pharmaceutical form of an active substance or placebo being tested or used as a 
reference in a clinical study, including products already with a marketing authorization but used 
or assembled (formulated or packaged) differently than the authorized form, or used for an 
unauthorized indication, or when used to gain further information about the authorized form.
The investigational product should be stored in a secure area according to local regulations. It is 
the responsibility of the investigator to ensure that investigational product is only dispensed to 
study subjects. The investigational product must be dispensed only from official study sites by 
authorized personnel according to local regulations.
In this protocol, investigational product(s) are:
•
Nivolumab
•
Topotecan
•
Amrubicin
4.1.1
Nivolumab
Nivolumab 240 mg (flat dose) on Day 1 of a 14-day cycle as an IV infusion over 30 minutes. 
Please refer to the current version of the Investigator Brochure and/or pharmacy reference sheets 
for complete storage, handling, preparation, and administration information for nivolumab.
4.1.2
Topotecan
Topotecan: 1.5 mg/m2 administered as 30-minute IV infusion or 2.3 mg/m2 administered as an 
oral capsule (round dose to nearest 0.25 mg) once daily on Days 1 to 5 of a 21-day cycle. Please 
refer to the current version of the Summary of Product Characteristics (SmPC), US Package 
Insert (USPI), or other country-specific labeling and/or pharmacy reference sheet for complete 
storage, handling, preparation, and administration information for topotecan.
4.1.3
Amrubicin
Amrubicin (upon investigator’s choice, where locally approved for 2nd line SCLC treatment): 
40 mg/m2 administered as 5-minute IV infusion once daily on Days 1 to 3 of a 21-day cycle. 
Please refer to the current version of the country-specific labeling and/or pharmacy reference 
sheet for complete storage, handling, preparation, and administration information for amrubicin.
4.2
Non-investigational Product
Other medications used as support or escape medication for preventative, diagnostic, or 
therapeutic reasons, as components of the standard of care for a given diagnosis, may be
considered as non-investigational products. 
In this protocol, non-investigational product(s) is/are: any pre-medications associated with the 
comparator arms and medications used to treat chemotherapy infusion-related reactions. Also, 
any medications used to treat nivolumab infusion-related reactions (eg. steroids). These non-
Revised Protocol No: 03
Date: 20-Mar-2018
39
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
investigational products should be sourced by the investigator sites if available and permitted by 
local regulations.
4.3
Storage and Dispensing
The product storage manager should ensure that the study drug is stored in accordance with the 
environmental conditions (temperature, light, and humidity) as determined by BMS. If concerns 
regarding the quality or appearance of the study drug arise, the study drug should not be 
dispensed and contact BMS immediately.
Study drug not supplied by BMS will be stored in accordance with the package insert.
Investigational product documentation (whether supplied by BMS or not) must be maintained 
that includes all processes required to ensure drug is accurately administered. This includes 
documentation of drug storage, administration and, as applicable, storage temperatures, 
reconstitution, and use of required processes (eg, required diluents, administration sets).
4.4
Method of Assigning Subject Identification
4.4.1
Screening
After informed consent has been obtained, the subject must be enrolled into the study by calling 
an interactive IVRS to obtain the subject number. The following information is required for 
subject registration:
•
Date of birth
•
Date of informed consent
•
Gender.
4.4.2
Randomization
Once a subject has been determined to meet eligibility criteria, site personnel will make another 
call to the IVRS. The following information is required for subject randomization:
•
Subject number
•
Confirmation that all randomization inclusion/exclusion are met
•
Confirmation that FFPE tumor tissue block or unstained slides were received by the central 
laboratory
•
Response to first-line platinum-based treatment: platinum sensitive vs platinum resistant
•
Brain metastases at baseline: yes vs no.
If the above are met, the IVRS will randomly assign subjects to treatment Arm A or Arm B in a 
1:1 ratio using a stratified permuted block randomization method with respect to the following 
stratification factors:
•
Response to first-line platinum based treatment: platinum sensitive vs platinum resistant 
•
Brain metastases at baseline: yes vs no.
Revised Protocol No: 03
Date: 20-Mar-2018
40
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
The first dose of study drug is to be administered within 3 business days following 
randomization.
Randomization will be performed based on a randomization schedule generated and maintained
by the Randomization Group within Bristol-Myers Squibb. 
The procedures for using the IVRS will be detailed in a separate document.
4.5
Selection and Timing of Dose for Each Subject
4.5.1
Dosing Schedule
The dosing schedule is detailed below Table 4.5.1-1.
Table 4.5.1-1:
Dosing Schedule
Week 1
Week 2 
Week 3
Week 4
Week 5
Week 6
Arm A
Nivolumab 
240 mga
q 2 weeks
Day 1
Nivolumab
Day 1
Nivolumab
Day 1
Nivolumab
Arm B
Topotecana
IV 1.5 mg/m2
or capsule 
2.3 mg/m2
or
Day 1 - 5
Topotecan
Day 1 - 5
Topotecan
Amrubicina
40 mg/m2
Day 1 - 3
Amrubicin
Day 1 - 3
Amrubicin
a Treatment continues until disease progression (or until discontinuation of study drug in subjects receiving 
nivolumab), discontinuation due to toxicity, withdrawal of consent, or the study ends.
All subjects will be monitored continuously for AEs while on study treatment. Treatment 
modifications (eg, dose delay, reduction, or discontinuation) will be based on specific laboratory 
and AE criteria, as described in Sections 4.5.2 and 4.5.3.
4.5.1.1
Nivolumab
For subjects randomized to Arm A, nivolumab will be administered as a flat dose of 240 mg on 
Day 1 of a 14-day cycle as an IV infusion over 30 minutes. The rationale for this dosage 
schedule is provided in Section 1.1.6.
Refer to the Pharmacy Information sheets for more detail. There are no pre-medications 
recommended on the first cycle. If an acute infusion reaction is noted, subjects should be 
managed according to Section 4.5.5.
Revised Protocol No: 03
Date: 20-Mar-2018
41
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Dosing Window: Subjects may be dosed no less than 12 days between doses and no more than 
3 days from scheduled dose. If an infusion cannot be administered at a scheduled visit, it should
be administered as soon as possible. Subsequent dosing visits will follow every 2 weeks after the 
delayed dose.
A dose given more than 3 days after the intended dose date will be considered a delay. 
A maximum delay of 6 weeks between doses is allowed. Longer delays may be allowed 
following discussion with the Medical Monitor, as described in Section 4.5.3.1.
Management Algorithms for Immuno-Oncology Agents 
Immuno-oncology agents are associated with AEs that can differ in severity and duration than 
AEs caused by other therapeutic classes. Nivolumab is considered immuno-oncology agent in 
this protocol. Early recognition and management of AEs associated with immuno-oncology 
agents may mitigate severe toxicity. Management algorithms have been developed to assist 
investigators in assessing and managing the following groups of AEs:
•
Gastrointestinal
•
Renal
•
Pulmonary
•
Hepatic
•
Endocrinopathies
•
Skin
•
Neurological.
The algorithms are found in the Investigator Brochure and Appendix 1 of this protocol.
Changes in tumor measurements and tumor responses will be assessed by the investigator using 
the RECIST 1.1 criteria. Please refer to Appendix 2 for the specifics of the RECIST 1.1 criteria 
to be utilized in this study.
4.5.1.2
Topotecan 
Subjects randomized to Arm B will receive treatment with topotecan 1.5 mg/m2 IV infusion or 
2.3 mg/m2 oral capsule (round dose to nearest 0.25 mg) on Days 1 through 5 every 3 weeks 
(21 days). Refer to the local product label for more details. 
Dosing Window: Subjects may be dosed no less than 14 days from the last dose of the previous 
cycle and no more than 3 days from scheduled dose. If an infusion cannot be administered at a 
scheduled visit, it should be administered as soon as possible. Subsequent dosing visits will 
follow every 3 weeks after the delayed dose.
A dose given more than 3 days after the intended dose date will be considered a delay. 
A maximum delay of 6 weeks between doses is allowed. Longer delays may be allowed 
following discussion with the Medical Monitor, as described in Section 4.5.3.1.
Revised Protocol No: 03
Date: 20-Mar-2018
42
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
4.5.1.3
Amrubicin
Subjects randomized to Arm B will receive treatment with amrubicin 40 mg/m2 on Days 1 
through 3 every 3 weeks (21 days). Refer to the local product label for more detail. 
Dosing Window: Subjects may be dosed no less than 16 days from the last dose of the previous 
cycle and no more than 3 days from scheduled dose. If an infusion cannot be administered at a 
scheduled visit, it should be administered as soon as possible. Subsequent dosing visits will 
follow every 3 weeks after the delayed dose.
A dose given more than 3 days after the intended dose date will be considered a delay. 
A maximum delay of 6 weeks between doses is allowed. Longer delays may be allowed 
following discussion with the Medical Monitor, as described in Section 4.5.3.1.
4.5.2
Dose Modifications and Dose Delays
This section includes information on dose modifications, dose delays, and provides guidelines 
for resuming treatment after a dose delay. Tumor assessments for all subjects should continue as 
per protocol even if dosing is delayed.
4.5.2.1
Nivolumab
No dose modifications of nivolumab are allowed for the management of toxicities experienced 
by individual subjects.
Dose delay criteria apply for all drug-related AEs. Treatment delays up to 6 weeks (42 days) 
from the last dose are allowable.
Nivolumab administration should be delayed for the following:
•
Grade 2 non-skin, drug-related adverse event, with the exception of fatigue
•
Grade 2 drug-related creatinine, AST, ALT and/or Total Bilirubin abnormalities
•
Grade 3 skin, drug-related adverse event
•
Grade 3 drug-related laboratory abnormality, with the following exceptions: 
o
Grade 3 lymphopenia or asymptomatic amylase or lipasedoes not require dose 
delay
o
Grade ≥3 AST, ALT, Total Bilirubin will require dose discontinuation (see 
Section 4.5.3.1)
•
Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the investigator, warrants delaying the dose of study medication.
Subjects who require delay of nivolumab should be re-evaluated weekly or more frequently if 
clinically indicated and resume nivolumab dosing when re-treatment criteria are met
Criteria to Resume Treatment
Subjects may resume treatment with nivolumab when the drug-related AE(s) resolve to 
Grade ≤ 1 or baseline value, with the following exceptions:
Revised Protocol No: 03
Date: 20-Mar-2018
43
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
•
Subjects may resume treatment in the presence of Grade 2 fatigue
•
Subjects who have not experienced a Grade 3 drug-related skin AE may resume treatment in 
the presence of Grade 2 skin toxicity
•
For subjects with Grade 2 AST, ALT and/or Total Bilirubin Abnormalities, dosing may 
resume when laboratory values return to baseline and management with corticosteroids, if 
needed, is complete.
•
Subjects with combined Grade 2 AST/ALT AND
total bilirubin values meeting 
discontinuation parameters (Section 4.5.3.1) should have treatment permanently discontinued
•
Drug-related pulmonary toxicity, diarrhea or colitis must have resolved to baseline before 
treatment is resumed. Subjects with persistent Grade 1 pneumonitis after completion of a 
steroid taper over at least 1 month may be eligible for retreatment if discussed with and 
approved by BMS Medical Monitor.
•
Subjects with drug-related endocrinopathies adequately controlled with only physiologic 
hormone replacement may resume treatment after consultation with the BMS Medical 
Monitor. Adrenal insufficiency requires discontinuation regardless of control with hormone 
replacement
If the criteria to resume treatment are met, the subject should restart treatment at the next 
scheduled timepoint per protocol. 
If treatment is delayed > 6 weeks (42 days) from the last dose, the subject must be permanently 
discontinued from study therapy, except as specified in Section 4.5.3.1.
4.5.2.2
Topotecan
Dose modifications and dose delays for the management of toxicities experienced by individual 
subjects in Arm B who are receiving topotecan are provided in Table 4.5.2.2-1. In addition, 
treatment may be delayed for any AE, laboratory abnormality, or intercurrent illness which, in 
the judgment of the investigator, warrants delaying the dose of study medication.
Revised Protocol No: 03
Date: 20-Mar-2018
44
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Table 4.5.2.2-1:
Topotecan Dose Modifications and Delays
Adverse Event
Dose Modification
ANC < 1000/mm3 and/or Platelets < 100,000/mm3 at 
Day 1
Delay treatment until: 
ANC ≥1000/mm3
Platelets > 100,000/mm3
Toxicity Grade < 2 during previous cycle
Optional, based on local treatment guidelines: 
Increase IV topotecan dosage to a maximum of 
2 mg/m2 per day in increments of 0.25 mg/m2 per 
day.
Increase oral topotecan dosage to a maximum of 
3.1 mg/m2 in increments of 0.4 mg/m2 per day.
Grade 4 neutropenia with fever or infection, or of 
duration ≥ 7 days
Grade 3 neutropenia during the preceding cycle 
persisting after Day 21
Grade 4 thrombocytopenia 
Reduce IV topotecan dosage by 0.25 mg/m2 per day.
Reduce oral topotecan dosage by 0.4 mg/m2 per day.
Grade 3/4 Nonhematologic toxicity, excluding Grade 3 
nausea
Reduce IV topotecan dosage by 0.25 mg/m2 per day 
or discontinue treatment.
Reduce oral topotecan dosage by 0.4 mg/m2 per day 
or discontinue treatment.
Treatment delay > 6 weeks
Discontinue treatment
ANC = absolute neutrophil count 
Note: The minimum permissible daily IV topotecan dosage is 1 mg/m2; the minimum daily oral topotecan dosage is 
1.5 mg/m2.
Criteria to Resume Treatment
Subjects may resume treatment with topotecan when the drug-related AE(s) resolve to Grade ≤ 1 
or baseline value, with the following exceptions:
•
Treatment can be resumed when ANC ≥1000/mm3 and platelets > 100,000/mm3
•
Subjects may resume treatment in the presence of Grade 2 fatigue
•
Subjects who have not experienced a Grade 3 drug-related skin AE may resume treatment in 
the presence of Grade 2 skin toxicity
•
Drug-related pulmonary toxicity must have resolved to baseline before treatment is resumed.
If the criteria to resume treatment are met, the subject should restart treatment at the next 
scheduled timepoint per protocol. 
If treatment is delayed > 6 weeks (42 days) from the last dose, the subject must be permanently 
discontinued from study therapy, except as specified in Section 4.5.3.2.
Revised Protocol No: 03
Date: 20-Mar-2018
45
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
When resuming topotecan treatment, please follow the dose reduction recommendations noted in
Table 4.5.2.2-1.
4.5.2.3
Amrubicin
Dose modifications and dose delays for the management of toxicities experienced by individual 
subjects in Arm B who are receiving amrubicin are provided in Table 4.5.2.3-1. In addition, 
treatment may be delayed for any AE, laboratory abnormality, or intercurrent illness which, in 
the judgment of the investigator, warrants delaying the dose of study medication.
Table 4.5.2.3-1:
Amrubicin Dose Modifications
Amrubicin: Dose Modifications and Delays
Adverse Event
Dose Modification
ANC < 1000/mm3 and/or Platelets < 100,000/mm3 at 
Day 1
Delay treatment until: 
ANC ≥1000/mm3
Platelets ≥100,000/mm3
Grade 4 neutropenia with fever or infection, or of 
duration ≥ 7 days
Grade 3 neutropenia during the preceding cycle 
persisting after Day 21
Grade 4 thrombocytopenia 
Reduce amrubicin dosage by 5 mg/m2 per day
Grade 3/4 Nonhematologic toxicity, excluding Grade 3 
nausea
Reduce amrubicin dosage by 5 mg/m2 per day
Treatment delay > 6 weeks
Discontinue treatment
ANC = absolute neutrophil count 
Criteria to Resume Treatment
Subjects may resume treatment with amrubicin when the drug-related AE(s) resolve to Grade ≤1 
or baseline value, with the following exceptions:
•
Treatment can be resumed when ANC ≥ 1000/mm3, and platelets ≥ 100,000/mm3
•
Subjects may resume treatment in the presence of Grade 2 fatigue
•
Subjects who have not experienced a Grade 3 drug-related skin AE may resume treatment in 
the presence of Grade 2 skin toxicity
•
Drug-related pulmonary toxicity must have resolved to baseline before treatment is resumed.
If the criteria to resume treatment are met, the subject should restart treatment at the next
scheduled timepoint per protocol. 
If treatment is delayed > 6 weeks (42 days) from the last dose, the subject must be permanently 
discontinued from study therapy, except as specified in Section 4.5.3.3.
Revised Protocol No: 03
Date: 20-Mar-2018
46
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
When resuming amrubicin treatment, please follow the dose reduction recommendations noted in
Table 4.5.2.3-1.
4.5.3
Discontinuation Criteria
4.5.3.1
Nivolumab
Treatment with nivolumab should be permanently discontinued for the following:
•
Grade 2 drug-related uveitis, eye pain or blurred vision that does not respond to topical 
therapy and does not improve to Grade 1 severity within the re-treatment period OR requires 
systemic treatment 
•
Grade 3 non-skin, drug-related adverse event lasting > 7 days or recurs, with the following 
exceptions for laboratory abnormalities, drug related uveitis, pneumonitis, bronchospasm, 
neurologic toxicity, hypersensitivity reactions, infusion reactions and endocrinopathies: 
−
Grade 3 drug-related uveitis, pneumonitis, bronchospasm, neurologic toxicity,  
myocarditis, hypersensitivity reaction, or infusion reaction of any duration require 
discontinuation
−
Grade 3 drug-related endocrinopathies adequately controlled with only physiologic 
hormone replacement do not require discontinuation; Adrenal insufficiency requires 
discontinuation regardless of control with hormone replacement.
−
Grade 3 drug-related laboratory abnormalities do not require treatment discontinuation 
except:
♦Grade 3 drug-related thrombocytopenia > 7 days or associated with bleeding requires 
discontinuation
♦Grade ≥3 drug-related AST, ALT or Total Bilirubin requires discontinuation*
♦Concurrent AST or ALT > 3 x ULN and total bilirubin > 2x ULN
* In most cases of Grade 3 AST or ALT elevation, study drug(s) will be permanently 
discontinued. If the investigator determines a possible favorable benefit/risk ratio that 
warrants continuation of study drug(s), a discussion between the investigator and the 
BMS Medical Monitor/designee must occur
•
Any Grade 4 drug-related adverse event or laboratory abnormality (including but not limited 
to creatinine, AST, ALT, or Total Bilirubin) except for the following events which do not 
require discontinuation:
−
Grade 4 neutropenia ≤7 days
−
Grade 4 lymphopenia or leukopenia or asymptomatic amylase or lipase
−
Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with clinical 
sequelae and are corrected with supplementation/appropriate management within 
72 hours of their onset
−
Grade 4 drug-related endocrinopathy adverse events, such as hyper- or hypothyroidism, 
or glucose intolerance, which resolve or are adequately controlled with physiologic 
hormone replacement (corticosteroids, thyroid hormones) or glucose-controlling agents, 
Revised Protocol No: 03
Date: 20-Mar-2018
47
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
respectively, may not require discontinuation after discussion with and approval from the 
BMS Medical Monitor.
•
Any event that leads to delay in dosing lasting > 6 weeks from the previous dose requires 
discontinuation, with the following exceptions:
−
Dosing delays to allow for prolonged steroid tapers to manage drug-related adverse 
events are allowed. 
−
Dosing delays lasting > 6 weeks from the previous dose that occur for non-drug-related 
reasons may be allowed if approved by the BMS medical monitor. 
Prior to re-initiating treatment in a subject with a dosing delay lasting > 6 weeks, the BMS 
medical monitor must be consulted. Tumor assessments should continue as per protocol even if 
dosing is delayed. Periodic study visits to assess safety and laboratory studies should also 
continue every 6 weeks or more frequently if clinically indicated during such dosing delays.
•
Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the Investigator, presents a substantial clinical risk to the subject with continued nivolumab 
dosing.
Tumor assessments for all subjects should continue as per protocol even if study drug dosing is 
interrupted.
4.5.3.2
Topotecan
Treatment with topotecan should be permanently discontinued for the following:
•
Confirmed new diagnosis of interstitial lung disease (ILD): Topotecan has been associated 
with reports of ILD, some of which have been fatal. Underlying risk factors include history 
of ILD, pulmonary fibrosis, lung cancer, thoracic exposure to radiation, and use of 
pneumotoxic drugs and/or colony stimulating factors. Monitor subjects for pulmonary 
symptoms indicative of interstitial lung disease (eg, cough, fever, dyspnea, and/or hypoxia), 
and discontinue topotecan if a new diagnosis of ILD is confirmed.
•
Any dosing interruption lasting > 6 weeks (42 days) from the last dose.
•
Any AE, laboratory abnormality, or intercurrent illness which, in the judgment of the 
Investigator, presents a substantial clinical risk to the subject with continued topotecan 
dosing.
•
Any dosing interruption lasting > 6 weeks from the last dose with the following exception:
−
Dosing interruptions > 6 weeks from the last dose that occur for non-drug-related reasons 
may be allowed if approved by the BMS Medical Monitor.
Tumor assessments for all subjects should continue as per protocol even if study drug dosing is 
delayed.
4.5.3.3
Amrubicin
Treatment with amrubicin should be permanently discontinued for the following:
Revised Protocol No: 03
Date: 20-Mar-2018
48
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
•
Confirmed new diagnosis of interstitial lung disease (ILD): Amrubicin has been associated 
with reports of ILD, some of which have been fatal. Underlying risk factors include history 
of ILD, pulmonary fibrosis, lung cancer, thoracic exposure to radiation, and use of 
pneumotoxic drugs and/or colony stimulating factors. Monitor subjects for pulmonary 
symptoms indicative of interstitial lung disease (eg, cough, fever, dyspnea, and/or hypoxia), 
and discontinue topotecan if a new diagnosis of ILD is confirmed
•
Any dosing interruption lasting > 6 weeks (42 days) from the last dose.
•
Any AE, laboratory abnormality, or intercurrent illness which, in the judgment of the 
Investigator, presents a substantial clinical risk to the subject with continued amrubicin 
dosing.
•
Any dosing interruption lasting > 6 weeks from the last dose with the following exception:
−
Dosing interruptions > 6 weeks from the last dose that occur for non-drug-related reasons 
may be allowed if approved by the BMS Medical Monitor.
Tumor assessments for all subjects should continue as per protocol even if study drug dosing is 
delayed.
4.5.4
Treatment Beyond Disease Progression
Accumulating evidence indicates a minority of subjects treated with immunotherapy may derive 
clinical benefit despite initial evidence of PD.22  
Subjects in Arm B who were treated with topotecan or amrubicin will not be permitted to 
continue treatment beyond RECIST 1.1 defined initial PD. 
Subjects in Arm A who were treated with Nivolumab will be permitted to continue treatment 
beyond initial RECIST 1.1 defined PD as long as they meet the following criteria:
•
Investigator-assessed clinical benefit and no rapid disease progression
•
Tolerating study drug
•
Stable performance status
•
Treatment beyond progression will not delay an imminent intervention to prevent serious 
complications of disease progression (eg, CNS metastases)
•
Provides written informed consent prior to receiving additional nivolumab treatment, using 
an ICF describing any reasonably foreseeable risks or discomforts, or other alternative 
treatment options.
The assessment of clinical benefit should be balanced by clinical judgment as to whether the 
subject is clinically deteriorating and unlikely to receive any benefit from continued treatment 
with nivolumab.
All decisions to continue treatment beyond initial progression must be discussed with the BMS 
Medical Monitor and documented in the study records. The subject will continue to receive 
monitoring according to the Time and Events Schedule on Table 5.1-2.
Revised Protocol No: 03
Date: 20-Mar-2018
49
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
A radiographic assessment/ scan should be performed within 6 weeks of original PD to 
determine whether there has been a decrease in the tumor size, or continued PD. 
For the subjects who continue nivolumab study therapy beyond progression, further progression 
is defined as an additional 10% increase in tumor burden volume from time of initial PD. This 
includes an increase in the sum of all target lesions and/ or the development of new measurable 
lesions. For subjects with evaluable disease only, further progression is defined as unequivocal 
disease progression of non target lesions or the development of new measurable lesions from 
time of initial PD. Treatment should be discontinued permanently upon documentation of further 
disease progression.
New lesions are considered measurable at the time of initial progression if the longest diameter is 
at least 10 mm (except for pathological lymph nodes, which must have a short axis of at least 
15 mm). Any new lesion considered non-measurable at the time of initial progression may 
become measurable and therefore included in the tumor burden measurement if the longest 
diameter increases to at least 10 mm (except for pathological lymph nodes, which must have an 
increase in short axis to at least 15 mm).
For statistical analyses that include the investigator-assessed progression date, subjects who 
continue treatment beyond initial investigator-assessed, RECIST 1.1-defined progression will be 
considered to have investigator-assessed progressive disease at the time of the initial progression 
event.
For subjects in both treatment arms, global deterioration of health status requiring 
discontinuation of treatment without objective evidence of disease progression at that time 
should be reported as ‘symptomatic deterioration’. Every effort should be made to document 
objective progression (ie radiographic confirmation) even after discontinuation of treatment.
4.5.5
Treatment of Nivolumab-related Infusion Reactions
Since nivolumab contains only human immunoglobulin protein sequences, it is unlikely to be 
immunogenic and induce infusion or hypersensitivity reactions. However, if such a reaction were 
to occur, it might manifest with fever, chills, rigors, headache, rash, pruritus, arthralgias, 
hypo- or hypertension, bronchospasm, or other symptoms. All Grade 3 or 4 infusion reactions 
should be reported within 24 hours to the BMS Medical Monitor and reported as a serious 
adverse event (SAE) if criteria are met. Infusion reactions should be graded according to NCI 
CTCAE (version 4.0) guidelines.
Treatment recommendations are provided below and may be modified based on local treatment 
standards and guidelines as appropriate:
For Grade 1 symptoms: (Mild reaction; infusion interruption not indicated; intervention not 
indicated)
•
Remain at bedside and monitor subject until recovery from symptoms. The following 
prophylactic premedications are recommended for future infusions: diphenhydramine 50 mg 
(or equivalent) and/or paracetamol 325 to 1000 mg (acetaminophen) at least 30 minutes 
before additional nivolumab administrations.
Revised Protocol No: 03
Date: 20-Mar-2018
50
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
For Grade 2 symptoms: (Moderate reaction requires therapy or infusion interruption but 
responds promptly to symptomatic treatment [eg, antihistamines, non-steroidal anti inflammatory 
drugs, narcotics, corticosteroids, bronchodilators, IV fluids]; prophylactic medications indicated 
for ≤24 hours).
•
Stop the nivolumab infusion, begin an IV infusion of normal saline, and treat the subject with 
diphenhydramine 50 mg IV (or equivalent) and/or paracetamol 325 to 1000 mg 
(acetaminophen); remain at bedside and monitor subject until resolution of symptoms. 
Corticosteroid or bronchodilator therapy may also be administered as appropriate. If the 
infusion is interrupted, then restart the infusion at 50% of the original infusion rate when 
symptoms resolve; if no further complications ensue after 30 minutes, the rate may be 
increased to 100% of the original infusion rate. Monitor subject closely. If symptoms recur 
then no further nivolumab will be administered at that visit. Administer diphenhydramine 
50 mg IV, and remain at bedside and monitor the subject until resolution of symptoms. The 
amount of study drug infused must be recorded on the case report form (CRF). 
•
The following prophylactic premedications are recommended for future infusions: 
diphenhydramine 50 mg (or equivalent) and/or paracetamol 325 to 1000 mg (acetaminophen) 
should be administered at least 30 minutes before additional nivolumab administrations. If 
necessary, corticosteroids (recommended dose: up to 25 mg of IV hydrocortisone or 
equivalent) may be used.
For Grade 3 or Grade 4 symptoms: (Severe reaction, Grade 3: prolonged [ie, not rapidly 
responsive to symptomatic medication and/or brief interruption of infusion]; recurrence of 
symptoms following initial improvement; hospitalization indicated for other clinical sequelae 
[eg, renal impairment, pulmonary infiltrates]). Grade 4: (life threatening; pressor or ventilatory 
support indicated).
•
Immediately discontinue infusion of nivolumab. Begin an IV infusion of normal saline, and 
treat the subject as follows. Recommend bronchodilators, epinephrine 0.2 to 1 mg of a 
1:1,000 solution for subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 solution 
injected slowly for IV administration, and/or diphenhydramine 50 mg IV with 
methylprednisolone 100 mg IV (or equivalent), as needed. Subject should be monitored until 
the investigator is comfortable that the symptoms will not recur. Nivolumab will be 
permanently discontinued. Investigators should follow their institutional guidelines for the 
treatment of anaphylaxis. Remain at bedside and monitor subject until recovery from 
symptoms. 
In the case of late-occurring hypersensitivity symptoms (eg, appearance of a localized or 
generalized pruritus within 1 week after treatment), symptomatic treatment may be given (eg, 
oral antihistamine, or corticosteroids)
4.6
Blinding/Unblinding
Not applicable.
Revised Protocol No: 03
Date: 20-Mar-2018
51
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
4.7
Treatment Compliance
Treatment compliance will be monitored by drug accountability as well as the subject’s medical 
record and CRF.
4.8
Destruction of Study Drug
For this study, study drugs (those supplied by BMS or sourced by the investigator) such as 
partially used study drug containers, vials and syringes may be destroyed on site. 
Any unused study drugs can only be destroyed after being inspected and reconciled by the 
responsible Study Monitor unless study drug containers must be immediately destroyed as 
required for safety, or to meet local regulations (eg, cytotoxics or biologics). 
On-site destruction is allowed provided the following minimal standards are met:
•
On-site disposal practices must not expose humans to risks from the drug.
•
On-site disposal practices and procedures are in agreement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
•
Written procedures for on-site disposal are available and followed. The procedures must be 
filed with the site’s SOPs and a copy provided to BMS upon request.
•
Records are maintained that allow for traceability of each container, including the date 
disposed of, quantity disposed, and identification of the person disposing the containers. The 
method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal 
vendor must be documented.
•
Accountability and disposal records are complete, up-to-date, and available for the Monitor 
to review throughout the clinical trial period.
If conditions for destruction cannot be met the responsible Study Monitor will make 
arrangements for return of study drug.
It is the investigator’s responsibility to arrange for disposal of all empty containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, local, 
and institutional guidelines and procedures, and provided that appropriate records of disposal are 
kept.
4.9
Return of Study Drug
If study drug will not be destroyed upon completion or termination of the study, all unused 
and/or partially used study drug that was supplied by BMS must be returned to BMS. The return 
of study drug will be arranged by the responsible Study Monitor. 
It is the investigator’s responsibility to arrange for disposal of all empty containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, local, 
and institutional guidelines and procedures, and provided that appropriate records of disposal are 
kept. 
Revised Protocol No: 03
Date: 20-Mar-2018
52
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
5
STUDY ASSESSMENTS AND PROCEDURES
5.1
Flow Chart/Time and Events Schedule 
Table 5.1-1:
Screening Procedural Outline (CA209331)
Procedure
Screening Visit
Notes
Eligibility Assessments
Informed Consent
X
Inclusion/Exclusion Criteria
X
All inclusion/exclusion criteria should be assessed at screening and confirmed 
prior to first dose
Medical History
X
Prior Systemic Therapy
X
Safety Assessments
Physical Examination
X
Physical Measurements
X
Include Height, Weight, and ECOG performance Status. Within 14 days prior to 
first dose
Vital Signs and Oxygen Saturation
X
Temperature, BP, HR, and O2 saturation by pulse oximetry at rest. Obtain vital 
signs at the screening visit and within 72 hours prior to first dose.
Assessment of Signs and Symptoms
X
Within 14 days prior to first dose
Concomitant Medication Collection
X
Within 14 days prior to first dose
Laboratory Tests
X
CBC with differential, Chemistry panel including LDH, AST, ALT, ALP, T.Bili, 
BUN or serum urea level, uric acid, creatinine, Ca, Mg, Na, K, Cl, P, glucose, 
bicarbonates (optional), albumin, amylase or lipase, TSH (reflex to free T3, free 
T4 for abnormal TSH result), hepatitis B surface antigen (HBVsAg), and 
hepatitis C antibody (HCV Ab) or hepatitis C RNA (HCV RNA), within 14 days 
prior to first dose. Screening labs done within 72 hours prior to first dose can also 
be used for on treatment lab purposes at Day 1 dosing.
ECG, Echocardiogram (LVEF) or 
MUGA
X
Revised Protocol No: 03
Date: 20-Mar-2018
53
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Table 5.1-1:
Screening Procedural Outline (CA209331)
Procedure
Screening Visit
Notes
Pregnancy Test
X
Performed within 24 hours prior to first dose for WOCBP only (serum or urine -
local/site)
Efficacy/Biomarker Assessments
Radiographic Tumor Assessment
X
Contrast-enhanced CT of the chest and CT or MRI of abdomen, pelvis, and any 
other known sites of disease. Brain MRI or CT. Subjects with incidental brain 
metastases findings at screening will need to undergo radiation treatment first to 
be eligible.
Should be performed within 28 days prior to randomization.
Additional sites of known or suspected disease (including CNS) should be 
imaged at the screening visit and at subsequent on-study assessments.
Collection of Tumor Tissue for 
Biomarker Evaluation
X
Tumor tissue obtained before randomization (formalin-fixed, paraffin-embedded 
(FFPE) tumor tissue block or minimum of 10 slides, obtained from core biopsy, 
punch biopsy, excisional biopsy or surgical specimen). Fine needle aspiration or 
cytospins are insufficient. For subjects where a biopsy is not feasible, archival 
tumor material must be made available.
Submission of fewer than 10 unstained slides may be accepted under certain 
circumstances and must be approved by BMS medical monitor
Specimens must be received by the central lab prior to subject randomization.
IVRS/Clinical Drug Supplies
Phone Calls to IVRS
X
Phone calls must be made to IVRS as follows:
For subject number assignment at the time informed consent is obtained.
For randomization to treatment after eligibility has been confirmed, or in the 
event of screen failure (subject does not meet eligibility criteria).
ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BP = blood pressure, BUN = blood urea nitrogen, 
Ca = calcium, CBC = complete blood count, Cl = chloride, CNS = central nervous system, CT = computed tomography, ECOG = Eastern Cooperative Oncology 
Group, HR = heart rate, IVRS = interactive voice response system, K = potassium, LDH = lactate dehydrogenase, Mg = magnesium, MRI = magnetic resonance 
imaging, Na = sodium, O2 = oxygen, P = phosphorus, T.Bili = total bilirubin, TSH = thyroid stimulating hormone, T3 = triiodothyronine, T4 = thyroxine, 
WOCBP = women of childbearing potential
Revised Protocol No: 03
Date: 20-Mar-2018
54
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Table 5.1-2:
On-Treatment Assessments for Subjects Randomized to Arm A, Nivolumab Monotherapy 
(CA209331)
Procedure
Cycle 1 Day 1 
(C1D1)
Cycle 1 
Day 8
(C1D8)
Each Cycle 
(Every 
2 Weeks) on 
Day 1 
(± 3 Days)
Notes
Safety Assessments
Targeted Physical Examination
X
X
Within 72 hours prior to dosing
Vital Signs and Oxygen Saturation
X
X
Temperature, BP, HR, O2 saturation by pulse oximetry at rest 
(also monitor amount of supplemental oxygen if applicable) 
within 72 hours prior to dosing and at any time a subject has 
any new or worsening respiratory symptoms
Physical Measurements
X
X
Includes Weight and ECOG performance status
Adverse Events Assessment
---------Continuously----------
Assessed using NCI CTCAE v. 4.0. SAEs should be approved 
in Trial Access Online (TAO) within 5 days from entry
Review of Concomitant Medications
X
X
Laboratory Tests
X
X
Extended on-study local laboratory assessments should be 
done within 72 hours prior to dosing for Cycle 1 through 
Cycle 5 and every alternate dose thereafter (Cycles 7, 9, 11, 
13, etc.) and include: CBC with differential, uric acid, serum 
urea level, creatinine, Na, K, Ca, Mg, phosphorus, chloride, 
bicarbonate (optional), amylase or lipase, glucose, AST, ALT, 
total bilirubin, alkaline phosphatase, LDH.
Limited on-study local laboratory assessment should be done 
within 72 hours prior to dosing (beginning at Cycle 6 and 
every alternate dose thereafter (Cycles 8, 10, 12, 14, etc.) and 
include: CBC with differential, LFTs (ALT, AST, t.bili, 
alkaline phosphatase) and creatinine.
Thyroid Function Testing
See Note
TSH (reflex to free T3 and free T4 if abnormal result) to be 
performed every 6 weeks (± 1 week).
Revised Protocol No: 03
Date: 20-Mar-2018
55
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Table 5.1-2:
On-Treatment Assessments for Subjects Randomized to Arm A, Nivolumab Monotherapy 
(CA209331)
Procedure
Cycle 1 Day 1 
(C1D1)
Cycle 1 
Day 8
(C1D8)
Each Cycle 
(Every 
2 Weeks) on 
Day 1 
(± 3 Days)
Notes
Pregnancy Test
X
See Note
For WOCBP only: Serum or urine within 24 hours prior to first 
dose and then at least once every 4 weeks regardless of dosing 
schedule.
Efficacy Assessments
Radiographic Tumor Assessment
See Note
CT of the chest. CT/MRI of abdomen and any other known 
sites of disease. Repeat CT/MRI of pelvis is required for 
subjects with pelvic metastases at baseline, or if clinically 
indicated. Subjects with a history of brain metastasis should 
have surveillance MRI every 6 weeks, or sooner if clinically 
indicated. 
The same methods should be used throughout the study.
See Table 5.4-1 for CT/MRI scan schedule.
Pharmacokinetic (PK) and 
Immunogenicity Assessments
PK samples
X
See Note
See Table 5.5-1 of PK and Immunogenicity Sampling
Immunogenicity samples
X
See Note
See Table 5.5-1 of PK and Immunogenicity Sampling
Revised Protocol No: 03
Date: 20-Mar-2018
56
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Table 5.1-2:
On-Treatment Assessments for Subjects Randomized to Arm A, Nivolumab Monotherapy 
(CA209331)
Procedure
Cycle 1 Day 1 
(C1D1)
Cycle 1 
Day 8
(C1D8)
Each Cycle 
(Every 
2 Weeks) on 
Day 1 
(± 3 Days)
Notes
Exploratory Biomarker Assessments
Biomarker samples (
, Whole 
Blood, Tumor Biopsy)
X
X
See Note
See Table 5.6-1of Biomarker Sampling Schedule
Outcomes Research Assessments
Patient Reported Outcomes (PRO)
X
See Note
For on-study visits:  Assessments (Lung Cancer Symptom 
Scale and EQ-5D) will be performed prior to treatment.
Assessments will be performed at each cycle on Day 1 for the 
first 6 months on study, then every 6 weeks thereafter for the 
remainder of the treatment phase.
Health Resource Utilization
X
Except Cycle 1. Note that concomitant medication collection 
will be included. 
Study Drug
Administer Study Drug
X
X
IVRS should be called within 1 day prior to study drug 
administration to receive vial assignment. Note: Treatment 
should begin within 3 business days of randomization. 
Subjects may be dosed no less than 12 days between doses and 
no more than 3 days from the scheduled dose.
IVRS should also be contacted at upon discontinuation of 
treatment.
ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BP = blood pressure, BUN = blood urea nitrogen, 
Ca = calcium, Cl = chloride, CNS = central nervous system, CT = computed tomography, ECG = electrocardiogram, ECOG = Eastern Cooperative Oncology 
Group, HR = heart rate, IVRS = interactive voice response system, K = potassium, LDH = lactate dehydrogenase, LFT = liver function tests, Mg = magnesium, 
MRI = magnetic resonance imaging, Na = sodium, NCI CTCAE = National Cancer Institute Common Toxicity Criteria for Adverse Events, O2 = oxygen, 
P = phosphorus, SAE = serious adverse event, T.Bili = total bilirubin, TSH = thyroid stimulating hormone, T3 = triiodothyronine, T4 = thyroxine, 
WOCBP = women of childbearing potential
Revised Protocol No: 03
Date: 20-Mar-2018
57
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Table 5.1-3:
On-Treatment Assessments for Subjects Randomized to Arm B, Chemotherapy (CA209331)
Procedure
Cycle 1 
Day 1 of a 
21-day Cycle 
(Every 
3 Weeks 
± 3 Days)
(C1D1)
Cycle 2 to x
Day 1 of a
21-day Cycle 
(Every 
3 Weeks 
± 3 Days)
C2D1 to CxD1
Notes
Safety Assessments
Targeted Physical Examination
X
X
Within 72 hours prior to dosing
Vital Signs and Oxygen Saturation
X
X
Temperature, BP, HR, O2 saturation by pulse oximetry at rest (also monitor 
amount of supplemental oxygen if applicable) prior to dosing and at any time 
a subject has any new or worsening respiratory symptoms
Physical Measurements
X
X
Includes Weight and ECOG performance status
Adverse Events Assessment
---------- Continuously ----------
Assessed using NCI CTCAE v. 4.0. SAEs should be approved in Trial 
Access Online (TAO) within 5 days from entry
Review of Concomitant Medications
X
X
Laboratory Tests
X (See Note)
X (See Note)
Extended on-study local laboratory assessments should be done within 
72 hours prior to dosing and include: CBC with differential, uric acid, serum 
urea level, serum creatinine, sodium, potassium, calcium, magnesium, 
phosphorus, chloride, bicarbonate (optional), amylase or lipase, glucose, 
AST, ALT, total bilirubin, alkaline phosphatase, LDH.
In addition, the following laboratory assessments should be done:
Day 15 of each cycle (optional according to local treatment guidelines): CBC 
with Differential, LFTs (ALT, AST, total bilirubin, alkaline phosphatase) and 
creatinine.
Thyroid Function Testing
See Note
TSH (reflex to free T3 and free T4 if abnormal result) to be performed every 
6 weeks (± 1 week).
Pregnancy Test
X
See Note
For WOCBP only: Serum or urine within 24 hours prior to first dose and then 
at least once every 4 weeks regardless of dosing schedule.
Revised Protocol No: 03
Date: 20-Mar-2018
58
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Table 5.1-3:
On-Treatment Assessments for Subjects Randomized to Arm B, Chemotherapy (CA209331)
Procedure
Cycle 1 
Day 1 of a 
21-day Cycle 
(Every 
3 Weeks 
± 3 Days)
(C1D1)
Cycle 2 to x
Day 1 of a
21-day Cycle 
(Every 
3 Weeks 
± 3 Days)
C2D1 to CxD1
Notes
Efficacy Assessments
Radiographic Tumor Assessment
See Note
CT of the chest. CT/MRI of abdomen and any other known sites of disease. 
Repeat CT/MRI of pelvis is required for subjects with pelvic metastases at 
baseline, or if clinically indicated. Subjects with a history of brain metastasis 
should have surveillance by MRI every 6 weeks or sooner if clinically 
indicated.
The same methods should be used throughout the study.
See Table 5.4-1 for schedule of CT/MRI assessments.
Exploratory Biomarker 
Assessments
Whole Blood
Tumor Biopsy
X
See Note
See Table 5.6-2of Biomarker Sampling Schedule
Outcomes Research Assessments
Patient Reported Outcomes (PRO)
X
See Note
For on-study visits:  Assessments (Lung Cancer Symptom Scale and EQ-5D) 
will be performed prior to treatment.
Assessments will be performed at each cycle on Day 1 for the first 6 months 
on study, then every 6 weeks thereafter for the remainder of the treatment 
period.
Health Resource Utilization
X 
Except Cycle 1. Note that concomitant medication collection will be 
included. 
Revised Protocol No: 03
Date: 20-Mar-2018
59
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Table 5.1-3:
On-Treatment Assessments for Subjects Randomized to Arm B, Chemotherapy (CA209331)
Procedure
Cycle 1 
Day 1 of a 
21-day Cycle 
(Every 
3 Weeks 
± 3 Days)
(C1D1)
Cycle 2 to x
Day 1 of a
21-day Cycle 
(Every 
3 Weeks 
± 3 Days)
C2D1 to CxD1
Notes
Study Drug
Administer Study Drug
X (See Note)
X (See Note)
Topotecan: 1.5 mg/m2 administered as 30-minute IV infusion or 2.3 mg/m2
oral capsule (round dose to nearest 0.25 mg) once daily on Days 1 to 5 of a 
21-day cycle. 
Amrubicin (upon investigator’s choice, where locally approved for 2nd line 
SCLC treatment): 40 mg/m² administered as 5-minute IV infusion once daily 
on Days 1 to 3 of a 21-day cycle.
IVRS should be called within 1 day prior to study drug administration to 
receive vial assignment. Note: Treatment should begin within 3 business days 
of randomization. Subjects assigned to topotecan may be dosed no less than 
14 days between doses and no more than 3 days from the scheduled dose. 
Subjects assigned to amrubicin may be dosed no less than 16 days between 
doses and no more than 3 days from the scheduled dose.
ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BP = blood pressure, BUN = blood urea nitrogen, 
Ca = calcium, Cl = chloride, CNS = central nervous system, CT = computed tomography, ECG = electrocardiogram, ECOG = Eastern Cooperative Oncology 
Group, HR = heart rate, IVRS = interactive voice response system, K = potassium, LDH = lactate dehydrogenase, LFT = liver function tests, Mg = magnesium, 
MRI = magnetic resonance imaging, Na = sodium, NCI CTCAE = National Cancer Institute Common Toxicity Criteria for Adverse Events, O2 = oxygen, 
P = phosphorus, SAE = serious adverse event, T.Bili = total bilirubin, TSH = thyroid stimulating hormone, T3 = triiodothyronine, T4 = thyroxine, 
WOCBP = women of childbearing potential
Revised Protocol No: 03
Date: 20-Mar-2018
60
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Table 5.1-4:
Follow-Up Assessments for All Treatment Groups (CA209331)
Procedure
X, Follow-Up Visits 1 and 2a
S, Survival Follow-Up Visitsb
Notes
Safety Assessments
Targeted Physical Examination
X
To assess for potential late emergent study 
drug related issues
Adverse Events Assessment
X
X
Non-SAEs and SAEs must be collected up 
to 100 days after study drug 
discontinuation. SAEs that relate to any 
later protocol specified procedure must be 
collected. SAEs should be approved in Trial 
Access Online (TAO) within 5 days from 
entry.
Review concomitant medications
X
This includes subsequent cancer therapy 
and concomitant medication taken up to 100 
days after study drug discontinuation
Laboratory Tests
X
CBC with differential, uric acid, BUN, 
serum creatinine, Na, K, Ca, Mg, Cl, P, 
bicarbonate (optional), glucose, AST, ALT, 
t.bili, ALP, LDH.
Thyroid Function Testing
X
TSH (reflex to free T3 and free T4 if 
abnormal result)
Pregnancy Test
X
Serum or urine
ECG, Echocardiogram (LVEF) or 
MUGA
X
Only at Follow-up Visit 1
Efficacy Assessments
Radiographic Tumor Assessment
See Note
See note
See Table 5.4-1 for schedule of CT/MRI 
assessments. For subjects without previous 
disease progression only.
Exploratory Biomarker 
Assessments
Biomarker samples (
, whole 
See Note
See note
Collection of Biomarker samples at time of 
Revised Protocol No: 03
Date: 20-Mar-2018
61
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Table 5.1-4:
Follow-Up Assessments for All Treatment Groups (CA209331)
Procedure
X, Follow-Up Visits 1 and 2a
S, Survival Follow-Up Visitsb
Notes
blood, tumor biopsy)
progression is optional.
See Table 5.6-1or Table 5.6-2 of Biomarker 
Sampling Schedule.
Outcomes Research Assessments
Patient Reported Outcomes (PRO)
X
EQ-5D only
Both the Lung Cancer Symptom Scale and 
EQ-5D will be given in Follow-up Visits 1 
& 2. In Survival Visits, EQ-5D is collected 
every 3 months for the first year of the 
Follow-up Phase, then every 6 months 
thereafter.
Subject Status
Survival Status
X
X
Every 3 months after X02; may be 
accomplished by visit or phone contact, to 
update survival information and assess 
subsequent anti-cancer therapy.
ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BP = blood pressure, BUN = blood urea nitrogen, 
Ca = calcium, Cl = chloride, CT = computed tomography, ECG = electrocardiogram, IVRS = interactive voice response system, K = potassium, LDH = lactate 
dehydrogenase, Mg = magnesium, MRI = magnetic resonance imaging, Na = sodium, NCI CTCAE = National Cancer Institute Common Toxicity Criteria for 
Adverse Events, O2 = oxygen, P = phosphorus, SAE = serious adverse event, T.Bili = total bilirubin, TSH = thyroid stimulating hormone, T3 = triiodothyronine, 
T4 = thyroxine, WOCBP = women of childbearing potential
a Follow-up visits occur as follows: X01 = 35 days (± 7 days) from last dose, X02 = 80 days (± 7 days) from X01
b S, Survival visits continue every 3 months (± 7 days) after Follow-up Visit 2 until death, lost to follow-up, or withdrawal of study consent
Revised Protocol No: 03
Date: 20-Mar-2018
62
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
5.1.1
Retesting During Screening
Retesting of laboratory parameters and/or other assessments within any single Screening period 
will be permitted (in addition to any parameters that require a confirmatory value).
5.2
Study Materials
The following materials will be provided to the site by BMS.
•
NCI CTCAE version 4.0
•
Nivolumab Investigator Brochure
•
Pharmacy Binder
•
Laboratory manuals for collection and handling of blood (including biomarker and 
immunogenicity) and tissue specimens
•
Site manual for operation of interactive voice response system, including enrollment 
worksheets
•
Manual for entry of local laboratory data
•
Pregnancy Surveillance Forms
•
Serious Adverse Events (or eSAE) case report forms
•
Lung Cancer Symptom Score and EuroQol Group’s EQ-5D questionnaires
•
RECIST 1.1 pocket guide.
5.3
Safety Assessments
Safety assessments include AEs, physical examinations, vital signs, ECOG performance status, 
assessment of signs and symptoms, laboratory tests, pregnancy tests as outlined in Section 5.1.
Some of the assessments outlined in Section 5.1 may not be captured as data in eCRF. They are 
intended to be used as safety monitoring by the treating physician. Additional testing or 
assessments may be performed as clinically necessary or where required by institutional or local 
regulations
5.3.1
Imaging Assessment for the Study
Any incidental findings of potential clinical relevance that are not directly associated with the 
objectives of the protocol should be evaluated and handled by the Study Investigator as per 
standard medical/clinical judgment.
5.4
Efficacy Assessments
Study evaluations will take place in accordance with the flow charts in Section 5.1. Baseline 
assessments should be performed within 28 days of randomization. 
Contrast-enhanced computed tomography (CT) of the chest and CT or magnetic resonance 
imaging (MRI) of abdomen and any other known sites of disease are the preferred methods of 
radiographic assessment of tumors. Imaging of the pelvis is required at screening; subsequent 
scans of the pelvis are required for subjects with lesions present at baseline, or as clinically 
indicated. Brain MRI scan is the preferred imaging method for evaluating CNS metastasis, and 
Revised Protocol No: 03
Date: 20-Mar-2018
63
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
assessment is required at screening. Subjects with incidental brain metastases findings at 
screening will need to undergo radiation treatment first to be eligible. If a subject has a known 
allergy to contrast material, please use local prophylaxis standards to obtain the assessment with 
contrast if at all possible, or use the alternate modality. In cases where contrast is strictly 
contraindicated, a non-contrast scan will suffice. 
All known or suspected sites of disease (including CNS) should be assessed at screening and at 
subsequent assessments using the same imaging method and technique. If more than one method 
is used at screening, then the most accurate method according to RECIST 1.1 should be used 
when recording data, and should again be used for all subsequent assessments. 
Bone scan, PET scan, or ultrasound are not adequate for assessment of RECIST 1.1 response. In 
selected circumstances where such modalities are the sole modality used to assess certain 
non-target organs, those non target organs may be evaluated less frequently. For example, bone 
scans may need to be repeated only when complete response is identified in target disease or 
when progression in bone is suspected. 
Previously treated CNS metastases are not considered measurable lesions for purposes of 
RECIST 1.1 response. Subjects with a history of brain metastasis should have surveillance MRI 
approximately every 6 weeks, or sooner if clinically indicated.
Subjects will be evaluated for tumor response beginning 6 weeks from the date of first dose 
(± 5 days), then every 6 weeks (± 5 days) thereafter up to 30 weeks, then it will be every 
12 weeks (± 5 days) until disease progression (or until discontinuation of study drug in subjects 
receiving nivolumab beyond progression), lost to follow-up, withdrawal of study consent, or the 
study ends. See Table 5.4-1 for a schedule of tumor assessments. Tumor assessments for all 
subjects should continue as per protocol even if dosing is delayed. Tumor measurements should 
be made by the same investigator or radiologist for each assessment whenever possible.
Tumor imaging assessments for ongoing study treatment decisions will be completed by the 
investigator using RECIST 1.1 criteria; see Appendix 2.
Table 5.4-1:
Schedule of CT/MRI Tumor Assessments(CA209331)
Time On Study
Assessment 
Frequency
Assessment Week
(Day 1 of Week Shown)
Assessment Window
Baseline
Week 0
−28 days
Between Week 6 and Week 30
Every 6 weeks
6, 12, 18, 24, 30
± 5 days
Beyond Week 30
Every 12 weeks
42, 54, 66+
± 5 days
Note:  Tumor assessments will continue until disease progression (or until discontinuation of study drug in subjects 
receiving nivolumab beyond progression), lost to follow-up, withdrawal of study consent, or the study ends. 
5.4.1
Primary Efficacy Assessment
The primary endpoint is OS in all randomized subjects. See Section 8.3.1 for the definition of 
OS. Every effort will be made to collect survival data on all subjects including subjects 
Revised Protocol No: 03
Date: 20-Mar-2018
64
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
withdrawn from treatment for any reason, who are eligible to participate in the study and who 
have not withdrawn consent for survival data collection. If the death of a subject is not reported, 
all dates in this study representing a date of subject contact will be used in determination of the 
subject’s last known date alive.
5.4.2
Secondary Efficacy Assessment
Key secondary endpoints include PFS and ORR, based on investigator assessment using 
RECIST 1.1 criteria. 
Subjects achieving a timepoint response of CR or PR will require confirmation for BOR 
determination as per RECIST 1.1, according to the protocol defined tumor assessment schedule. 
In the case of SD, measurements must have met the SD criteria at least once after study entry at a 
minimum interval of 6 weeks (± 5 days).
The investigator assessed ORR will be further characterized by the investigator-determined DOR 
and time to response (TTR).
See Section 8.3.2 for further details.
5.5
Pharmacokinetic and Immunogenicity Assessments
PK and immunogenicity samples will be collected according to the schedule listed in Table 5.5-1
for all subjects treated with nivolumab and analyzed by validated assays. 
All on-treatment PK timepoints are intended to align with days on which nivolumab is 
administered. If it is known that a dose is going to be delayed, then the predose sample should be 
collected just prior to the delayed dose. However, if a predose sample is collected, but the dose is 
subsequently delayed, an additional predose sample should not be collected. Separate, detailed 
instructions for the collection, processing, handling, labeling, storage, and shipment of PK and 
immunogenicity samples will be provided in the central lab manual.
Revised Protocol No: 03
Date: 20-Mar-2018
65
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Table 5.5-1:
Pharmacokinetics and Immunogenicity Sampling Schedule
(Nivolumab) (CA209331)
Study Day
Time 
(Relative to 
Dosing)
Hour
Time 
(Relative to 
Dosing)
Hour: Min
Nivolumab PK
Blood Sample
Nivolumab 
Immunogenicity
Sample
Cycle 1 Day 1
predosea
00:00
X
X
Cycle 3 Day 1
predosea
00:00
X
X
Cycle 11 Day 1
predosea
00:00
X
X
Cycle 19 Day 1
predosea
00:00
X
X
Cycle 27 Day 1
predosea
00:00
X
X
Cycle 39 Day 1
predosea
00:00
X
X
Day 1 of every 12th 
cycle from Cycle 39 
until discontinuation 
of study drug or 
maximum up to 
2 years of treatment
predosea
00:00
X
X
PK - pharmacokinetics
a Predose (0 Hour) samples may be collected up to 4 days prior to dosing. However, if a predose sample is 
collected, and the dose is subsequently delayed, an additional predose sample should not be collected.
5.6
Biomarker Assessments
A variety of factors that could potentially predict clinical response to nivolumab will be 
investigated in tumor specimens obtained at screening, and in peripheral blood taken both at 
screening (prior to first dose of study drug) and during the study, from all randomized subjects as 
outlined in Table 5.6-1 and Table 5.6-2. Complete instructions on the collection, processing, 
handling, and shipment of all samples described herein will be provided in a separate procedure 
manual. 
Revised Protocol No: 03
Date: 20-Mar-2018
66
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Table 5.6-1:
Biomarker Sampling Schedule for Subjects Randomized to 
Nivolumab (CA209331)
Collection Timinga
Tumor
Whole Blood
Study Day
Tumor Biopsyc
SNP
Screening
Xd
C1D1
X
C1D8e
C2D1
C4D1
Upon Progressionf
X
a Biomarker sampling occurs prior to dosing and can occur ± 3 days from the scheduled time.
c Optional biopsies upon progression may be taken at the discretion of the investigator
d Submission of a tumor sample prior to randomization is mandatory.
e Samples on non-study drug dosing days are optional.
f Samples from subjects who have confirmed progression are optional. For subjects being treated beyond 
progression (per Section 4.5.4), samples should be collected at the time of confirmed progression, requiring 
discontinuation of study therapy
Revised Protocol No: 03
Date: 20-Mar-2018
67
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Table 5.6-2:
Biomarker Sampling Schedule for Subjects Randomized to 
Chemotherapy (CA209331)
Collection Timinga
Tumor
Whole Blood
Study Day
Tumor Biopsyc
SNP
Screening
Xd
C1D1
X
C1D15e
C2D1
C3D1
Upon Progressionf
X
a Biomarker sampling occurs prior to dosing and can occur ± 3 days from the scheduled time. 
c Optional biopsies on-treatment and upon progression and may be taken at the discretion of the investigator.
d Submission of a tumor sample prior to randomization is mandatory.
e Samples on non-study drug dosing days are optional.
f Samples from subjects who have confirmed progression are optional.
5.6.1
Tumor Tissue Specimens
Archival or recently collected FFPE tumor tissue collected prior to enrollment must be sent at 
screening to a central laboratory for retrospective determination of PD-L1 status using an 
analytically verified IHC assay.
A biopsy sample of subjects who experience progression at any time while on treatment is 
optional, but strongly encouraged for the purposes of understanding mechanisms of resistance to 
therapy.
Biopsy samples may be used for the following assessments. Tumor tissue collection details are 
provided in Section 5.6.1.3.
 
 
 
 
Revised Protocol No: 03
Date: 20-Mar-2018
68
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
5.6.1.2
DNA and RNA Genomic Assessment
DNA or RNA extracted from tumor provided may be subject to whole genome or exome 
sequencing using next-generation sequencing to identify mutational load and transcriptional 
expression.
5.6.1.3
Tumor Sample Collection Details
Archival tumor specimens are acceptable. For subjects without available/acceptable archival 
tissue, new biopsies must be obtained.
Biopsy samples should be excisional, incisional, or core needle. Fine needle aspirates are not 
acceptable. Tumor samples obtained from bone metastases are not acceptable for PD-L1 testing 
because the PD-L1 assay does not include a decalcification step.
Formalin-fixed paraffin embedded tissue may be evaluated also by fluorescence in situ 
hybridization (FISH), genetic mutation detection methods, and/or by quantitative polymerase 
chain reaction (QPCR) for exploratory analyses of prognostic or predictive molecular markers 
associated with SCLC (eg, gene mutation, amplification or overexpression), to determine if these 
factors influence response to nivolumab. Such analyses will be completed retrospectively and 
within the scope of informed consent. 
If feasible, tumor biopsies may be obtained for subjects who have progressed on nivolumab 
treatment. Changes in expression of immunoregulatory proteins will be assessed in these 
specimens.
If a new biopsy is taken, up to 4 core biopsies are recommended. An assessment of biopsy 
quality by a pathologist is encouraged at the time of the procedure. The tumor tissue that is 
obtained from these biopsies will be divided equally into FFPE samples and RNAlater. 
The investigator, in consultation with the radiology staff, must determine the degree of risk 
associated with the procedure and find it acceptable. Biopsies may be done with local anesthesia 
or conscious sedation. Institutional guidelines for the safe performance of biopsies should be 
followed. Excisional biopsies may be performed to obtain tumor biopsy samples. Invasive 
procedures that require general anesthesia should not be performed to obtain a biopsy specimen. 
However, if a surgical procedure is performed for a clinical indication, excess tumor tissue may 
be used for research purposes with the consent of the subject. 
Pathology report should be provided with tumor samples.
5.6.2
Peripheral Blood Markers
 
 
 
 
Revised Protocol No: 03
Date: 20-Mar-2018
69
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
5.6.2.1
Single Nucleotide Polymorphisms (SNPs)
Whole blood will be collected from all subjects prior to treatment to generate genomic DNA for 
Single Nucleotide Polymorphism (SNP) analyses and serve as a reference for tumor mutational 
profiling, unless restricted by local regulations.
 
 
 
 
 
 
 
 
5.7
Outcomes Research Assessments
The evaluation of health related quality of life is an increasingly important aspect of a clinical 
efficacy. Such data provides an understanding of the impact of treatment from the subjects’ 
perspective and offers insights into the patient experience that may not be captured through 
physician reporting.
The LCSS will be collected to assess the impact of study treatment on patient reported disease 
related symptoms. The LCSS is a validated instrument designed to assess the impact of treatment 
on disease-related symptoms. It consists of 6 symptom specific questions related to dyspnea, 
cough, fatigue, pain, hemoptysis and anorexia plus 3 summary items: symptom distress, 
interference with activity, and global health related quality of life (HRQoL). The degree of 
impairment is recorded on a 100 mm visual analogue scale with scores from 0 to 100 with zero 
representing the best score.24,25,26
The EQ-5D will also be collected in order to assess the impact of study treatment on generic 
health related quality of life, which will also be used in populating health economic models most 
notably, cost effectiveness analysis. The EQ-5D is a standardized instrument for use as a
measure of self-reported health status. The EQ-5D comprises 5 dimensions (mobility, self-care, 
usual activities, pain/discomfort, and anxiety) and a visual analog rating scale (VAS). The utility 
data generated from the EQ-5D is recommended for and commonly used in cost effectiveness 
analysis.27
Healthcare resource utilization data (eg, hospitalizations, non-protocol specified medical visits, 
etc) will be collected for all randomized subjects. Specifically, healthcare resource utilization is 
evaluated based on the number of medical care encounters such as hospital admissions and their 
Revised Protocol No: 03
Date: 20-Mar-2018
70
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
duration, outpatient visits, diagnostic tests and procedures, concomitant medications and reasons 
for the encounters.
5.8
Other Assessments 
5.8.1
Immunogenicity Assessments
Serum samples collected at timepoints identified in Table 5.5-1 will be analyzed by a validated 
immunogenicity assay. As part of the immunogenicity assessment, samples may also be analyzed 
for neutralizing antibodies by a validated method. All on-treatment immunogenicity timepoints 
are intended to align with days on which nivolumab is administered. If a predose sample is
collected, but the dose is subsequently delayed, an additional predose sample should not be 
collected. If it is known that a dose is going to be delayed, then the predose sample should be 
collected just prior to the delayed dose. Selected serum samples may be analyzed by an 
exploratory method that measures anti-nivolumab antibodies for technology exploration 
purposes. 
In addition, serum samples designated for PK 
 assessments may also be used for 
immunogenicity analysis if required (eg, insufficient volume for complete immunogenicity 
assessment or to follow up on suspected immunogenicity related AE).
6
ADVERSE EVENTS
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a 
preexisting medical condition in a clinical investigation subject administered study drug and that 
does not necessarily have a causal relationship with this treatment. An AE can therefore be any 
unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of study drug, whether or not considered related to the study 
drug.
The causal relationship to study drug is determined by a physician and should be used to assess 
all adverse events (AE). The causal relationship can be one of the following:
Related: There is a reasonable causal relationship between study drug administration and 
the AE.
Not related: There is not a reasonable causal relationship between study drug 
administration and the AE.
The term "reasonable causal relationship" means there is evidence to suggest a causal 
relationship. 
Adverse events can be spontaneously reported or elicited during open-ended questioning, 
examination, or evaluation of a subject. (In order to prevent reporting bias, subjects should not be
questioned regarding the specific occurrence of one or more AEs.)
Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or 
immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor 
progression) have been ruled out. IMAEs can include events with an alternate etiology which 
were exacerbated by the induction of autoimmunity.
Revised Protocol No: 03
Date: 20-Mar-2018
71
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Every adverse event must be assessed by the investigator with regard to whether it is considered 
immune-mediated. For events which are potentially immune-mediated, additional information 
will be collected on the subject’s case report form
6.1
Serious Adverse Events
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: 
•
results in death
•
is life-threatening (defined as an event in which the subject was at risk of death at the time of 
the event; it does not refer to an event which hypothetically might have caused death if it 
were more severe)
•
requires inpatient hospitalization or causes prolongation of existing hospitalization (see 
NOTE below)
•
results in persistent or significant disability/incapacity
•
is a congenital anomaly/birth defect 
•
is an important medical event (defined as a medical event(s) that may not be immediately 
life-threatening or result in death or hospitalization but, based upon appropriate medical and 
scientific judgment, may jeopardize the subject or may require intervention [eg, medical, 
surgical] to prevent one of the other serious outcomes listed in the definition above.) 
Examples of such events include, but are not limited to, intensive treatment in an emergency 
room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not 
result in hospitalization.) Potential drug induced liver injury (DILI) is also considered an 
important medical event. (See Section 6.6 for the definition of potential DILI.)
Suspected transmission of an infectious agent (eg, pathogenic or nonpathogenic) via the study 
drug is an SAE.
Although pregnancy, overdose, cancer, and potential drug induced liver injury (DILI) are not 
always serious by regulatory definition, these events must be handled as SAEs. (See 
Section 6.1.1 for reporting pregnancies).
Any component of a study endpoint that is considered related to study drug (eg, death is an 
endpoint, if death occurred due to anaphylaxis, anaphylaxis must be reported) should be reported 
as SAE (see Section 6.1.1 for reporting details).
NOTE: 
The following hospitalizations are not considered SAEs in BMS clinical studies: 
−
a visit to the emergency room or other hospital department < 24 hours, that does not 
result in admission (unless considered an important medical or life-threatening event)
−
elective surgery, planned prior to signing consent
−
admissions as per protocol for a planned medical/surgical procedure
−
routine health assessment requiring admission for baseline/trending of health status (eg, 
routine colonoscopy)
Revised Protocol No: 03
Date: 20-Mar-2018
72
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
−
medical/surgical admission other than to remedy ill health and planned prior to entry into 
the study. Appropriate documentation is required in these cases
−
admission encountered for another life circumstance that carries no bearing on health 
status and requires no medical/surgical intervention (eg, lack of housing, economic 
inadequacy, caregiver respite, family circumstances, administrative reason).
−
Admission for administration of anticancer therapy in the absence of any other SAEs 
(applies to oncology protocols).
6.1.1
Serious Adverse Event Collection and Reporting
Sections 5.6.1 and 5.6.2 in the Investigator Brochure represent the Reference Safety Information 
to determine expectedness of serious adverse events for expedited reporting. Following the 
subject’s written consent to participate in the study, all SAEs, whether related or not related to 
study drug, must be collected, including those thought to be associated with protocol-specified 
procedures. All SAEs must be collected that occur during the screening period and within
100 days of discontinuation of dosing. If applicable, SAEs must be collected that relate to any
later protocol-specified procedure (eg, a follow-up skin biopsy). Subjects, who are randomized 
but never treated with study drug, must have SAEs collected for 30 days from the date of 
randomization.
The investigator should report any SAE that occurs after these time periods and that is believed 
to be related to study drug or protocol-specified procedure. 
An SAE report should be completed for any event where doubt exists regarding its seriousness. 
If the investigator believes that an SAE is not related to study drug, but is potentially related to 
the conditions of the study (such as withdrawal of previous therapy or a complication of a study 
procedure), the relationship should be specified in the narrative section of the SAE Report Form.
SAEs, whether related or not related to study drug, and pregnancies must be reported to BMS (or 
designee) within 24 hours of awareness of the event. SAEs must be recorded on the SAE Report 
Form; pregnancies on a Pregnancy Surveillance Form (electronic or paper forms). The preferred 
method for SAE data reporting collection is through the CRF. The paper SAE/pregnancy 
surveillance forms are only intended as a back-up option when the electronic CRF system is not 
functioning. In this case, the paper forms are to be transmitted via email or confirmed facsimile 
(fax) transmission to:
SAE Email Address: Refer to Contact Information list.
SAE Facsimile Number: Refer to Contact Information list.
For studies capturing SAEs through electronic data capture (EDC), electronic submission is the 
required method for reporting. The paper forms should be used and submitted immediately, only 
in the event the electronic system is unavailable for transmission. When paper forms are used, 
the original paper forms are to remain on site.
Revised Protocol No: 03
Date: 20-Mar-2018
73
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
SAE Telephone Contact (required for SAE and pregnancy reporting): Refer to Contact
Information list.
If only limited information is initially available, follow-up reports are required. (Note: Follow-up 
SAE reports should include the same investigator term(s) initially reported.) 
If an ongoing SAE changes in its intensity or relationship to study drug or if new information 
becomes available, a follow-up SAE report should be sent within 24 hours to the BMS (or 
designee) using the same procedure used for transmitting the initial SAE report.
All SAEs should be followed to resolution or stabilization.
6.2
Nonserious Adverse Events
A nonserious adverse event is an AE not classified as serious.
6.2.1
Nonserious Adverse Event Collection and Reporting
The collection of nonserious AE information should begin at initiation of study drug. Nonserious 
AE information should also be collected from the start of a placebo lead-in period or other 
observational period intended to establish a baseline status for the subjects.
Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they 
become serious (see Section 6.1.1). Follow-up is also required for nonserious AEs that cause 
interruption or discontinuation of study drug and for those present at the end of study treatment 
as appropriate. All identified nonserious AEs must be recorded and described on the nonserious 
AE page of the CRF (paper or electronic). 
All nonserious AEs (not only those deemed to be treatment-related) should be collected 
continuously during the treatment period and for a minimum of 100 days following the last dose 
of study treatment.
Completion of supplemental CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported/identified during the course of the study.
6.3
Laboratory Test Result Abnormalities
The following laboratory test result abnormalities should be captured on the nonserious AE CRF 
page or SAE Report Form (paper or electronic) as appropriate:
•
Any laboratory test result that is clinically significant or meets the definition of an SAE 
•
Any laboratory test result abnormality that required the subject to have study drug 
discontinued or interrupted
•
Any laboratory test result abnormality that required the subject to receive specific corrective 
therapy.
It is expected that wherever possible, the clinical rather than laboratory term would be used by 
the reporting investigator (eg, anemia versus low hemoglobin value).
Revised Protocol No: 03
Date: 20-Mar-2018
74
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
6.4
Pregnancy
If, following initiation of the study drug, it is subsequently discovered that a study subject is 
pregnant or may have been pregnant at the time of study exposure, including during at least 
5 half lives after product administration, the investigator must immediately notify the BMS 
Medical Monitor/designee of this event and complete and forward a Pregnancy Surveillance 
Form to BMS Designee within 24 hours of awareness of the event and in accordance with SAE 
reporting procedures described in Section 6.1.1.
In most cases, the study drug will be permanently discontinued in an appropriate manner (eg, 
dose tapering if necessary for subject safety).
In the rare event that the benefit of continuing study drug is thought to outweigh the risk, after 
consultation with BMS, the pregnant subject may continue study drug after a thorough 
discussion of benefits and risk with the subject
The investigator must immediately notify the BMS (or designee) Medical Monitor of this event 
and complete and forward a Pregnancy Surveillance Form to BMS (or designee) within 24 hours 
of awareness of the event and in accordance with SAE reporting procedures described in 
Section 6.1.1. 
Follow-up information regarding the course of the pregnancy, including perinatal and neonatal 
outcome and, where applicable, offspring information must be reported on the Pregnancy 
Surveillance Form.
Any pregnancy that occurs in a female partner of a male study participant should be reported to 
BMS. Information on this pregnancy will be collected on the Pregnancy Surveillance Form.
6.5
Overdose
An overdose is defined as the accidental or intentional administration of any dose of a product 
that is considered both excessive and medically important. All occurrences of overdose must be 
reported as an SAE (see Section 6.1.1 for reporting details.).
6.6
Potential Drug Induced Liver Injury (DILI)
Wherever possible, timely confirmation of initial liver-related laboratory abnormalities should 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, 
meeting the defined criteria, must be reported as SAEs (see Section 6.1.1 for reporting details).
Potential drug induced liver injury is defined when all three of the following are present:
1) Aminotransaminase (AT, ALT or AST) elevation > 3 times upper limit of normal (ULN)
2) Total bilirubin > 2 times ULN, without initial findings of cholestasis (elevated serum alkaline 
phosphatase),
3) No other immediately apparent possible causes of AT elevation and hyperbilirubinemia, 
including, but not limited to, viral hepatitis, pre-existing chronic or acute liver disease, or the 
administration of other drug(s) known to be hepatotoxic.
Revised Protocol No: 03
Date: 20-Mar-2018
75
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
6.7
Other Safety Considerations
Any 
significant 
worsening 
noted 
during 
interim 
or 
final 
physical 
examinations, 
electrocardiogram, x-ray filming, any other potential safety assessment required or not required 
by protocol should also be recorded as a nonserious or serious AE, as appropriate, and reported 
accordingly. 
7
DATA MONITORING COMMITTEE AND OTHER EXTERNAL 
COMMITTEES
One independent committee will be utilized, a DMC. The DMC will be utilized to provide 
general oversight and safety considerations for this study, CA209331. The DMC will provide 
advice to the Sponsor regarding actions the committee deems necessary for the continuing 
protection of subjects enrolled in this study. The DMC will be charged with assessing such 
actions in light of an acceptable risk/benefit profile for nivolumab. The DMC will act in an 
advisory capacity to BMS and will monitor subject safety data for the study.
The DMC will be advisory to the clinical study leadership team. The clinical study leadership
will have responsibility for overall conduct of the study including managing the communication 
of study data. The group will be responsible for promptly reviewing the DMC recommendations, 
for providing guidance regarding the continuation or termination of the study, and for 
determining whether amendments to the protocol or changes to the study conduct are required.
Details of the DMC responsibilities and procedures will be specified in the DMC charter.
When required, adjudicated events will be submitted to the DMC and Health Authorities for 
review on a specified timeframe in accordance with the adjudication documentation.
8
STATISTICAL CONSIDERATIONS
8.1
Sample Size Determination
In this study, the primary endpoint of OS will be evaluated for treatment effect at the overall 
alpha level of 0.05 (two-sided). Approximately 560 subjects will be randomized at a ratio of 1:1 
into two arms: Arm A (nivolumab); Arm B (chemotherapy: topotecan or amrubicin). For sample 
size calculation, non-proportional hazard model with a piecewise exponential distributions in 
both arms are assumed. Based on published survival curves for topotecan, a 2-piece exponential 
distribution with an 8-month median OS and taking into account that a limited number of 
subjects might receive immuno-oncology as subsequent therapy, a conservative 5% 2-year 
survival rate is assumed for the control arm. A delayed effect for nivolumab with a hazard ratio 
(HR) of 1 for the first 8 months and an HR of 0.5 thereafter is assumed The final analysis will 
take place 34 months after the first patient have been randomized and no formal interim analysis 
will be conducted. The 560 subjects are expected to be randomized in 18 months, resulting in 
about 16 months of follow-up for the last subject randomized at the time of the primary analysis. 
It is anticipated that approximately 480 events will be observed at the time of the analysis, 
leading to 90% power to detect a difference in overall survival as tested via a log-rank test with 
a two-sided 0.05 type I error rate. Power calculations were performed using EAST® Software 
(version 6.4.1).
Revised Protocol No: 03
Date: 20-Mar-2018
76
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
The decision to incorporate the China subset into the overall population for analysis is the result 
of a review of the protocol statistical assumptions in comparison to recent data from the 
CA209032 study in 2L+ SCLC subjects.28 The data from CA209032, which were not available 
at the time of protocol design, suggest a delayed effect of nivolumab with a non-proportional 
hazard for survival. Additionally, review of recently generated real-world data for topotecan 
resulted in updated assumptions for the control arm. Given the updated statistical assumptions, 
incorporation of the China subset into the study analyses grants adequate statistical power by 
increasing the study sample size.
Table 8.1-1:
Sample Size Justification
Primary Endpoint
OS
Power 
90%
Alpha level
0.05
Sample size
560
Accrual duration 
18 months 
Timing of the analysis from randomization of first 
subject (months)
34
Hypothesized OS rate at 8 months
50% in both arms (HR=1 up to Month 8)
Hypothesized OS rate at 24 months
5% vs 16% (HR=0.5 from Month 8)
Expected Average HR 
~0.745
Expected number of event at 34 months
482
8.2
Populations for Analyses
•
All enrolled subjects: All subjects who sign an informed consent form and are registered into 
the IVRS
•
All randomized subjects: All enrolled subjects who are randomized to any treatment arm in 
the study. This is the primary dataset for analyses of efficacy and baseline characteristics.
•
All treated subjects: All enrolled subjects who received at least one dose of nivolumab, or 
chemotherapy. This is the primary dataset for dosing and safety.
•
PK subjects: All enrolled subjects with available serum time-concentration data from 
randomized subjects dosed with nivolumab.
•
All PD-L1 tested subjects: All subjects, randomized or not, who had a tumor biopsy 
specimen available for PD-L1 expression testing (validated assay). This includes both 
randomized and screen failure subjects.
•
All randomized subjects with quantifiable PD-L1 expression at baseline: Randomized 
subjects with at least one tumor sample collected at baseline, with number viable tumor cells 
≥ 100, and percentage of viable tumor cells exhibiting PD-L1 membrane staining ≥0%.
•
Tumor Mutational Burden (TMB) evaluable Subjects: All randomized subjects with baseline 
evaluable TMB
Revised Protocol No: 03
Date: 20-Mar-2018
77
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
•
Biomarker subjects: All treated subjects with biomarker data available.
•
China Population: all subjects enrolled in China. Additional analyses exploring the 
consistency of findings in the China cohort may be conducted. Details of these analyses will 
be provided in the analysis plan.
8.3
Endpoints
8.3.1
Primary Endpoint(s)
The primary endpoint for the study is OS. It is defined as the time from randomization to the date 
of death. A subject who has not died will be censored at last known date alive. OS will be 
followed continuously while subjects are on the study drug and every 3 months via in-person or 
phone contact after subjects discontinue the study drug. 
8.3.2
Secondary Endpoint(s)
Secondary endpoints include ORR and PFS.
8.3.2.1
Progression Free Survival
PFS is defined as the time from randomization to the date of the first documented tumor 
progression (per RECIST 1.1) or death due to any cause. Subjects who die without a reported 
prior progression will be considered to have progressed on the date of their death. Subjects who 
did not progress or die will be censored on the date of their last evaluable tumor assessment. 
Subjects who did not have any on study tumor assessments and did not die will be censored on 
the date they were randomized. Subjects who started any subsequent anti-cancer therapy without 
a prior reported progression will be censored at the last evaluable tumor assessment prior to 
initiation of the subsequent anti-cancer therapy. Tumor response will be assessed every 6 weeks 
(± 5 days) (from the first dose of study drug) until Week 30, and every 12 weeks (± 5 days). 
Tumor assessment will continue until disease progression (or until discontinuation of study drug 
in subjects receiving nivolumab beyond progression), lost to follow-up, withdrawal of study 
consent, or the study ends.
8.3.2.2
Objective Response Rate
The ORR will be based on the best overall response on study defined using RECIST 1.1, as 
assessed by the investigator. ORR is defined as the proportion of all randomized subjects whose 
BOR from baseline is either a CR or PR per RECIST 1.1 criteria. BOR is determined by the best 
response between the date of randomization and the date of objectively documented progression 
or the date of subsequent anti-cancer therapy, whichever occurs first. For subjects without 
documented progression or subsequent anti-cancer therapy, all available response designations 
will contribute to the BOR determination. For subjects who continue nivolumab beyond 
progression, the BOR should be determined based on tumor assessments before initial 
RECIST 1.1 defined progression. The comparison of ORR will be carried out using a two-sided 
Cochran-Mantel-Haenszel (CMH) test stratified by the stratification factors as described in 
Section 3.1 associated odds ratio and 95% CI will be calculated. Rates and their 2-sided exact CI 
will be calculated by the method of Clopper and Pearson for each randomized arm.
Revised Protocol No: 03
Date: 20-Mar-2018
78
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
In addition, DOR and TTR will be summarized in each randomized arm. DOR is defined as the 
time between the date of first confirmed response to the date of the first documented tumor 
progression (per RECIST 1.1) or death due to any cause. Subjects who neither progress nor die 
will be censored on the date of their last assessment. TTR is defined as the time from 
randomization to the date of the first confirmed CR or PR. DOR and TTR will be evaluated for 
responders (confirmed CR or PR) only.
8.3.3
Exploratory Endpoint(s) 
PD-L1 expression is defined as the percent of tumor cells demonstrating plasma membrane 
PD-L1 staining of any intensity using an IHC assay.
Safety and tolerability objective will be measured by the incidence of AEs, serious adverse 
events, deaths, and laboratory abnormalities.
Adverse event assessments and laboratory tests are performed at baseline, and continuously 
throughout the study at the beginning of each subsequent cycle.
Tumor Mutational Burden (TMB) is measured using FoundationOne CDxTM (F1CDx) assay, 
a comprehensive genomic profile (CGP) assay based on baseline tumor tissue. TMB is defined 
as the number of somatic, coding, base substitution, and indel mutations per megabase of 
genome examined. All base substitutions and indels present at 5% allele frequency or greater in 
the coding region of targeted genes, including synonymous alterations, are initially counted 
before filtering as described below. Synonymous mutations are counted in order to reduce 
sampling noise. While synonymous mutations are not likely to be directly involved in creating 
immunogenicity, their presence is a signal of mutational processes that will also have resulted in 
nonsynonymous mutations and neoantigens elsewhere in the genome. Non-coding alterations 
were not counted. Alterations listed as known somatic alterations in COSMIC and truncations in 
tumor suppressor genes were not counted, since our assay genes are biased toward genes with 
functional mutations in cancer. 
Alterations predicted to be germline by the somatic-germline-zygosity algorithm were not 
counted. Alterations that were recurrently predicted to be germline in our cohort of clinical 
specimens were not counted. Known germline alterations in dbSNP were not counted. Germline 
alterations occurring with two or more counts in the ExAC database were not counted.
To calculate the TMB per megabase, the total number of mutations counted is divided by the size 
of the coding region of the targeted territory.
Definition of high tumor mutational burden: high TMB will be provided in Statistical Analysis 
Plan.
Time to Symptom deterioration (TTSD) is defined as the time between the date of 
randomization and the first date of a 10 point or more increase from baseline in the LCSS 
Average Symptom Burden Index (ABSI). Subjects who did not meet the criteria of a 10 points or 
more increase from baseline in LCSS ASBI will be censored on their last LCSS assessment date. 
Subjects who did not have any on study LCSS assessment will be censored on their date of 
randomization. 
Revised Protocol No: 03
Date: 20-Mar-2018
79
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
The LCSS is a measure of disease-related symptoms and quality of life suited to use in patients 
suffering from lung cancer. It includes six items measuring loss of appetite, fatigue, coughing, 
shortness of breath, hemoptysis, and pain. Three additional items measure overall symptom 
burden, disease-related functional limitations, and quality of life. The questionnaire uses a 24 
hour recall period, and responses for each item are captured using a 100-mm visual analog scale 
(VAS). Scores for individual items ranging from 0 (no symptomatology or highest quality of 
life) to 100 (worst symptomatology or quality of life) are derived by dividing the length of the 
line drawn from the lowest possible response to the patient’s response by the length of the VAS 
and multiplying the resulting quotient by 100.
An average symptom burden index (ASBI) score can be derived as the average of scores for the 
six symptom-related items with a clinically meaningful change in ASBI score being defined as 
10 points. 
Disease-related symptom deterioration rate by Week 12 and by Week 24 is defined as the 
proportion of randomized subjects who had 10 points or more increase from baseline in ABSI 
score at any time between randomization and Week 12/Week 24, respectively. 
Subjects’ overall health status will be assessed using The EuroQol Group’s self-reported health 
status measure (EQ-5D). EQ-5D essentially has 2 health status components - the EQ-5D 
descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D descriptive system 
comprises the following 5 dimensions:  mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. Each dimension has 3 levels:  no problems, some problems, severe problems. 
The EQ Vas records the subject’s self-rated health state on a 100-point vertical, visual analogue 
scale (0 = worst imaginable health state; 100 = best imaginable health state).29
Serum concentrations will be used to characterize the PK of nivolumab using a population PK 
approach and to explore exposure-safety and exposure-efficacy relationships.
Other exploratory endpoints for phamacogenomics, immunogenicity and outcomes research are 
discussed in detail in Sections 8.4.5 through 8.4.7.
8.4
Analyses
8.4.1
Demographics and Baseline Characteristics
Demographics and baseline laboratory results will be summarized by treatment arm as 
randomized using descriptive statistics for all randomized subjects.
8.4.2
Efficacy Analyses
All hypothesis testing will be two-sided based on a significance level of 0.05 except for OS. If 
superiority of OS is demonstrated, a hierarchical hypothesis testing approach for the key 
secondary endpoints will be used to preserve a study-wise type I error rate at 0.05. The key 
secondary endpoints will be tested in the following hierarchical order: 
1) PFS
2) ORR.
Revised Protocol No: 03
Date: 20-Mar-2018
80
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
The formal statistical testing for PFS will take place only if OS is statistically significant and the 
statistical testing for ORR will take place only if both OS and PFS are statistically significant.
8.4.2.1
Methods of Primary Endpoint
The distribution of OS will be compared in two randomized arms via a two-sided, log-rank test 
stratified by the stratification factors as described in Section 3.1. The HR and the corresponding 
two-sided 95% CI will be estimated in a stratified Cox proportional hazards model using 
randomized arm as a single covariate. The OS curves for each randomized arm will be estimated 
using the Kaplan-Meier (KM) product-limit method. Two-sided, 95% confidence intervals for 
median OS will be computed by Brookmeyer and Crowley method (using a log-log 
transformation). Survival rates at 6, 12, 18, 24, 36, 48 months and 5 years will be estimated using 
KM estimates on the OS curve for each randomized arm provided minimum follow-up is longer 
than timepoint to generate the rate. Associated two-sided 95% CIs will be calculated using the 
Greenwood formula.
8.4.2.2
Methods for Secondary Endpoint
The distribution of PFS will be compared in two randomized arms using a two-sided, log-rank 
test stratified by the stratification factors as described in Section 3.1. The HR and the 
corresponding two-sided 95% CI will be estimated in a stratified Cox proportional hazards 
model using randomized arm as a single covariate. The PFS curves for each randomized arm will 
be estimated using the KM product-limit method. Two-sided, 95% confidence intervals for 
median PFS will be computed by Brookmeyer and Crowley method (using a log-log 
transformation).
ORR in two randomized arms will be compared using a two-sided CMH test, stratified by the 
same factors. An associated odds ratio and 95% CI will also be calculated. Rates and their 
corresponding 95% exact CI will be calculated by Clopper-Pearson method for each randomized 
arm.
The estimation of DOR and TTR in two randomized arms will be computed for subjects who 
achieve PR or CR using KM product-limit method. Median values of duration and time-to, along 
with two-sided 95% CI, will be calculated. 
8.4.3
Safety Analyses
The safety analysis will be performed in all treated subjects. Descriptive statistics of safety will 
be presented using NCI CTCAE version 4.0 by treatment arm. All on-treatment AEs, 
drug-related AEs, late-emergent drug-related AEs, SAEs and drug-related SAEs will be 
tabulated using worst grade per NCI CTCAE version 4.0 criteria by system organ class and 
preferred term. On-study lab parameters including hematology, coagulation, chemistry, liver 
function and renal function will be summarized using worst grade per NCI CTCAE v 4.0 criteria.
8.4.4
Pharmacokinetic Analyses
The concentration vs time data obtained in this study may be combined with data from other 
studies in the clinical development program to develop a population PK model. This model may 
be used to evaluate the effects of intrinsic and extrinsic covariates on the PK of nivolumab and to
Revised Protocol No: 03
Date: 20-Mar-2018
81
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
determine measures of individual exposure (such as steady-state peak, trough, and time-averaged 
concentration). Model determined exposures may be used for exposure-response analyses of 
selected efficacy and safety end points. Results of population PK and exposure-response 
analyses will be reported separately.
8.4.5
Biomarker Analyses
8.4.5.1
Pharmacodynamic Analyses
To assess pharmacodynamic effects in serum obtained from subjects on each treatment arm, 
summary statistics for biomarkers of 
 
and their corresponding changes (or percent changes)
from baseline will be tabulated by planned study visit. In addition, the time course of biomarker 
outcomes will be investigated graphically. If there is indication of a meaningful pattern across 
time, further analysis may be completed to characterize the relationship. Possible associations 
between changes in biomarker measures of interest and exposure to study drug will be explored 
graphic. 
8.4.5.2
Pharmacogenomic Analyses
Pharmacogenomic and Exploratory Analyses
Potential relationships between biomarker data and efficacy or safety endpoints will be 
investigated as part of an analysis plan aimed at identifying baseline biomarkers that may be 
used to prospectively identify subjects likely (or not likely) to respond to nivolumab and to 
identify subjects who may be predisposed to having adverse reactions to treatment. These 
exploratory predictive biomarker analyses will be completed with biomarkers measured in blood 
and in tumor samples and will focus primarily--as outlined in the exploratory objectives--on 
SNPs in select genes associated with immunity or on the expression of 
, PD-L1, 
 
proteins in tumor specimens. Similar analyses will be completed with data regarding 
 and putative additional analyses to be completed 
using FFPE tissue. 
Associations between biomarkers and efficacy measures will be analyzed on all randomized 
subjects with available biomarker data. Efficacy measures will include response, PFS, and OS. 
Demographic and case-history factors will be examined to determine whether stratification or 
adjustments should be made within the subsequent statistical analyses, and if necessary, the 
appropriate stratification or adjustment will be made.
Biomarkers will be summarized graphically as they relate to efficacy and safety endpoints, as 
applicable. Summary statistics will be tabulated. SNP allele frequencies will be summarized. The 
relationships between binary measures (eg, response) and candidate biomarkers will be 
investigated using logistic regression. Associations will be summarized in terms of point and 
interval estimates of hazard ratios, odds ratios, or other statistics, as appropriate for the analyses 
completed. Models to predict clinical activity based on combinations of biomarkers may also be 
investigated.
Revised Protocol No: 03
Date: 20-Mar-2018
82
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Additional post hoc statistical analyses not specified in the protocol, such as alternative modeling 
approaches may be completed. All analyses described in this section are based on the availability 
of the data. 
8.4.6
Outcomes Research Analyses
LCSS questionnaire complete rate, defined as the proportion of questionnaires actually received 
out of the expected number (ie, the number of subjects still on treatment or in follow-up), will be 
calculated and summarized at each assessment point.
Baseline and change from baseline of the average symptom burden index score at each 
assessment point will be summarized using descriptive statistics. 
Subject’s overall health state on a visual analog scale (EQ-VAS) at each assessment time point 
will be summarized using descriptive statistics Proportion of subjects reporting problems for the 
5 EQ-5D dimensions at each assessment time point will be summarized by level of problem.
Summary statistics will be calculated for the population preference-based health state utility 
score (EQ-5D Index).
8.4.7
Other Analyses 
Methodology for exploratory analyses including immunogenicity, other HRQoL assessments 
(PRO), and healthcare resource utilization is described in the statistical analysis plan.
8.5
Interim Analyses
No formal analysis for OS will be performed for this study.
A DMC will have access to periodic unblinded interim reports of efficacy and safety to allow a 
risk/benefit assessment. No formal test will be performed and the study will not stop for 
superiority. Details will be included in the DMC charter. 
9
STUDY MANAGEMENT
9.1
Compliance
9.1.1
Compliance with the Protocol and Protocol Revisions
The study shall be conducted as described in this approved protocol. All revisions to the protocol 
must be discussed with, and be prepared by, BMS. The investigator should not implement any 
deviation or change to the protocol without prior review and documented approval/favorable 
opinion from the IRB/IEC of an amendment, except where necessary to eliminate an immediate 
hazard(s) to study subjects. 
If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior 
to obtaining IRB/IEC approval/favorable opinion, as soon as possible the deviation or change 
will be submitted to:
•
IRB/IEC for review and approval/favorable opinion
•
BMS
•
Regulatory Authority(ies), if required by local regulations
Revised Protocol No: 03
Date: 20-Mar-2018
83
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Documentation of approval signed by the chairperson or designee of the IRB(s)/IEC(s) must be 
sent to BMS.
If an amendment substantially alters the study design or increases the potential risk to the 
subject: (1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review and 
approval/favorable opinion; (2) the revised form must be used to obtain consent from subjects 
currently enrolled in the study if they are affected by the amendment; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment.
If the revision is done via an administrative letter, investigators must inform their IRB(s)/IEC(s).
9.1.2
Monitoring
BMS representatives will review data centrally to identify potential issues to determine a 
schedule of on-site visits for targeted review of study records. 
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity. On site they will review study records and directly compare 
them with source documents, discuss the conduct of the study with the investigator, and verify 
that the facilities remain acceptable. 
In addition, the study may be evaluated by BMS internal auditors and government inspectors 
who must be allowed access to CRFs, source documents, other study files, and study facilities. 
BMS audit reports will be kept confidential.
The investigator must notify BMS promptly of any inspections scheduled by regulatory 
authorities, and promptly forward copies of inspection reports to BMS. 
9.1.2.1
Source Documentation
The Investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attributable, whether the data are hand-written on paper or 
entered electronically. If source data are created (first entered), modified, maintained, archived, 
retrieved, or transmitted electronically via computerized systems (and/or any other kind of 
electronic devices) as part of regulated clinical trial activities, such systems must be compliant 
with all applicable laws and regulations governing use of electronic records and/or electronic 
signatures. Such systems may include, but are not limited to, electronic medical/health records 
(EMRs/EHRs), AE tracking/reporting, protocol required assessments, and/or drug accountability 
records).
When paper records from such systems are used in place of electronic format to perform 
regulated activities, such paper records should be certified copies. A certified copy consists of a 
copy of original information that has been verified, as indicated by a dated signature, as an exact 
copy having all of the same attributes and information as the original. 
Revised Protocol No: 03
Date: 20-Mar-2018
84
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
9.1.3
Investigational Site Training
Bristol-Myers Squibb will provide quality investigational staff training prior to study initiation. 
Training topics will include but are not limited to: GCP, AE reporting, study details and 
procedure, electronic CRFs, study documentation, informed consent, and enrollment of WOCBP.
9.2
Records
9.2.1
Records Retention
The investigator must retain all study records and source documents for the maximum period 
required by applicable regulations and guidelines, or institution procedures, or for the period 
specified by BMS, whichever is longer. The investigator must contact BMS prior to destroying 
any records associated with the study.
BMS will notify the investigator when the study records are no longer needed.
If the investigator withdraws from the study (eg, relocation, retirement), the records shall be 
transferred to a mutually agreed upon designee (eg, another investigator, IRB). Notice of such 
transfer will be given in writing to BMS.
9.2.2
Study Drug Records 
It is the responsibility of the investigator to ensure that a current disposition record of study drug 
(inventoried and dispensed) is maintained at the study site to include investigational product. 
Records or logs must comply with applicable regulations and guidelines and should include:
•
amount received and placed in storage area
•
amount currently in storage area
•
label identification number or batch number 
•
amount dispensed to and returned by each subject, including unique subject identifiers
•
amount transferred to another area/site for dispensing or storage
•
nonstudy disposition (eg, lost, wasted) 
•
amount destroyed at study site, if applicable
•
amount returned to BMS
•
retain samples for bioavailability/bioequivalence, if applicable 
•
dates and initials of person responsible for Investigational Product dispensing/accountability, 
as per the Delegation of Authority Form.
BMS will provide forms to facilitate inventory control if the investigational site does not have an 
established system that meets these requirements.
Revised Protocol No: 03
Date: 20-Mar-2018
85
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
9.2.3
Case Report Forms
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other data pertinent to the investigation on each individual treated 
or entered as a control in the investigation. Data that are derived from source documents and 
reported on the CRF must be consistent with the source documents or the discrepancies must be 
explained. Additional clinical information may be collected and analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
For sites using the BMS electronic data capture tool, electronic CRFs will be prepared for all 
data collection fields except for fields specific to SAEs and pregnancy, which will be reported on 
the paper or electronic SAE form and Pregnancy Surveillance form, respectively. Spaces may be 
left blank only in those circumstances permitted by study-specific CRF completion guidelines 
provided by BMS. 
The confidentiality of records that could identify subjects must be protected, respecting the 
privacy and confidentiality rules in accordance with the applicable regulatory requirement(s).
The investigator will maintain a signature sheet to document signatures and initials of all persons 
authorized to make entries and/or corrections on CRFs. 
The completed CRF, including any paper or electronic SAE/pregnancy CRFs, must be promptly 
reviewed, signed, and dated by the investigator or qualified physician who is a subinvestigator
and who is delegated this task on the Delegation of Authority Form. For electronic CRFs, review 
and approval/signature is completed electronically through the BMS electronic data capture tool. 
The investigator must retain a copy of the CRFs including records of the changes and 
corrections.
Each individual electronically signing electronic CRFs must meet BMS training requirements 
and must only access the BMS electronic data capture tool using the unique user account 
provided by BMS. User accounts are not to be shared or reassigned to other individuals.
9.3
Clinical Study Report and Publications
A Signatory Investigator must be selected to sign the clinical study report. 
For this protocol, the Signatory Investigator will be selected as appropriate based on the 
following criteria:
•
External Principal Investigator designated at protocol development
•
National Coordinating Investigator 
•
Study Steering Committee chair or their designee
•
Subject recruitment (eg, among the top quartile of enrollers)
•
Involvement in trial design
•
Regional representation (eg, among top quartile of enrollers from a specified region 
or country)
•
Other criteria (as determined by the study team).
Revised Protocol No: 03
Date: 20-Mar-2018
86
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
The data collected during this study are confidential and proprietary to BMS. Any publications 
or abstracts arising from this study must adhere to the publication requirements set forth in the 
clinical trial agreement (CTA) governing [Study site or Investigator] participation in the study. 
These requirements include, but are not limited to, submitting proposed publications to BMS at 
the earliest practicable time prior to submission or presentation and otherwise within the time 
period set forth in the CTA.
Revised Protocol No: 03
Date: 20-Mar-2018
87
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
10
GLOSSARY OF TERMS
Term
Definition
Complete Abstinence
If one form of contraception is required, Complete 
Abstinence is defined as complete avoidance of heterosexual 
intercourse and is an acceptable form of contraception for all 
study drugs. Female subjects must continue to have 
pregnancy tests. Acceptable alternate methods of highly 
effective contraception must be discussed in the event that 
the subject chooses to forego complete abstinence.
If two forms of contraception is required, Complete 
abstinence is defined as complete avoidance of heterosexual 
intercourse and is an acceptable form of contraception for all 
study drugs. Subjects who choose complete abstinence are 
not required to use a second method of contraception, but 
female subjects must continue to have pregnancy tests. 
Acceptable alternate methods of highly effective 
contraception must be discussed in the event that the subject 
chooses to forego complete abstinence.
Expanded definition Complete abstinence as defined as 
complete avoidance of heterosexual intercourse is an 
acceptable form of contraception for all study drugs. This 
also means that abstinence is the preferred and usual lifestyle 
of the subject. This does not mean periodic abstinence (eg, 
calendar, ovulation, symptothermal, profession of abstinence 
for entry into a clinical trial, post-ovulation methods) and 
withdrawal, which are not acceptable methods of 
contraception. Subjects who choose complete abstinence are 
not required to use a second method of contraception, but 
female subjects must continue to have pregnancy tests. 
Acceptable alternate methods of highly effective 
contraception must be discussed in the event that the subject 
chooses to forego complete abstinence
Revised Protocol No: 03
Date: 20-Mar-2018
88
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
11
LIST OF ABBREVIATIONS
Term
Definition
AE
adverse event
ALT
alanine aminotransferase
ANC
absolute neutrophil count
AST
aspartate aminotransferase
AT
aminotransaminases
BOR
best overall response
BMS
Bristol-Myers Squibb
BP
blood pressure
BUN
blood urea nitrogen
C
Celsius
Ca
calcium
CAV
cyclophosphamide, doxorubicin, vincristine
CBC
complete blood count
CFR
Code of Federal Regulations 
CI
confidence interval
CMH
Cochran-Mantel-Haenszel
CNS
central nervous system
CR
complete response
CRF
Case Report Form, paper or electronic
CT
computed tomography
CTA
clinical trial agreement
DILI
drug-induced liver disease
DMC
data monitoring committee
DOR
duration of objective response
ECG
electrocardiogram
ECOG
Eastern Cooperative Oncology Group
EDC
electronic data capture
ED-SCLC
Extensive Stage Disease
eg
exempli gratia (for example)
Revised Protocol No: 03
Date: 20-Mar-2018
89
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Term
Definition
FDA
Food and Drug Administration
FFPE
formalin-fixed, paraffin-embedded
FSH
follicle stimulating hormone
GCP
Good Clinical Practice
HBsAg
hepatitis B surface antigen
HBV
hepatitis B virus
HCV
hepatitis C virus
HIV
Human Immunodeficiency Virus
HR
heart rate
HR
hazard ratio
HRQoL
health related quality of life
HRT
hormone replacement therapy
ICD
International Classification of Diseases
ICF
informed consent form
ICH
International Conference on Harmonisation 
ie
id est (that is)
IEC
Independent Ethics Committee
IHC
immunohistochemistry
ILD
interstitial lung disease
IMP
investigational medicinal products
IND
Investigational New Drug Exemption
IRB
Institutional Review Board
ITIM
immunoreceptor tyrosine inhibitory motif
ITSM
immunoreceptro tyrosine-based switch motif
IU
International Unit
IUD
intrauterine device
IV
Intravenous(ly)
IVRS
interactive voice response system
K
potassium
KM
Kaplan-Meier
Revised Protocol No: 03
Date: 20-Mar-2018
90
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Term
Definition
LCSS
Lung Cancer Symptom Scale
LDH
lactate dehydrogenase
LD-SCLC
Limited Stage Disease
LVEF
Left ventricular ejection fraction
mAbs
monoclonal antibodies
MRI
magnetic resonance imaging
N
number of subjects or observations
Na
sodium
N/A
not applicable
NCCN
National Comprehensive Cancer Network
NCI CTCAE
National Cancer Institute Common Toxicity Criteria for Adverse Events
NIMP
non-investigational medicinal products 
NSCLC
non-small cell lung cancer
ORR
objective response rate
OS
overall survival
PBMC
peripheral blood mononuclear cell
PD
progressive disease
PD-1
Programmed death receptor-1
PFS
progression free survival
PK
pharmacokinetics
PO
per os (by mouth route of administration)
Pop PK
Population PK
PR
partial response
Q2W
every 2 weeks
RCC
renal cell carcinoma
RECIST
Response Evaluation Criteria in Solid Tumors
SAE
serious adverse event
SCLC
small-cell lung cancer
SD
stable disease
SNP
single nucleotide polymorphism
Revised Protocol No: 03
Date: 20-Mar-2018
91
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Term
Definition
TAO
Trial Access Online, the BMS implementation of an EDC capability
TCR
T-cell receptor
TMB
Tumor mutational burden
TTR
time to response
ULN
upper limit of normal
VAS
visual analogue scale
WBC
white blood cell
WOCBP
women of childbearing potential
Revised Protocol No: 03
Date: 20-Mar-2018
92
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
12
REFERENCES
1
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2
Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 
111:1710-1717.
3
National Comprehensive Cancer Network. Small Cell Lung Cancer, v 1.2015. NCCN. 
Available at http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf.
4
Sorensen M, Pijls-Johannesma M, Felip E. Small-cell lung cancer: ESMO clinical practice 
guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2010; 21 (Supplement 
5):v120-v125.
5
Jänne PA, Freidlin B, Saxman S, et al. Twenty-five years of clinical research for patients 
with limited-stage small cell lung carcinoma in North America. Cancer 2002;95:1528-38.
6
Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for 
patients with extensive-stage small-cell lung cancer: perceptible progress. JCO 
1999;17:1794-1801.
7
Puglisi M, Dolly S, Faria A, et al. Treatment options for small cell lung cancer - do we have
more choice? Br J Cancer 2010;102:629-638.
8
Von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, 
doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. JCO 
1999;17:658-667.
9
O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone 
with supportive care with oral topotecan in patients with relapsed small cell lung cancer. 
J Clin Oncol 2006;24(34):5441-7
10 Von Pawel J, Jotte R, Spigel D, et al. Randomized phase III trial of amrubicin versus 
topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 
2014;4012-4019.
11 Owinokoko TK, Behera M, Chen Z, et al. A systematic analysis of efficacy of second-line
chemotherapy in sensitive and refractory small cell lung cancer. J Thorac Oncol 
2012;7(5):866–872.
12 Koyama K, Kagamu H, Miura S, et al. Reciprocal CD4+ T-cell balance of effector 
CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer 
reflects disease stage. Clin Cancer Res 2008; 14:6770-6779.
13 Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and 
carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a 
randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013;24(1):75-83.
14 Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of 
anti-PD-1 antibody in cancer. New Engl J Med 2012;366:2443-2454. 
Revised Protocol No: 03
Date: 20-Mar-2018
93
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
15 Gettinger S, Horn L, Antonia SJ, et al. Clinical activity and safety of anti-programmed death-
1 (PD-1) (BMS-936558/MDX-01106/ONO-4538) in patients (PTS) with advanced small-cell 
lung cancer (NSCLC). Ann Oncol 2012; 23 (Suppl 9): Abstract 1237PD. 
16 National Comprehensive Cancer Network. Small Cell Lung Cancer, v 2.2015. NCCN. 
Available 
at 
http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. 
Accessed 
13 Apr 2015.
17 Frueh M, DeRuysscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO Clinical 
Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2013;00:1-7.
18 Eckardt J, von Pawel J, Pujol J, et al., Phase III Study of Oral Compared With Intravenous 
Topotecan As Second-Line Therapy in Small-Cell Lung Cancer. J Clin Oncol 2007;25:2086-
2092.
19 Yana T, Negoro S, Takada M, et al. Phase II study of amrubicin in previously untreated 
patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group 
(WJTOG) study. Invest New Drugs. 2007;25:253-258.
20 Ishii H, Azuma K, Kawahara A, et al., Significance of programmed cell death-ligand 
1 expression and its association with survival in patients with small cell lung cancer. J Thorac 
Oncol 2015;10(3):426-30.
21 Antonia SJ, Callahan MK, Awad MM et al. Impact of Tumor Mutation Burden on the 
Efficacy of Nivolumab or Nivolumab + Ipilimumab in Small Cell Lung Cancer: An 
Exploratory Analysis of CheckMate 032. International Association for the Study of Lung 
Cancer 18th World Conference on Lung Cancer, Yokohama, Japan 2018.
22 Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus Ipilimumab in Advanced 
Melanoma. NEJM 2013. doi:10.1056/NEJMoal1302369.
23 Antonia S, Bendell J, Taylor M, et al. Phase 1/2 study of nivolumab with or without 
ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209032. Submitted 
for ASCO 2015, accepted for presentation.
24 Hollen P. Lung Cancer Symptom Scale (LCSS). 2013 December 1. Available at: URL: 
http://www.lcss-ql.com/. Accessed September 30, 2014
25 Hollen PJ, Gralla RJ, Kris MG, Potanovich LM. Quality of life assessment in individuals 
with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 1993;29A 
Suppl 1:S51-S58
26 Hollen PJ, Gralla RJ, Kris MG, Cox C, Belani CP, Grunberg SM, Crawford J, Neidhart JA. 
Measurement of quality of life in patients with lung cancer in multicenter trials of new 
therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 
1994;73:2087-98
27 Rabin R, de Charro F. EQ-5D: a measure of health status from EuroQol group. Ann Med. 
2001; 33: 337-43
Revised Protocol No: 03
Date: 20-Mar-2018
94
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
28 Hellmann MD, Ott PA, Zugazagoitia J et al. Nivolumab ± Ipilimumab in Advanced Small 
Cell Lung Cancer: First Report of a Randomized Cohort from CheckMate 032. American 
Society of Clinical Oncology Annual Meeting, Chicago, Illinois 2017.
29 Rabin R, de Charro F. EQ-5D: a measure of health status from EuroQol group. Ann Med. 
2001; 33: 337-43.
Revised Protocol No: 03
Date: 20-Mar-2018
95
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
APPENDIX 1
MANAGEMENT ALGORITHMS
Revised Protocol No: 03
Date: 20-Mar-2018
96
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Revised Protocol No: 03
Date: 20-Mar-2018
97
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Revised Protocol No: 03
Date: 20-Mar-2018
98
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Revised Protocol No: 03
Date: 20-Mar-2018
99
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Revised Protocol No: 03
Date: 20-Mar-2018
100
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Revised Protocol No: 03
Date: 20-Mar-2018
101
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Revised Protocol No: 03
Date: 20-Mar-2018
102
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Revised Protocol No: 03
Date: 20-Mar-2018
103
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
APPENDIX 2
RECIST 1.1
1
ASSESSMENT OF OVERALL TUMOR BURDEN AND MEASURABLE 
DISEASE
To assess objective response or future progression, it is necessary to estimate the overall tumor
burden at baseline and use this as a comparator for subsequent measurements. Measurable 
disease is defined by the presence of at least one measurable tumor lesion. When CT scans have 
slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the 
slice thickness.
At baseline, tumor lesions/lymph nodes will be categorized measurable or non-measurable as 
follows:
1.1
Measurable Lesions
Measurable lesions must be accurately measured in at least one dimension (longest diameter in 
the plane of the measurement to be recorded) with a minimum size of:
•
10 mm by CT/MRI scan - (CT/MRI scan slice thickness no greater than 5 mm)
•
20 mm by chest x-ray
•
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph 
node must be ≥15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm). At baseline and in follow-up, only the short axis 
will be measured and followed.
1.2
Non-measurable Lesions
•
All other lesions, including small lesions (longest diameter < 10 mm or pathological lymph 
nodes with ≥10 to < 15 mm short axis), as well as truly non-measurable lesions.  
•
Lesions considered truly non-measurable include:  leptomeningeal disease, ascites, pleural or 
pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, 
abdominal masses/abdominal organomegaly identified by physical exam that is not 
measurable by reproducible imaging techniques.  
1.3
Special Considerations Regarding Lesion Measurability
1.3.1
Bone Lesions
•
Bone scan, PET scan or plain films are not considered adequate imaging techniques to 
measure bone lesions. However, these techniques can be used to confirm the presence or 
disappearance of bone lesions. 
Revised Protocol No: 03
Date: 20-Mar-2018
104
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
•
Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components, that 
can be evaluated by cross sectional imaging techniques such as CT or MRI can be considered 
as measurable lesions if the soft tissue component meets the definition of measurability 
described above.
•
Blastic bone lesions are non-measurable.
1.3.2
Cystic Lesions
•
Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non-measurable) since they are, by 
definition, simple cysts. 
•
‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above. However, if non-cystic 
lesions are present in the same subject, these are preferred for selection as target lesions.
1.3.3
Lesions with Prior Local Treatment
Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-
regional therapy, are usually not considered measurable unless there has been demonstrated 
progression in the lesion. 
1.4
Specifications by Methods of Measurements
1.4.1
Measurement of Lesions
All measurements should be recorded in metric notation (mm). All baseline evaluations should 
be performed as close as possible to the treatment start and never more than 30 days before the 
beginning of the treatment.
1.4.2
Method of Assessment
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up. Imaging based evaluation should 
always be done rather than clinical examination unless the lesion(s) being followed cannot be 
imaged but are assessable by clinical exam.
1.4.2.1
CT/MRI Scan
CT/MRI is the best currently available and reproducible method to measure lesions selected for 
response assessment. Measurability of lesions on CT/MRI scan is based on the assumption that 
CT/MRI slice thickness is 5 mm or less. When CT scans have slice thickness greater than 5 mm, 
the minimum size for a measurable lesion should be twice the slice thickness.
Revised Protocol No: 03
Date: 20-Mar-2018
105
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
1.4.2.2
Chest X-ray
Chest CT is preferred over chest X-ray, particularly when progression is an important endpoint, 
since CT is more sensitive than X-ray, particularly in identifying new lesions. However, lesions 
on chest X-ray may be considered measurable if they are clearly defined and surrounded by 
aerated lung.
1.4.2.3
Clinical Lesions 
Clinical lesions will only be considered measurable when they are superficial and ≥10 mm 
diameter as assessed using calipers. For the case of skin lesions, documentation by color 
photography including a ruler to estimate the size of the lesion is suggested. As previously noted, 
when lesions can be evaluated by both clinical exam and imaging, imaging evaluation should be 
undertaken since it is more objective and may also be reviewed at the end of the study.
1.4.2.4
Ultrasound 
Ultrasound is not useful in assessment of lesion size and should not be used as a method of 
measurement. If new lesions are identified by ultrasound in the course of the study, confirmation 
by CT or MRI is advised. 
1.4.2.5
Endoscopy, Laparoscopy
The utilization of these techniques for objective tumor evaluation is not advised.
1.4.2.6
Tumor Markers 
Tumor markers alone cannot be used to assess objective tumor response.  
2
BASELINE DOCUMENTATION OF ‘TARGET’ AND ‘NON-TARGET’ 
LESIONS
2.1
Target Lesions
When more than one measurable lesion is present at baseline all lesions up to a maximum of 
five lesions total (and a maximum of two lesions per organ) representative of all involved 
organs should be identified as target lesions and will be recorded and measured at baseline. 
Target lesions should be selected on the basis of their size (lesions with the longest diameter), be 
representative of all involved organs, and should lend themselves to reproducible repeated
measurements.
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be 
included in the sum, then as noted below, only the short axis is added into the sum. The baseline 
sum diameters will be used as reference to further characterize any objective tumor regression in 
the measurable dimension of the disease.
Revised Protocol No: 03
Date: 20-Mar-2018
106
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
2.1.1
Lymph Nodes
Lymph nodes merit special mention since they are normal anatomical structures which may be 
visible by imaging even if not involved by tumor. Pathological nodes which are defined as 
measurable and may be identified as target lesions must meet the criterion of a short axis of 
≥15 mm by CT scan. Only the short axis of these nodes will contribute to the baseline sum. 
Nodes that have a short axis < 10 mm are considered non-pathological and should not be 
recorded or followed.
2.2
Non-target Lesions
All other lesions (or sites of disease) including pathological lymph nodes should be identified as 
non-target lesions and should also be recorded at baseline. Measurements are not required and 
these lesions should be followed as ‘present’, ‘absent’, or in rare cases ‘unequivocal 
progression’. In addition, it is possible to record multiple non-target lesions involving the same 
organ as a single item on the case record form (e.g. ‘multiple enlarged pelvic lymph nodes’ or 
‘multiple liver metastases’).
3
TUMOR RESPONSE EVALUATION 
3.1
Evaluation of Target Lesions
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to < 10 mm.
Partial Response (PR):  At least a 30% decrease in the sum of diameters of target lesions,
taking as reference the baseline sum diameters.
Progressive Disease (PD):  At least a 20% increase in the sum of diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an 
absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also 
considered progression).
Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on study.
3.1.1
Special Notes on the Assessment of Target Lesions
3.1.1.1
Lymph Nodes
Lymph nodes merit special mention since they are normal anatomical structures which may be 
visible by imaging even if not involved by tumor. Pathological nodes which are defined as 
measurable and may be identified as target lesions must meet the criterion of a short axis of 
≥15 mm by CT scan. Only the short axis of these nodes will contribute to the baseline sum. 
Nodes that have a short axis < 10 mm are considered non-pathological and should not be 
recorded or followed.
Revised Protocol No: 03
Date: 20-Mar-2018
107
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
3.1.1.2
Target Lesions that Become ‘Too Small to Measure’  
All lesions (nodal and non-nodal) recorded at baseline should have their actual measurements 
recorded at each subsequent evaluation, even when very small (e.g. 2 mm). If the radiologist is 
able to provide an actual measurement, that should be recorded, even if it is below 5 mm.
However, when such a lesion becomes difficult to assign an exact measure to then:
•
If it is the opinion of the radiologist that the lesion has likely disappeared, the measurement 
should be recorded as 0 mm. 
•
If the lesion is believed to be present and is faintly seen but too small to measure, a default 
value of 5 mm should be assigned (note: in case of a lymph node believed to be present and 
faintly seen but too small to measure, a default value of 5 mm should be assigned in this 
circumstance as well). This default value is derived from the 5 mm CT slice thickness (but 
should not be changed with varying CT slice thickness).   
3.1.1.3
Target Lesions that Split or Coalesce on Treatment
•
When non-nodal lesions ‘fragment’, the longest diameters of the fragmented portions should 
be added together to calculate the target lesion sum. 
•
As lesions coalesce, a plane between them may be maintained that would aid in obtaining 
maximal diameter measurements of each individual lesion. If the lesions have truly coalesced 
such that they are no longer separable, the vector of the longest diameter in this instance 
should be the maximal longest diameter for the ‘coalesced lesion’.
3.2
Evaluation of Non-target Lesions
While some non-target lesions may actually be measurable, they need not be measured and 
instead should be assessed only qualitatively at the time points specified in the protocol. 
Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor 
marker level. All lymph nodes must be non-pathological in size (< 10 mm short axis).
Non-CR/Non-PD:  Persistence of one or more non-target lesion(s) and/or maintenance of tumor 
marker level above the normal limits.
Progressive Disease (PD):  Unequivocal progression of existing non-target lesions. (Note: the 
appearance of one or more new lesions is also considered progression).
3.2.1
Special Notes on Assessment of Non-target Lesions
The concept of progression of non-target disease requires additional explanation as follows:
Revised Protocol No: 03
Date: 20-Mar-2018
108
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
3.2.1.1
When the Subject Also Has Measurable Disease
•
To achieve ‘unequivocal progression’ on the basis of the non-target disease, there must be an 
overall level of substantial worsening in non-target disease such that, even in presence of SD 
or PR in target disease, the overall tumor burden has increased sufficiently to merit 
discontinuation of therapy. 
•
A modest ‘increase’ in the size of one or more non-target lesions is usually not sufficient to 
quality for unequivocal progression status. 
3.2.1.2
When the Subject Has Only Non-measurable Disease
•
To achieve ‘unequivocal progression’ on the basis of the non-target disease, there must be an 
overall level of substantial worsening such that the overall tumor burden has increased 
sufficiently to merit discontinuation of therapy. 
•
A modest ‘increase’ in the size of one or more non-target lesions is usually not sufficient to 
qualify for unequivocal progression status. 
•
Because worsening in non-target disease cannot be easily quantified (by definition: if all 
lesions are non-measurable) a useful test that can be applied when assessing subjects for 
unequivocal progression is to consider if the increase in overall disease burden based on the 
change in non-measurable disease is comparable in magnitude to the increase that would be 
required to declare PD for measurable disease: i.e. an increase in tumor burden representing 
an additional 73% increase in ‘volume’ (which is equivalent to a 20% increase diameter in a 
measurable lesion). Examples include an increase in a pleural effusion from ‘trace’ to ‘large’, 
an increase in lymphangitic disease from localized to widespread, or may be described in 
protocols as ‘sufficient to require a change in therapy’. 
•
If ‘unequivocal progression’ is seen, the subject should be considered to have had overall PD 
at that point. 
3.2.1.3
Tumor Markers
Tumor markers alone cannot be used to assess objective tumor responses. If markers are initially 
above the upper normal limit, however, they must normalize in order for a subject to be 
considered as having attained a complete response. 
3.3
New Lesions  
The appearance of new malignant lesions denotes disease progression. The finding of a new 
lesion should be unequivocal: i.e. not attributable to differences in scanning technique, change in 
imaging modality or findings thought to represent something other than tumor (for example, 
some ‘new’ bone lesions may be simply healing or flare of pre-existing lesions). This is 
particularly important when the subject’s baseline lesions show partial or complete response. For 
example, necrosis of a liver lesion may be reported on a CT scan report as a ‘new’ cystic lesion, 
which it is not.
Revised Protocol No: 03
Date: 20-Mar-2018
109
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
A lesion identified on a follow-up study in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progression. An example of this is 
the subject who has visceral disease at baseline and while on study has a CT or MRI brain scan
ordered which reveals metastases. The subject’s brain metastases are considered to be evidence 
of PD even if he/she did not have brain imaging at baseline.
If a new lesion is equivocal, for example because of its small size, continued therapy and follow-
up evaluation will clarify if it represents truly new disease. If repeat scans confirm there is 
definitely a new lesion, then progression should be declared using the date of the initial scan.
3.3.1
FDG-PET Evaluation
While FDG-PET response assessments need additional study, it is sometimes reasonable to 
incorporate the use of the qualitative assessment of FDG-PET scanning to complement CT 
scanning in assessment of progression (particularly possible ‘new’ disease). New lesions on the 
basis of FDG-PET imaging can be identified according to the following algorithm: 
•
Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of PD based 
on a new lesion. 
•
No FDG-PET at baseline and a positive FDG-PET at follow-up: 
−
If the positive FDG-PET at follow-up corresponds to a new site of disease confirmed by 
CT, this is PD. 
−
If the positive FDG-PET at follow-up is not confirmed as a new site of disease on CT, 
additional follow-up CT scans are needed to determine if there is truly progression 
occurring at that site (if so, the date of PD will be the date of the initial positive
FDG-PET scan).
−
If the positive FDG-PET at follow-up corresponds to a pre-existing site of disease on CT 
that is not progressing on the basis of the anatomic images, this is not PD.
4
RESPONSE CRITERIA
4.1
Time Point Response
A response assessment should occur at each time point specified in the protocol.
For subjects who have measurable disease at baseline Table 1 provides a summary of the 
overall response status calculation at each time point.
Table 1:
Time Point Response: Subjects with Target (± Non-target) 
Disease
Target Lesions
Non-target Lesions
New Lesions
Overall Response
CR
CR
No
CR
CR
Non-CR/non-PD
No
PR
CR
Not evaluated
No
PR
Revised Protocol No: 03
Date: 20-Mar-2018
110
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Table 1:
Time Point Response: Subjects with Target (± Non-target) 
Disease
Target Lesions
Non-target Lesions
New Lesions
Overall Response
PR
Non-PD or not all 
evaluated
No
PR
SD
Non-PD or not all 
evaluated
No
SD
Not all evaluated
Non-PD
No
NE
PD
Any
Yes or No
PD
Any 
PD
Yes or No
PD
Any
Any 
Yes
PD
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, NE =not evaluable
4.1.1
Missing Assessments and Not Evaluable Designation
When no imaging/measurement is done at all at a particular time point, the subject is not 
evaluable (NE) at that time point. If only a subset of lesion measurements are made at an 
assessment, the case is also considered NE at that time point, unless a convincing argument can 
be made that the contribution of the individual missing lesion(s) would not have changed the 
assigned time point response.
4.1.2
Confirmation Scans
Verification of Response: Confirmation of response (CR or PR) is required. Confirmed CR or 
PR will be claimed only if the criteria for each are met at a subsequent timepoint (minimum 
4 weeks after criteria for an objective response are first met).
Verification of Progression: Progression of disease should be verified in cases where 
progression is equivocal. If repeat scans confirm PD, then progression should be declared using 
the date of the initial scan. If repeat scans do not confirm PD, then the subject is considered not 
to have progressive disease per RECIST 1.1.
4.2
Best Overall Response: All Timepoints
The best overall response is defined as the best response designation, as determined by the 
investigators, recorded between the date of randomization and the date of objectively 
documented progression per RECIST 1.1 or the date of subsequent anticancer therapy, 
whichever occurs first. The subject’s best overall response assignment will depend on the 
findings of both target and non-target disease and will also take into consideration the
appearance of new lesions. 
Revised Protocol No: 03
Date: 20-Mar-2018
111
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
Best response is defined as the best response across all time points (for example, a subject who 
has SD at first assessment, PR at second assessment, and PD on last assessment has a best 
overall response of PR). 
When SD is believed to be best response, it must also meet the protocol specified minimum time 
from baseline. If the minimum time is not met when SD is otherwise the best time point 
response, the subject’s best response depends on the subsequent assessments. For example, a 
subject who has SD at first assessment, PD at second and does not meet minimum duration for 
SD, will have a best response of PD. The same subject lost to follow-up after the first SD 
assessment would be considered not evaluable.
Best response is defined as the best response across all time points with subsequent confirmation. 
Complete or partial responses may be claimed only if the criteria for each are met at a 
subsequent time point as specified in the protocol (generally 4 weeks later). 
In this circumstance, the best overall response can be interpreted as specified in Table 2. When 
SD is believed to be best response, it must meet the protocol specified minimum time from 
baseline. Measurements must have met the SD criteria at least once after study entry at a 
minimum interval (in general not less than 6 - 8 weeks) that is defined in the study protocol.
Table 2:
Best Overall Response when Confirmation of CR and PR IS 
Required
Overall response
Overall response
BEST overall response
First time point
Subsequent time point
CR
CR
CR
CR
PR
SD, PD, or PRa
CR
SD
SD provided minimum criteria for 
SD duration met, otherwise, PD
CR
PD
SD provided minimum criteria for 
SD duration met, otherwise, PD
CR
NE
SD provided minimum criteria for 
SD duration met, otherwise NE
PR
CR
PR
PR
PR
PR
PR
SD
SD
PR
PD
SD provided minimum criteria for 
SD duration met, otherwise, PD
PR
NE
SD provided minimum criteria for 
SD duration met, otherwise NE
NE
NE
NE
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, NE = not evaluable.
Revised Protocol No: 03
Date: 20-Mar-2018
112
4.0
Approved
930089510
4.0
v
Approved
1.0
v


Clinical Protocol
CA209331
BMS-936558
nivolumab
a If a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease meeting PR 
criteria relative to baseline, makes the disease PD at that point (since disease must have reappeared after CR). 
Best response would depend on whether minimum duration for SD was met. However, sometimes ‘CR’ may be 
claimed when subsequent scans suggest small lesions were likely still present and in fact the subject had PR, not 
CR at the first time point. Under these circumstances, the original CR should be changed to PR and the best 
response is PR.
4.3
Duration of Response
4.3.1
Duration of Overall Response
The duration of overall response is measured from the time measurement criteria are first met for 
CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease is 
objectively documented (taking as reference for progressive disease the smallest measurements 
recorded on study).
The duration of overall complete response is measured from the time measurement criteria are 
first met for CR until the first date that recurrent disease is objectively documented.
4.3.2
Duration of Stable Disease  
Stable disease is measured from the start of the treatment (in randomized trials, from date of 
randomization) until the criteria for progression are met, taking as reference the smallest sum on 
study (if the baseline sum is the smallest, this is the reference for calculation of PD).
Revised Protocol No: 03
Date: 20-Mar-2018
113
4.0
Approved
930089510
4.0
v
Approved
1.0
v

SAP_001.pdf: 
Official Title of Study: 
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF NIVOLUMAB OR 
CHEMOTHERAPY IN SUBJECTS WITH RELAPSED SMALL-CELL LUNG CANCER 
AFTER PLATINUM-BASED FIRST LINE CHEMOTHERAPY (CHECKMATE 331: 
CHECKPOINT PATHWAY AND NIVOLUMAB CLINICAL TRIAL EVALUATION 331) 
NCT Number: NCT02481830 
Document Date (Date in which document was last revised): August 14, 2018 


STATISTICAL ANALYSIS PLAN
FOR CLINICAL STUDY REPORT
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF NIVOLUMAB OR 
CHEMOTHERAPY IN SUBJECTS WITH RELAPSED SMALL-CELL LUNG CANCER 
AFTER PLATINUM-BASED FIRST LINE CHEMOTHERAPY (CHECKMATE 331: 
CHECKPOINT PATHWAY AND NIVOLUMAB CLINICAL TRIAL EVALUATION 331)
PROTOCOL CA209-331
VERSION # 2.0
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
2
TABLE OF CONTENTS
STATISTICAL ANALYSIS PLAN FOR CLINICAL STUDY REPORT ...................................1
TABLE OF CONTENTS............................................................................................................2
LIST OF TABLES......................................................................................................................5
LIST OF FIGURES ....................................................................................................................5
2
STUDY DESCRIPTION ..........................................................................................6
2.1
Study Design ............................................................................................................6
2.2
Treatment Assignment..............................................................................................8
2.3
Blinding and Unblinding...........................................................................................9
2.4
Protocol Amendments...............................................................................................9
2.5
Data Monitoring Committee ...................................................................................10
3
OBJECTIVES ........................................................................................................11
3.1
Primary...................................................................................................................11
3.2
Secondary...............................................................................................................11
4
ENDPOINTS..........................................................................................................12
4.1
Primary Endpoints..................................................................................................12
4.2
Secondary Endpoints ..............................................................................................12
4.2.1
Progression - Free Survival....................................................................................12
4.2.2
Objective Response Rate.........................................................................................13
4.2.3
Duration of Objective Response..............................................................................14
4.2.4
Time to Objective Response ....................................................................................14
4.3.1
Time to deterioration(TTD) in symptoms, as measured by the LCSS ASBI...............14
5
SAMPLE SIZE AND POWER...............................................................................15
6
STUDY PERIODS, TREATMENT REGIMENS AND POPULATIONS 
FOR ANALYSES ..................................................................................................16
6.1
Study Periods..........................................................................................................16
6.2
Treatment Regimens...............................................................................................16
6.3
Populations for Analyses ........................................................................................17
7
STATISTICAL ANALYSES..................................................................................17
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
3
7.1
General Methods ....................................................................................................17
7.2
Study Conduct........................................................................................................18
7.2.1
Accrual...................................................................................................................18
7.2.2
Relevant Protocol Deviations..................................................................................18
7.3
Study Population ....................................................................................................19
7.3.1
Subject Disposition.................................................................................................19
7.3.2
Demographics and Other Baseline Characteristics.................................................19
7.3.3
Medical History......................................................................................................20
7.3.4
Prior Therapy Agent...............................................................................................20
7.3.5
Baseline Examinations............................................................................................20
7.3.6
Discrepancies between IVRS and CRF Stratification Factors .................................21
7.4
Extent of Exposure .................................................................................................21
7.4.1
Administration of Study Therapy.............................................................................21
7.4.2
Modifications of Study Therapy ..............................................................................22
7.4.2.1
Cycle Delays...........................................................................................................22
7.4.2.2
Topotecan/Amrubicin Dose interruptions - IV.........................................................22
7.4.2.3
Dose Reductions/Omissions/Increases ....................................................................22
7.5
Efficacy..................................................................................................................25
7.5.1
Overall Survival .....................................................................................................25
7.5.1.1
Primary Analysis ....................................................................................................25
7.5.1.2
OS Sensitivity Analyses...........................................................................................25
7.5.1.3
Consistency of Treatment Effect on OS in Subsets...................................................26
7.5.1.4
Multivariate Analysis..............................................................................................26
7.5.1.5
Subject Follow-up for OS........................................................................................27
7.5.1.6
Follow-up Therapy .................................................................................................27
7.5.1.7
Analysis of Survival by Tumor Response.................................................................27
7.5.2
Progression Free Survival ......................................................................................28
7.5.2.1
Primary Analysis of PFS.........................................................................................28
7.5.2.2
Sensitivity Analyses of PFS.....................................................................................28
7.5.3
Objective Response Rate.........................................................................................29
7.5.3.1
Primary Analysis of ORR........................................................................................29
7.5.3.2
Sensitivity Analyses of ORR....................................................................................29
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
4
7.5.4
Duration of Objective Response..............................................................................29
7.5.5
Time to Objective Response ....................................................................................30
7.5.6
Hierarchy for Key Secondary Efficacy Endpoints ...................................................30
7.5.7
Follow-up Therapy .................................................................................................30
7.5.8
Other Efficacy Analyses..........................................................................................31
7.5.9
Interim Analysis......................................................................................................31
7.6
Safety.....................................................................................................................31
7.6.1
Deaths ....................................................................................................................31
7.6.2
Serious Adverse Events...........................................................................................31
7.6.3
Adverse Events Leading to Discontinuation of Study Therapy.................................31
7.6.4
Adverse Events Leading to Dose Delay of Study Therapy........................................31
7.6.5
Adverse Events .......................................................................................................31
7.6.6
Adverse Events by Subgroups .................................................................................31
7.6.7
Multiple Events.......................................................................................................32
7.6.8
Adverse Events of Special Interest ..........................................................................32
7.6.9
Clinical Laboratory Evaluations.............................................................................32
7.6.9.1
Hematology ............................................................................................................32
7.6.9.2
Serum Chemistry ....................................................................................................32
7.6.10
Vital Signs and Pulse Oximetry...............................................................................32
7.6.11
Immunogenicity Analysis ........................................................................................32
7.6.12
Pregnancy ..............................................................................................................32
7.6.13
Clinical Safety Program (CSP)...............................................................................32
7.7
Pharmacokinetics....................................................................................................32
7.8.1
Tumor Mutation Burden .........................................................................................33
7.8.1.1
Descriptive analysis of TMB...................................................................................33
7.8.1.2
Demography/Baseline Characteristics/Efficacy of the TMB-evaluable 
population ..............................................................................................................33
7.8.1.3
Association between TMB and Efficacy...................................................................33
7.9
Outcomes Research Analyses .................................................................................35
7.9.1
LCSS questionnaire ................................................................................................35
7.9.2
EQ-5D questionnaire..............................................................................................35
8
CONVENTIONS....................................................................................................36
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
5
9
CONTENT OF REPORTS .....................................................................................37
10
REFERENCES.......................................................................................................37
LIST OF TABLES
Table 2.4-1:
Protocol Amendment................................................................................9
Table 4.2.1-1:
Censoring Scheme for Primary Definition of PFS...................................13
Table 5-1:
Sample Size Justification........................................................................16
Table 7.4.1-1:
Administration of study therapy: definition of parameters.......................21
Table 7.4.2.3-1:
Dose Modifications ................................................................................23
LIST OF FIGURES
Figure 2.1-1:
Study Schematic.......................................................................................8
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
6
 
 
 
 
 
 
 
Research Hypothesis:  
Treatment with nivolumab will increase OS as compared with chemotherapy in subjects with 
relapsed SCLC treated with prior platinum-based, first-line chemotherapy.
Schedule of Analyses:
The final analysis will take place 34 months after first patient was randomized and no formal 
interim analysis will be conducted. The 560 subjects (including at least 78 subjects randomized 
in China) are expected to be randomized in 18 months, resulting in about 16 months of follow-up 
for the last subject randomized at the time of the primary analysis. It is anticipated that 
approximately 482 events will be observed at the time of the analysis (see Section 5 for details).
2
STUDY DESCRIPTION
2.1
Study Design
This is a randomized, open-label, two-arm, multicenter, Phase 3 study in adult subjects with 
relapsed SCLC treated with prior platinum-based, first-line chemotherapy. Subjects must have 
had at least 4 cycles of platinum-based, first-line chemotherapy, or if they received less than 4 
cycles, they must have had a best overall response (BOR) of a partial or complete response after 
completion of chemotherapy.
Approximately 480 subjects will be randomized in a 1:1 ratio to treatment with either nivolumab 
(Arm A) or chemotherapy (either topotecan or amrubicin, Arm B) in the Global Population. In 
addition, this study includes a cohort of at least 78 additional randomized patients from China 
(~16% of the global number of randomized subjects). The primary population for safety and 
efficacy analysis will include subjects from the Global Population as well as subjects from the 
additional Chinese cohort, leading to a total sample size of about 560 subjects.
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
7
Subjects will be stratified according to the following factors:

Response to first-line platinum based treatment: platinum sensitive (progression-free interval 
90 days after completion of platinum therapy) vs platinum resistant (progression-free 
interval < 90 days after completion of platinum therapy)

Brain metastases at baseline: yes vs. no.
On-study tumor assessments will begin at Week 6 post randomization (5 days) and be 
performed every 6 weeks (5 days) until Week 30. After Week 30, tumor assessments will be 
performed every 12 weeks (5 days) until disease progression (or until discontinuation of study 
drug in subjects receiving nivolumab beyond investigator-assessed progression) lost to follow-
up, withdrawal of study consent, or the study ends.
Enrollment will end after approximately 560 subjects have been randomized (including ~78 
additional subjects in China).
The primary endpoint of the study is OS.
The study design schematic is presented in Figure 2.1-1.
Accrual duration is expected to be approximately 18 months; overall study duration will be
approximately 34 months (18 months accrual + minimum follow up of 16 months). The study 
will end when analysis of survival is complete. Additional survival follow-up may continue for 
up to 5 years from the time of this analysis. 
A DMC will be utilized to provide general oversight and safety considerations for this study, 
CA209331.
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
8
Figure 2.1-1:
Study Schematic
a
Subjects must have had at least 4 cycles of platinum-based, first-line chemotherapy, or if they received less than 
4 cycles of platinum-based first-line chemotherapy, they must have had a best overall response (BOR) of at least 
a partial or complete response after completion of chemotherapy.
2.2
Treatment Assignment
Subjects are enrolled using the Interactive Voice Response System (IVRS) to obtain a subject 
ID. Subjects who have signed informed consent and met all eligibility criteria will be ready to be 
randomized through the IVRS, upon confirmation of receipt of required tissue sample by the 
central lab. The following information is required for subject randomization:

Date of birth

Date of informed consent

Gender.

Subject number
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
9

Confirmation that all randomization inclusion/exclusion are met

Confirmation that FFPE tumor tissue block or unstained slides were received by the central 
laboratory

Response to first-line platinum-based treatment: platinum sensitive vs platinum resistant

Brain metastases at baseline: yes vs. no.
If the above are met, the IVRS will randomly assign subjects to treatment Arm A or Arm B in a 
1:1 ratio using a stratified permuted block randomization method with respect to the following 
stratification factors:

Response to first-line platinum based treatment: platinum sensitive vs platinum resistant 

Brain metastases at baseline: yes vs. no.
The randomization will be carried out via permuted blocks within each stratum.
2.3
Blinding and Unblinding
Not applicable. This is an open-label study.
2.4
Protocol Amendments
Table 2.4-1:
Protocol Amendment
Document
Date of Issue
Summary of Change
Revised 
Protocol 03
15-Mar-2018
Incorporates Amendment 17 and Administrative Letters 04, 05 and 06
Amendment 17
15-Mar-2018

Updated study personnel

Added additional China cohorts in Arm A and Arm B

 

Updated protocol as per nivolumab program standards
Administrative 
Letter 06
19-Dec-2017
Change in Medical Monitor contact
Administrative 
Letter 05
06-Dec-2017
Change in Medical Monitor contact
Administrative 
Letter 04
29-Jun-2017
Change in Medical Monitor contact
Revised 
Protocol 02
07-Sep-2016
Incorporates Amendment(s) 15 and Administrative Letter 03
Amendment 15
07-Sep-2016
Remove the planned interim analysis and to modify the timing of the 
final analysis as a result from a phase 1/2 study (CheckMate 032) which 
suggested a treatment delayed effect for immunotherapy in Small Cell 
Lung Cancer. The amendment will also add a sub-study in China to 
comply with regulatory requirement in that country
 
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
10
Table 2.4-1:
Protocol Amendment
Document
Date of Issue
Summary of Change
on results of Checkmate 017 and Checkmate 057
Other changes include correction of inconsistencies, alignment with 
latest Nivolumab standards, and investigator brochure.
Administrative 
Letter 03
05-Feb-2016
Edited misleading/ambiguous sentence about the contraception method 
to be used.
Revised 
Protocol 01
15-Dec-2015
Incorporates Amendment(s) 11 and Administrative Letters 01 & 02
Amendment 11
15-Dec-2015
The main purpose of this amendment is to allow the use of different 
topotecan formulations (powder for injection and oral capsules).
Other changes include modification of the treatment assignment for
Arm B to allow for treatment with topotecan or amrubicin (upon 
investigator’s choice, where locally approved for 2nd line SCLC 
patients), clarification of some inclusion/exclusion criteria, correction of 
inconsistencies and typographical revisions throughout the protocol.
Change of Medical Monitor
Administrative 
Letter 02
08-Dec-2015
Change of Study Director and Medical Monitor
Administrative 
Letter 01
14-Jun-2015
Criterion deleted given because not applicable to the approved original 
protocol
Original 
Protocol
22April2015
Not applicable
2.5
Data Monitoring Committee
An independent Data Monitoring Committee (DMC)will be utilized. The DMC will be utilized 
to provide general oversight and safety considerations for this study, CA209331. The DMC will 
provide advice to the Sponsor regarding actions the committee deems necessary for the 
continuing protection of subjects enrolled in this study. The DMC will be charged with assessing 
such actions in light of an acceptable risk/benefit profile for nivolumab. The DMC will act in an 
advisory capacity to BMS and will monitor subject safety data for the study. The DMC will be 
advisory to the clinical study leadership team. The clinical study leadership will have 
responsibility for overall conduct of the study including managing the communication of study 
data. The group will be responsible for promptly reviewing the DMC recommendations, for 
providing guidance regarding the continuation or termination of the study, and for determining 
whether amendments to the protocol or changes to the study conduct are required. Details of the 
DMC responsibilities and procedures will be specified in the DMC charter. 
In addition, the Sponsor will independently review safety data in a blinded manner during the 
conduct of this trial to ensure that any safety issues are identified and addressed.
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
11
3
OBJECTIVES
3.1
Primary
To compare the OS of nivolumab versus chemotherapy in subjects with relapsed SCLC after 
platinum-based, first-line chemotherapy.
3.2
Secondary
Secondary objectives are:

To compare the PFS of nivolumab versus chemotherapy

To compare the ORR of nivolumab versus chemotherapy.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
12
4
ENDPOINTS
4.1
Primary Endpoints
OS is defined as the time from randomization to the date of death. A subject who has not died 
will be censored at last known date alive.
4.2
Secondary Endpoints
4.2.1
Progression - Free Survival
Progression-free survival (PFS) is defined as the time from randomization to the date of the first 
documented tumor progression as determined by the investigator using RECIST 1.1 criteria or 
death due to any cause. Clinical deterioration in the absence of unequivocal evidence of 
progression (per RECIST 1.1) is not considered progression for purposes of determining PFS. 
Subjects who die without a reported prior progression will be considered to have progressed on 
the date of their death. Subjects who did not progress or die will be censored on the date of their 
last evaluable tumor assessment. Subjects who did not have any baseline or on-study tumor 
assessments and did not die will be censored on the date they were randomized. Subjects who 
received any subsequent anti-cancer therapy (including on-treatment palliative RT of non-target 
bone lesions) without a prior reported progression will be censored at the last evaluable tumor 
assessment prior to or on the date of initiation of the subsequent anti-cancer therapy.
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
13
BASELINE 
SCAN 
AVAILABLE? 
No: Censored at 
rand (regardless of 
death) 
Yes
ON-STUDY SCANS 
AVAILABLE?
No
DEATH?
Yes
Death with prior 
Subsequent Therapy: 
Censored at rand
Death without prior 
Subsequent Therapy: 
Event at Death date
No: Censored 
at rand
Yes
NO PD, NO DEATH
Started Subsequent 
Therapy?
Yes: Censored at max 
( rand, last tumor 
scan <= Subseq Ther 
date)
No: Censored at last 
tumor scan date
PD OR DEATH OR BOTH
Subsequent Therapy < 
PD or death or min (PD, 
death)?
Yes: Censored at max 
(rand, last tumor scan <= 
Subseq Ther date)
No: Event at PD or  
death or min (PD, death 
date)
Table 4.2.1-1:
Censoring Scheme for Primary Definition of PFS
4.2.2
Objective Response Rate
Objective response rate (ORR) is defined as the number of subjects whose best objective 
response (BOR) is a confirmed CR or confirmed PR, as determined by the investigator, divided 
by the number of randomized subjects. BOR is defined as the best response designation, 
recorded between the date of randomization and the date of objectively documented progression 
per RECIST v1.1 or the date of subsequent anticancer therapy (excluding on-treatment palliative 
radiotherapy), whichever occurs first. For subjects without documented progression or 
subsequent anticancer therapy, all available response designations will contribute to the BOR 
determination. For subjects who continue treatment beyond progression, the BOR will be 
determined based on response designations recorded up to the time of the initial RECIST 1.1-
defined progression.
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
14
4.2.3
Duration of Objective Response
DOR is defined as the time between the date of first confirmed response to the date of the first 
documented tumor progression (per RECIST 1.1), as determined by the investigator, or death 
due to any cause, whichever occurs first. For subjects who neither progress nor die, the duration 
of objective response will be censored on the date of their last evaluable tumor assessment. 
Subjects who started any subsequent anti-cancer therapy without a prior reported progression 
will be censored at the last evaluable tumor assessment prior to or on the date of initiation of the 
subsequent anti-cancer therapy. DOR will be evaluated for confirmed responders (i.e. subjects 
with confirmed CR or PR) only.
Duration of Stable Disease will also be evaluated for subjects with SD as best response. Duration 
of SD is defined as the time between the randomization date to the date of the first documented 
tumor progression (per RECIST 1.1), as assessed by the investigator, or death due to any cause,
whichever occurs first. Censoring rules will be the same as for DOR analysis.
4.2.4
Time to Objective Response
Time to Objective Response (TTR) is defined as the time from randomization to the date of the 
first confirmed response. TTR will be evaluated for confirmed responders only.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
15
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.
5
SAMPLE SIZE AND POWER
Results of a Phase 1/2 study of nivolumab, with or without ipilimumab, for treatment of 
recurrent SCLC (CA209032)5 seem to suggest a delayed treatment effect for immunotherapy in 
SCLC. Statistical assumptions for CA209331 have been updated accordingly, based on the 
median OS observed in subjects treated with nivolumab after failing first-line chemotherapy in 
CA209032. This delayed effect would be consistent with what has been observed in other 
published trials comparing nivolumab to chemotherapy in other solid tumor types.6,7
In this study, the primary endpoint of OS will be evaluated for treatment effect at the overall 
alpha level of 0.05 (two-sided). Approximately 560 subjects will be randomized at a ratio of 1:1 
into 
two arms: Arm A (nivolumab); Arm B (chemotherapy: topotecan or amrubicin). For sample size 
calculation, non-proportional hazard model with a piecewise exponential distributions in both 
arms are assumed. Based on published survival curves for topotecan, a 2-piece exponential 
distribution with an 8-month median OS and taking into account that a limited number of 
subjects might receive immuno-oncology as subsequent therapy, a conservative 5% 2-year 
survival rate is assumed for the control arm. A delayed effect for nivolumab with a hazard ratio 
(HR) of 1 for the first 8 months and an HR of 0.5 thereafter is assumed. The final analysis will 
take place 34 months after the first patient have been randomized and no formal interim analysis 
will be conducted. The 560 subjects are expected to be randomized in 18 months, resulting in 
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
16
about 16 months of follow-up for the last subject randomized at the time of the primary analysis. 
It is anticipated that approximately 480 events will be observed at the time of the analysis, 
leading to 90% power to detect a difference in overall survival as tested via a log-rank test with a 
two-sided 0.05 type I error rate. Power calculations were performed using EASTSoftware 
(Version 6.4.1).The decision to incorporate the China subset into the overall population for 
analysis is the result of a review of the protocol statistical assumptions in comparison to recent 
data from the CA209032 study in 2L+ SCLC subjects8. The data from CA209032, which were 
not available at the time of protocol design, suggest a delayed effect of nivolumab with a non-
proportional hazard for survival. Additionally, review of recently generated real-world data for 
topotecan resulted in updated assumptions for the control arm. Given the updated statistical 
assumptions, incorporation of the China subset into the study analyses grants adequate statistical 
power by increasing the study sample size.
Table 5-1:
Sample Size Justification
Primary Endpoint
OS
Power 
90%
Alpha level
0.05
Sample size
560
Accrual duration 
18 months 
Timing of the analysis from randomization of first 
subject (months)
34
Hypothesized OS rate at 8 months
50% in both arms (HR=1 up to Month 8)
Hypothesized OS rate at 24 months
5% vs. 16% (HR=0.5 from Month 8)
Expected Average HR
~0.745
Expected number of event at 34 months
482
The secondary endpoints PFS and ORR will be tested hierarchically (see Section 7.5.6). 
6
STUDY PERIODS, TREATMENT REGIMENS AND POPULATIONS FOR 
ANALYSES
6.1
Study Periods
See Core Safety SAP.
6.2
Treatment Regimens
The treatment group “as randomized” will be retrieved from the IVRS system

Arm A: Experimental Arm (monotherapy) nivolumab

Arm B: Control arm Topotecan/amrubicin (investigator’s choice)
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
17
The treatment group “as treated” will be the same as the arm randomized by IVRS. However, if 
a subject received the incorrect drug for the entire period of treatment, the subject’s treatment 
group will be defined as the incorrect drug the subject actually received.
6.3
Populations for Analyses

All enrolled subjects: All subjects who sign an informed consent form and are registered 
into the IVRS

All randomized subjects: All enrolled subjects who are randomized to any treatment arm in 
the study. This is the primary dataset for analyses of efficacy and baseline characteristics.

All treated subjects: All enrolled subjects who received at least one dose of nivolumab, or 
chemotherapy. This is the primary dataset for dosing and safety.

PK subjects: All enrolled subjects with available serum time-concentration data from 
randomized subjects dosed with nivolumab.

Tumor Mutational Burden (TMB) evaluable Subjects: All randomized subjects with 
baseline evaluable TMB
.

China Cohort: all subjects enrolled in China. Additional analyses exploring the consistency 
of findings in the China cohort may be conducted. Details of these analyses will be provided 
in the analysis plan.
7
STATISTICAL ANALYSES
7.1
General Methods
Unless otherwise noted, the following subsections describe tabulations of discrete variables, by 
the frequency and proportion of subjects falling into each category, grouped by treatment (with 
total). Percentages given in these tables will be rounded and, therefore, may not always sum to 
100%. Continuous variables will be summarized by treatment group (with total) using the mean, 
standard deviation, median, minimum and maximum values.
Time to event distribution (i.e. progression free survival, overall survival and duration of 
response) will be estimated using Kaplan Meier techniques. 
Median survival time along with 95% CI will be constructed based on Brookmeyer and Crowley 
methodology (using log-log transformation for constructing the confidence intervals)9,10. Rates 
at fixed timepoints (e.g. OS at 6 months) will be derived from the Kaplan Meier estimate and 
corresponding confidence interval will be derived based on Greenwood formula11 for variance 
derivation and on log-log transformation applied on the survivor function S(t)12.
Unless otherwise specified, the stratified log-rank test will be performed to test the comparison 
between time to event distributions (OS and PFS). Stratification factors will be Response to first-
line platinum based treatment: platinum sensitive vs. platinum resistant, and Brain metastases at 
baseline: yes vs no, as entered into the IVRS.
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
18
Unless otherwise specified, the stratified hazard ratio between 2 treatment groups along with CI 
will be obtained by fitting a stratified Cox model with the treatment group variable as unique 
covariate. Stratification factors will be same as above.
The difference in rates between the two treatment arms along with their two-sided 95% CI will 
be estimated using the following Cochran-Mantel-Haenszel (CMH) method of weighting13, 
adjusting for the stratification factors:
^
2
^
2
(1
)
(1
)
1
1
~
,
iy
iy
ix
ix
i
i
i
i
ix
iy
i
i
i
i
i
p
p
p
p
w
w
n
n
N
w
w









































where 
^
ix
iy
p
p


is the rate difference of the ith stratum,
ix
iy
i
ix
iy
n n
w
n
n


, and 
ix
n and 
iy
n are the 
number of subjects randomized to treatments x and y, respectively, in the ith stratum.
Stratification factors will be the same as above. Associated odds-ratio will be derived.
The p-values from sensitivity analyses for efficacy endpoints are for descriptive purpose only 
and not adjusted for multiplicity.
7.2
Study Conduct
7.2.1
Accrual
The accrual pattern will be summarized per country, investigational site and per month for all 
enrolled subjects. Randomization date, first dosing date, country, investigational site will be 
presented in a by subject listing of accrual.
7.2.2
Relevant Protocol Deviations
The relevant Protocol Deviations will be summarized for all randomized subjects, by treatment 
group and overall. The following programmable deviations from inclusion and exclusion criteria 
will be considered as relevant protocol deviations. Non-programmable relevant eligibility and 
on-treatment protocol deviations, as well as significant (both programmable and non-
programmable) eligibility and on-treatment protocol deviations will be reported through 
ClinSIGHT listings.
At entrance:

Subjects without confirmed SCLC.

Subject with baseline ECOG PS > 1.

Subjects without evaluable disease at baseline. 

Subjects who received prior treatment with topotecan or amrubicin, 
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
19

Subjects who received less than 4 cycles of platinum-based, first-line chemotherapy without 
a best overall response (BOR) of a partial or complete response after completion of 
chemotherapy
On-Study: 

Subjects receiving concurrent anti-cancer therapy (defined as chemotherapy, hormonal 
immunotherapy, radiation therapy, standard or investigational agents for treatment of SCLC). 

Subject treated differently as randomized (subjects who received the wrong treatment, 
excluding the never treated).
A subject listing will also be produced.
7.3
Study Population
7.3.1
Subject Disposition
The total number of subjects enrolled (randomized or not randomized) will be presented along 
with the reason for not being randomized.
Number of subjects randomized but not treated along with the reason will be tabulated by 
treatment group as randomized. This analysis will be performed on the all randomized 
population only.
Number of subjects who discontinued study treatment along with corresponding reason will be 
tabulated by treatment group as treated.
A subject listing for all randomized subjects will be provided showing the subject’s 
randomization date, first and last dosing date, off study date and reason for going off-study. A 
subject listing for subjects not randomized will also be provided, showing the subject’s race, 
gender, age, consent date and reason for not being randomized.
7.3.2
Demographics and Other Baseline Characteristics
The following baseline characteristics will be summarized by treatment arm as randomized. All 
baseline presentations identify subjects with missing measurements. Listings will also be 
provided.

Age (descriptive statistics).

Age category (< 65, 65 - < 75, 75, 65).

Gender, Race/Ethnicity, Region (US/Canada vs. Europe vs. Asia vs. Rest of World).

Baseline ECOG PS, 

Baseline Weight (kg).

Baseline LDH (ULN, > ULN)

Baseline LDH (x ULN, > 2x ULN)

CNS Metastasis (Yes/no)
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
20

Cell type: (SCLC; other)

Smoking Status (current/former; never smoked; unknown)

Disease stage: Extensive versus Limited subjects (Source: eCRF)

All lesions (Investigator Tumor Assessments at Baseline): sites of disease, number of disease 
sites per subject.

Target Lesions (Investigator Tumor Assessments at Baseline): Presence of target lesions, site 
of target lesion, sum of diameters of target lesions.
7.3.3
Medical History
General medical history will be listed by subject and pretreatment events will be tabulated. 
7.3.4
Prior Therapy Agent
Prior therapy will be summarized in a single table (Source: CRF). 
Prior anti-cancer therapy.

Line of therapy (First/Unknown)

Number of cycle of Platinum first line therapy

Number of cycle of Etoposide as first line therapy

Number of cycle of Irinotecan as first line therapy

Best response to 1st line (CR/PR vs. SD vs. PD).

Primary reason for discontinuation of 1st line therapy

Time from completion of most recent regimen to treatment (< 3, 3 - 6, > 6 months).

Prior surgery related to cancer (yes or no).

Prior PCI (yes or no).

Prior radiotherapy (yes/no)

Prior systemic therapy classified by therapeutic class and generic name.
Other Prior therapy:

Prior/current non-study medication classified by anatomic and therapeutic classes.
Agents and medication will be reported using the generic name. A listing by subject will also be 
provided.
7.3.5
Baseline Examinations
Subjects with abnormal baseline physical examination will be tabulated by examination criteria 
and by treatment group.
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
21
7.3.6
Discrepancies between IVRS and CRF Stratification Factors
Summary tables (cross-tabulations) by treatment group for stratification factor will be provided 
to show any discrepancies between what was reported through IVRS vs. CRF data (baseline).
7.4
Extent of Exposure
7.4.1
Administration of Study Therapy
The following parameters will be summarized (descriptive statistics) by treatment group:

Relative dose intensity (%) using the following categories: < 50%; 50 - < 70%; 70 - < 90%; 
90 - < 110%; 110%. 

Number of doses received (summary statistics).

Cumulative dose 
Duration of treatment will be presented by treatment group using a Kaplan-Meier curve whereby 
the last dose date will be the event date for those subjects who are off study therapy. Median 
duration of treatment and associated 95% CI will be provided. Subjects who are still on study 
therapy will be censored on their last dose date.
A by-subject listing of dosing of study medication (record of study medication, infusion details, 
dose change) and a listing of batch number will be also provided.
Below table summarizes the key parameters used to calculate dosing data.
Table 7.4.1-1:
Administration of study therapy: definition of parameters
Nivolumab
Topotecan IV
Topotecan Oral
Amrubicin
Dosing 
schedule per 
protocol
240mg every 2 weeks 
1.5mg/m² for days 1 to 
5 of every 3 weeks 
cycle
2.3mg/m² for days 1 
to 5 of every 3 weeks 
cycle
40mg/m² for days 1 to 
3 of every 3 weeks 
cycle
Dose
Dose is defined as Total 
Dose administered (mg) 
Dose (mg/m²) is 
defined as Total Dose 
administered (mg) / 
Most recent BSA. 
Dose administered in 
mg at each dosing date 
and BSA (computed 
using recent weight 
and bsl height) are 
collected on the CRF.
Dose (mg/m²) is 
defined as Total Dose 
administered (mg) / 
Most recent BSA. 
Dose administered in 
mg at each dosing 
date and BSA 
(computed using 
recent weight and bsl 
height) are collected 
on the CRF.
Dose (mg/m²) is 
defined as Total Dose 
administered (mg) / 
Most recent BSA. 
Dose administered in 
mg at each dosing 
date and BSA
(computed using 
recent weight and bsl 
height) are collected 
on the CRF.
Cumulative 
Dose
Cum dose is sum of the 
doses (mg) administered 
to a subject during the 
treatment period.
Cum dose (mg/m²) is 
sum of the doses 
(mg/m²) administered 
to a subject during the 
treatment period.
Cum dose (mg/m²) is 
sum of the doses 
(mg/m²) administered 
to a subject during the 
treatment period.
Cum dose (mg/m²) is 
sum of the doses 
(mg/m²) administered 
to a subject during the 
treatment period.
Relative 
dose 
intensity (%)
Cum dose (mg) / [(Last 
dose date - Start dose 
date + 14) x 240 / 14] x 
Cum dose (mg/m²) / 
[(First dose date in last 
cycle - Start dose date 
Cum dose (mg/m²) / 
[(First dose date in 
last cycle - Start dose 
Cum dose (mg/m²) / 
[(First dose date in 
last cycle - Start dose 
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
22
Table 7.4.1-1:
Administration of study therapy: definition of parameters
Nivolumab
Topotecan IV
Topotecan Oral
Amrubicin
100
+ 21) x 7.5 / 21] x 100
date + 21) x 11.5 / 21] 
x 100
date + 21) x 120 / 21] 
x 100
Duration of 
treatment 
Last dose date - Start 
dose date +1
Last dose date - Start 
dose date +1
Last dose date - Start 
dose date +1
Last dose date - Start 
dose date +1
7.4.2
Modifications of Study Therapy
7.4.2.1
Cycle Delays
A cycle will be considered as actually delayed if the delay is exceeding 3 days (i.e., greater than 
or equal to 4 days from scheduled dosing date) for both nivolumab and topotecan/amrubicin. It is 
defined as (duration of previous cycle in days -14) for nivolumab (or -21 for 
topotecan/amrubicin). Cycle delays will be divided into following categories: on-time, 4 - 7 days, 
8 
-
14 
days, 
15 
-
42, 
> 42 days. Reason for Cycle delay will be retrieved from CRF dosing pages.
Each nivolumab or topotecan/amrubicin infusion can be interrupted and/or the IV infusion rate 
can be reduced. This information will be retrieved from CRF dosing pages.
The following parameters will be summarized by treatment arm:

Number of cycle delayed per subject, Length of Delay and Reason for cycle Delay.

Number of subject with at least one dose infusion interrupted along with reason for the 
interruptions and number of infusions interrupted per subject.
7.4.2.2
Topotecan/Amrubicin Dose interruptions - IV
Topotecan/amrubicin dose interruption will occur if, on Day 1 to Day 5 of each cycle for 
topotecan or on Day 1 to Day 3 of each cycle for amrubicin, the subject had an IV infusion 
interruption. Reason for dose interruption will be retrieved from CRF dosing pages.
7.4.2.3
Dose Reductions/Omissions/Increases
There will be no dose escalations or reductions of nivolumab allowed. Subjects may be dosed no 
less than 12 days from the previous dose.
Each nivolumab or topotecan/amrubicin infusion can be interrupted and/or the IV infusion rate 
of nivolumab or topotecan can be reduced. This information will be retrieved from CRF dosing 
pages.
Dose of topotecan/amrubicin may be modified for toxicity. Subjects may be dosed no less than 
14 days from the previous dose. Based on local guideline, providing subjects is not experiencing 
significant toxicity, increase topotecan IV dosage to a maximum of 2mg/m² per day (3.1mg/m² 
per day for the oral formulation) in increments of 0.25mg/m² per day (0.4mg/m² per day for oral 
formulation) is possible. 
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
23
Per the Protocol, dose levels of topotecan IV are defined as:

Dose level +2: 2mg/m²

Dose level +1: 1.75mg/m²

Dose level 0: 1.5mg/m²

Dose level -1: 1.25mg/m²

Dose level -2: 1mg/m²
Per the Protocol, dose levels of Oral topotecan are defined as:

Dose level +2: 3.1mg/m²

Dose level +1: 2.7mg/m²

Dose level 0: 2.3mg/m²

Dose level -1: 1.9mg/m²

Dose level -2: 1.5mg/m²
Per Protocol, dose levels of amrubicin are defined as follow:

Dose level 0: 40mg/m²

Dose level -1: 35 mg/m²

Dose level -2: 30mg/m²

Dose level -3: 25mg/m²
Dose reduction/increase, on Day 1 to Day 5 of each cycle for topotecan or on Day 1 to Day 3 of 
each cycle for amrubicin, is defined as at least one day with a non zero dose smaller/higher than 
1mg/m² for topotecan IV (1.5mg.m² for Topotecan oral and 40mg/m² for amrubicin) and smaller 
than previous non zero dose (with a CRF reason different from “Dosing Error” for oral 
topotecan).
Dose Omission: a dose is considered as being omitted during a cycle when less than 5 or less 
than 3 non zero doses have been reported for Topotecan (unless, for oral topotecan, CRF reason 
is “Dosing Error”) and for amrubicin, respectively. 
Dose ranges for dose levels of Topotecan and amrubicin are defined in Table below
Table 7.4.2.3-1:
Dose Modifications
Dose Range (mg/m2)
Dose Level
Topotecan IV 
Topotecan Oral
Amrubicin

2.9

Level +2



Level +1

2.1 - <2.5
37.5
Level 0
1.125 1.375
1.7 -  <2.1
32.5 37.5
Level -1
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
24
Table 7.4.2.3-1:
Dose Modifications
Dose Range (mg/m2)
Dose Level
Topotecan IV 
Topotecan Oral
Amrubicin
1.125
1.3 - <1.7
27.5 32.5
Level -2
NA
NA
27.5
Level -3
The reason for dose reduction as reported by the investigator will be tabulated for all instances of 
dose reduction based on the Dose Change CRF page. A category ‘Unknown’ will be defined for 
all reductions with no reason reported by the investigator.
For Nivolumab and Topotecan, the following will be summarized by treatment group:

Number of subjects with at least one infusion with IV rate reduced along with the reason of 
the rate reduction.
The following will be summarized for topotecan and amrubicin subjects:

Number and percentage of subjects with at least one dose reduction and reason of the dose 
reduction, number and percentage of subjects with a dose reduction to dose level -1, number 
and percentage of subjects with a dose reduction to dose level -2

Number and percentage of subjects with at least one dose increase of topotecan, number and 
percentage of subjects with a dose increase to dose level +1, number and percentage of 
subjects with a dose reduction to dose level
 
 
 
 
A by-subject listing will accompany the table.
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
25
7.5
Efficacy
7.5.1
Overall Survival
7.5.1.1
Primary Analysis
The distribution of OS will be compared in two randomized arms at the interim and final 
analyses via a two-sided, log-rank test stratified by baseline stratification factors, as entered into 
the IVRS. 
The hazard ratio (HR) and the corresponding 100(1-)% CI (adjusted for the interim) will be 
estimated in a stratified Cox proportional hazards model using randomized arm as a single 
covariate.
The OS curves for each treatment group will be estimated using the Kaplan-Meier (KM) 
product-limit method. Two-sided, 95% confidence intervals for median OS will be constructed 
based on a log-log transformed CI for the survivor function S(t) 10. 
Based on the availability of the data, survival rates at 6, 12, 18, 24, 36, 48 months and at 5 year 
will also be estimated using KM estimates on the OS curve for each randomized arm. Minimum 
follow-up must be longer than timepoint to generate the rate. Associated two-sided 95% CIs will 
be calculated using the Greenwood’s formula11 for variance derivation and on log-log 
transformation applied on the survivor function S(t) 
The status of subjects who are censored in the OS Kaplan-Meier analysis will be tabulated for 
each treatment group using following categories:

on-study (on-treatment and not progressed, on-treatment progressed, in follow-up);

off-study: (lost to follow-up, withdraw consent, etc.).
Unless otherwise specified, the primary population will be the all randomized population.
7.5.1.2
OS Sensitivity Analyses
Non-Proportional Hazard Assumption
To examine the assumption of proportional hazards in the Cox regression model, in addition to 
treatment, a time-dependent variable defined by treatment by time interaction will be added into 
the model. A two-sided Wald Chi-square p-value of less than 0.1 may indicate a potential 
nonconstant treatment effect. In that case, 
.
In case non-proportionality cannot be ruled out by the test described above, piecewise hazard 
ratios (e.g. from 0 to 8 months and after 8months) will be presented together with their 
corresponding 95% CI. 
To investigate the impact of potential non-proportional hazard, the distribution of OS will also be
compared using a two-sided weighted log-rank test stratified by the stratification factors, as 
entered into the IVRS. The weighted log-rank test will use G (rho = 0, gamma = 1) weights, in 
the terminology of Fleming and Harrington14,15. This p-value will be considered as descriptive. 
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
26
Additional Sensitivity Analyses
The following OS sensitivity analyses will be performed. 

OS will be compared between treatment groups using a two-sided (adjusted for the 
interim) unstratified log-rank test. 

OS will be compared between treatment groups using the strata as determined at baseline 
(CRF source). This analysis will be performed only if at least one stratification variable at 
IVRS and at baseline disagrees for at least 10% of the randomized subjects.

OS will be compared between treatment groups using a two-sided (adjusted for the 
interim) stratified log-rank test in the All Treated Subjects population, using arm as 
randomized. This analysis will be performed only if the proportion of randomized but never 
treated subjects exceeds 10%.
Estimate of the hazard ratio, its two sided 100(1-)% CI (adjusted for the interim) and p-value 
will be presented.
7.5.1.3
Consistency of Treatment Effect on OS in Subsets
To assess consistency of treatment effects in different subsets, a “forest” plot of the OS 
unstratified hazard ratio (and 95% CI) will be produced for the following subgroups. 

CNS metastases (yes/no). (CRF source).

Response to Platinum based Therapy (sensitive/resistant) (CRF source).

Age category (< 65 - 65).

Gender, Race, Region (US vs. Europe vs. Asia vs. Rest of World).

Baseline ECOG PS.

Baseline LDH (ULN vs. > ULN).

Disease Stage at initial diagnosis (extensive vs. limited).

Time from Initial Disease Diagnosis to Randomization (< 1 year, Other).

Best response to 1st line (CR/PR vs. SD vs. PD).

Time from completion of 1st line therapy (< 3, 3 - 6, > 6 months).
If subset category has less than 10 subjects per treatment group, HR will not be 
computed/displayed. Number of events and median OS along with 95% CI will be displayed for 
each treatment group.
7.5.1.4
Multivariate Analysis
A multivariate stratified Cox model will be fitted to assess the treatment effect on OS when 
adjusted for potential prognostic factors. The following potential prognostic factors will be 
included in the model.

Age category (< 65 - 65).

Gender
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
27

Baseline ECOG PS, 

Disease Stage at initial diagnosis (extensive vs. limited)

Time from Initial Disease Diagnosis to Randomization (< 1 year, Other).
HR and 95% CI will be provided for treatment variable and all covariates. Descriptive p-values 
will be provided.
7.5.1.5
Subject Follow-up for OS
The minimum follow-up will be reported. The minimum follow-up is defined as the time interval 
between the last patient’s randomization date and the clinical cutoff date.
The extent of follow-up defined as the time between randomization date and last known date 
alive (for subjects who are alive) or death date (for subjects who died) will be summarized 
descriptively (median, min, max) for all subjects randomized.
The currentness of follow-up, defined as the time between last OS contact (i.e., last known date 
alive or death date) and data cut-off date, will be summarized by treatment group. Subjects who 
died before data cut-off date will automatically have zero value for currentness of follow-up. For 
subjects with last known date alive after data cut-off date, they will have zero value for 
currentness of follow-up as well. The currentness of follow-up will be categorized into the 
following categories: 0 days, 1-3 months, 3-6 months, 6-9 months, 9-12 months and 
months. 
7.5.1.6
Follow-up Therapy
Subsequent therapies will be summarized and listed.

Subsequent Therapy

Chemotherapy by drug name

Hormonal or biologic therapy by drug name

Immunotherapy (anti-PD1 agents, anti-CTLA4 agents and others, by drug name)

Tyrosine kinase inhibitor by drug name

Other investigational agent by drug name

Surgery

Radiotherapy

Any combination of the above

By Subject Listing of Subsequent Therapy
7.5.1.7
Analysis of Survival by Tumor Response
Survival by response category will be analyzed by arm using the landmark method16. Subjects 
still on study at the landmark time will be separated into two response categories according to 
whether they have responded before that time. This will assess whether survival from the 
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
28
landmark depends on the subject's response status at the landmark. Subjects who go off protocol 
(e.g. subjects who die) before the time of landmark will be excluded from the analysis.
The survival curves from Week 6, Month 4, Month 6, Month 8, Month 12, by response status, 
for each randomized arm will be produced using the KM product-limit method. Two sided, 95% 
confidence intervals for median OS will be constructed based on a log-log transformed CI for the 
survivor function S(t).
7.5.2
Progression Free Survival
7.5.2.1
Primary Analysis of PFS
PFS for each treatment arm will be estimated using Kaplan-Meier product limit method and 
graphically displayed. A two-sided 95% CI for median duration will be constructed based on a 
log-log transformed CI for the survivor function S(t) 9,10 .
The comparison of PFS distribution will be performed via a stratified log-rank test at two-sided, 
5% level. In addition, the stratified hazard ratios between treatment groups will be provided 
along with the 95% CI.
PFS rates at 6, 12, 18, 24, 36, 48 months and at 5 year will also be estimated using KM estimates 
on the PFS curve for each randomized arm. Minimum follow-up must be longer than or equal to 
timepoint to generate the rate. Associated two-sided 95% CIs will be calculated using the 
Greenwood’s formula11. 
The source of progression (death vs. progression) will be summarized by treatment group.
The status of subjects who are censored in the PFS Kaplan-Meier analysis will be tabulated for 
each treatment group using following categories:

Never treated

On-study (on treatment, in follow-up) 

Off-study: (lost to follow-up, withdrew consent, other).

Received subsequent anti-cancer therapy

No baseline tumor assessment
To assess consistency of treatment effect on PFS in different subsets, a “forest” plot of the PFS 
unstratified hazard ratio (and 95% CI) will be produced for the same variable as in the OS 
analysis.
7.5.2.2
Sensitivity Analyses of PFS
Sensitivity analyses of PFS will also be performed using the following modification of PFS 
primary definition.

PFS will be compared between treatment groups using the strata as determined at baseline
(CRF source). This analysis will be performed only if at least one stratification variable at 
IVRS and at baseline disagrees for at least 10% of the randomized subjects.
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
29

PFS accounting for assessment after subsequent therapy subjects will be defined similarly to 
the primary definition except that events (progression or death) and tumor assessments that 
occurred on or after subsequent anticancer therapy will be taken into account.

PFS accounting for missing tumor assessment prior to PFS event (progression or death). 
This analysis will be performed only if at least 20% of events have missing prior tumor 
assessment. It will apply the following restriction to the primary definition: If the elapsed 
time between the PFS event and the last on-study assessment immediately prior to the event 
(or randomization date if no on-study scan) is two or more missed visits (more than 12 weeks 
+ 10 days), the subject will be censored at his last tumor assessment prior to the PFS event 
(or randomization date if no on-study scan).

PFS accounting for assessment after on-treatment palliative radiotherapy . This analysis is 
similar to the primary analysis except that no censoring will occur for on-treatment palliative 
radiotherapy.
7.5.3
Objective Response Rate
7.5.3.1
Primary Analysis of ORR
BOR will be summarized by response category for each treatment group. ORR will be computed 
in each treatment group along with the exact 95% CI using Clopper-Pearson method17.
An estimate of the difference in ORRs and corresponding 95% CI will be calculated using CMH 
methodology and adjusted by the same stratification factors as for primary analysis of OS.
In addition, the stratified (source: IVRS) odds ratios (Mantel-Haenszel estimator) between the 
treatments will be provided along with the 95% CI. The difference will be tested via the Cochran
Mantel-Haenszel (CMH) test using a two-sided, 5% level.
To assess consistency of treatment effect on ORR in different subsets, ORR will be computed 
across the same subsets as defined in the OS analysis (see Section 7.5.1.3).
7.5.3.2
Sensitivity Analyses of ORR
If one stratification variable at IVRS and at baseline (CRF) disagrees for at least 10% of the 
randomized subjects, similar analysis of ORR as primary analysis will be performed using the 
strata as determined at baseline.
7.5.4
Duration of Objective Response
Duration of response in each treatment group will be estimated using KM product-limit method 
for subjects who achieve PR or CR. Duration of stable disease will also be estimated in each 
treatment groups using KM product-limit method for subjects with SD as best response. Median 
values along with two-sided 95% CI will be calculated. Summary statistics will be computed 
constructed based on a log-log transformed CI for the survivor function S(t).
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
30
7.5.5
Time to Objective Response
Summary statistics of time to objective response will be provided for each treatment group for 
subjects who achieve PR or CR. 
To assess further tumor response kinetics, time to response will be analyzed using the KM 
methodology, for all randomized subjects. Kaplan-Meier curve will represent the cumulative rate 
of response over time. For the non-responders, time to response will be censored at the 
maximum time of response + 1 day of all subjects in their respective treatment group. 
Cumulative Response Rates will be tabulated for Week 6, Month 4, 6, 8, and 12, and overall 
Response Rate will be provided for each treatment group.
7.5.6
Hierarchy for Key Secondary Efficacy Endpoints
In order to preserve an experimental-wise type I error rate at 5%, a pre-planned hierarchy for key 
secondary endpoints will be applied when interpreting the statistical significance of treatment 
comparisons. The hierarchical ordering of the key secondary endpoints is as follows:
1) Progression-Free Survival
2) Objective Response Rate
The statistical testing will be carried out using the following sequential procedure:
1) The primary endpoint of OS will be tested first. 
2) If the p-value of OS is not statistically significant against nominal significance level either at 
interim or final analysis, then no further statistical testing regarding the secondary endpoints 
will be conducted. However estimates along with their 95% CI will be provided for those 
(i.e. medians and HR, rates and odds ratio)
3) If the p-value of OS is statistically significant against nominal significance level either at 
interim or final analysis, the secondary endpoint with the highest ranking in the hierarchy 
will be tested (PFS in this case). If the p-value of PFS is statistically significant at 5% level, 
the second highest ranking endpoint in the hierarchy will be tested (ORR in this case) and the 
p-value of ORR will be provided. If the p-value of PFS is not statistically significant at 5% 
level, then no further statistical testing regarding the other secondary endpoint (i.e., ORR) 
will be conducted. Estimates (medians and HR) and their 95% CI will be provided for ORR
regardless of the outcome of PFS testing. 
7.5.7
Follow-up Therapy
Number and percentage of subjects receiving subsequent therapies including radiotherapies, 
surgeries and systemic therapies will be reported.
Subsequent therapies will be summarized and listed.

Subsequent Therapy

Chemotherapy by drug name

Hormonal or biologic therapy by drug name

Immunotherapy (anti-PD1 agents, anti-CTLA4 agents and others, by drug name)
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
31

Tyrosine kinase inhibitor by drug name

Other investigational agent by drug name

Surgery

Radiotherapy

Any combination of the above

By Subject Listing of Subsequent Therapy
7.5.8
Other Efficacy Analyses
The following subject-level graphics will also be provided by treatment group as randomized: 

For the responders only, time courses of the following events of interest will be graphically 
displayed: tumor response, tumor progression, last dose received, and death.

For response evaluable subjects, a waterfall plot showing the best reduction in target lesion 
will be produced. 
7.5.9
Interim Analysis
No formal Analysis will be run
7.6
Safety
7.6.1
Deaths
See Core Safety SAP
7.6.2
Serious Adverse Events
See Core Safety SAP
7.6.3
Adverse Events Leading to Discontinuation of Study Therapy
See Core Safety SAP
7.6.4
Adverse Events Leading to Dose Delay of Study Therapy
See Core Safety SAP
7.6.5
Adverse Events
See Core Safety SAP
7.6.6
Adverse Events by Subgroups
See Core Safety SAP
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
32
7.6.7
Multiple Events
See Core Safety SAP
7.6.8
Adverse Events of Special Interest
See Core Safety SAP
7.6.9
Clinical Laboratory Evaluations
The analysis population for each laboratory test is restricted to treated subjects who underwent 
that laboratory test.
7.6.9.1
Hematology
See Core Safety SAP
7.6.9.2
Serum Chemistry
See Core Safety SAP
7.6.10
Vital Signs and Pulse Oximetry
See Core Safety SAP
7.6.11
Immunogenicity Analysis
Nivolumab arm only. See Core Safety SAP
7.6.12
Pregnancy
By-subject listing of pregnancy tests results will be provided 
7.6.13
Clinical Safety Program (CSP)
See Core Safety SAP
7.7
Pharmacokinetics
Pharmacokinetics analyses will be performed on nivolumab arm only. 
The concentration vs. time data obtained in this study will be combined with data from other 
studies in the clinical development program to develop a population PK model. This model will 
be used to evaluate the effects of intrinsic and extrinsic covariates on the PK of nivolumab and to 
determine measures of individual exposure (such as steady-state peak, trough, and time-averaged 
concentration). Model determined exposures will be used for exposure-response analyses of 
selected efficacy and safety end points. Results of population PK and exposure-response 
analyses will be reported separately.
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
33
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.8.1.3
Association between TMB and Efficacy 
 
 
 
 
2.0
Approved
930099527
1.0
v




Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
35
7.9
Outcomes Research Analyses
The outcome research analyses will be performed using all randomized subjects.
7.9.1
LCSS questionnaire
LCSS questionnaire completion rate, defined as the proportion of questionnaires actually 
received out of the expected number (i.e., the number of subjects still on treatment or in follow-
up), will be calculated and summarized at each assessment point.
Baseline and change from baseline of the average symptom burden index score at each
assessment point will be summarized using descriptive statistics (N, mean, median, SD, 25th and 
75th percentiles) by treatment group, as randomized. 
Kaplan-Meier plots for TTD in symptoms as measured by LCSS ASBI would be presented along 
with median TTD and corresponding 95% CI.
TTD rates at fixed timepoints Week 6, 12 and 24 will be derived from the Kaplan Meier estimate 
and corresponding confidence interval will be derived based on Greenwood formula18 for 
variance derivation and on log-log transformation applied on the survivor function S(t)19.
7.9.2
EQ-5D questionnaire
AS done for LCSS, EQ-5D questionnaire completion rate, defined as the proportion of 
questionnaires actually received out of the expected number (i.e., the number of subjects still on 
treatment or in follow-up), will be calculated and summarized at each assessment point.
Subject’s overall health state on a visual analog scale (EQ-VAS) at each assessment time point 
will be summarized along with change from baseline using descriptive statistics (N, mean, SD, 
median, 25th and 75th percentiles) by treatment group, as randomized.
Subject’s overall health state on EQ-5D index using UK weighting algorithm at each assessment 
time point will be summarized along with change from baseline using descriptive statistics 
(N, mean, SD, median, 25th and 75th percentiles) by treatment group, as randomized.
Proportion of subjects reporting problems for the 5 EQ-5D dimensions at each assessment time 
point will be summarized by level of problem and by treatment group, as randomized. 
Percentages will be based on number subjects assessed at assessment time point.
A by-subject listing of EQ-5D with the problem levels for each of the 5 dimensions (mobility, 
self-care, usual activities, pain/discomfort and anxiety/depression), health state (5 dimensions 
digits combined in a 5-digit number) and EQ-VAS will be provided. 
Results of EQ5D-Index will be presented separately and will be described in the GHEOR SAP.
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
36
8
CONVENTIONS
The following conventions may be used for imputing partial dates for analyses requiring dates:

For missing and partial adverse event onset dates, imputation will be performed using the 
Adverse Event Domain Requirements Specification20. 

Missing and partial Non-Study Medication Domain dates will be imputed using the 
derivation algorithm described in Section 4.3.3 of BMS Non-Study Medication Domain 
Requirements Specification21.
For death dates, the following conventions will be used for imputing partial dates:

If only the day of the month is missing, the 1st of the month will be used to replace the 
missing day. The imputed date will be compared to the last known date alive and the 
maximum will be considered as the death date.

If the month or the year is missing, the death date will be imputed as the last known date 
alive. If the date is completely missing but the reason for death is present the death date will 
be imputed as the last known date alive 
For date of progression, the following conventions will be used for imputing partial dates:

If only the day of the month is missing, the 1st of the month will be used to replace the 
missing day*.

If the day and month are missing or a date is completely missing, it will be considered as 
missing.

In case of the date of death is present and complete, the imputed progression date will be 
compared to the date of death. The minimum of the imputed progression date and date of 
death will be considered as the date of progression.

For other partial/missing dates, the following conventions may be used:

If only the day of the month is missing, the 15th of the month will be used to replace the 
missing day.

If both the day and the month are missing, “July 1” will be used to replace the missing 
information.

If a date is completely missing, it will be considered as missing.
The following conversion factors will be used to convert days to months or years: 
1 month = 30.4375 days and 1 year = 365.25 days.
Duration (e.g. time from first diagnosis of SCLC to first dosing date, duration response, and time 
to response) will be calculated as follows:
Duration = (Last date - first date + 1)
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
37
9
CONTENT OF REPORTS
All analyses describe in this SAP will be included in the final Clinical Study Report. Refer to the 
Data Presentation Plan for mock-ups of all tables and listings.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.0
Approved
930099527
1.0
v


Statistical Analysis Plan
CA209-331
BMS-936558
nivolumab
38
 
 
 
 
 
 
 
 
 
2.0
Approved
930099527
1.0
v